

Schultz, J.
101673063 Page 1
Seq ID 3GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 10:20:44 ; Search time 1762 Seconds
(without alignments)
1210.005 Million cell updates/sec

Title: US-10-673-063-3_COPY_900_943

Perfect score: 44
Sequence: 1 gcgggtccgcgtcctctcta.....ccggtcgcgcgttataagaa 44Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 4708233 seqs, 24227607955 residues

Total number of hits satisfying chosen parameters: 1839042

Minimum DB seq length: 0
Maximum DB seq length: 50Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 100 summaries

Database :

GenBank: *
1: gb_ba: *
2: gb_hc: *
3: gb_in: *
4: gb_on: *
5: gb_ov: *
6: gb_pat: *
7: gb_ph: *
8: gb_pl: *
9: gb_pr: *
10: gb_ro: *
11: gb_sts: *
12: gb_sy: *
13: gb_un: *
14: gb_vi: *Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	16.2	36.8	32	6	AX468571 Sequence
C 2	16	36.4	27	6	AX338903 Sequence
C 3	16	36.4	27	6	AX338904 Sequence
C 4	16	36.4	38	6	A09534 Sequence
C 5	16	36.4	38	6	A09567 Sequence
C 6	16	36.4	50	12	SYNRNA3C
C 7	15.8	35.9	38	6	AX515653 Sequence
C 8	15.8	35.9	41	6	AX515653 Sequence
C 9	15.8	35.9	41	6	AX515653 Sequence
C 10	15.8	35.9	50	3	DROPRM1 Sequence
C 11	15.2	34.5	33	6	AR365669 Sequence
C 12	15.2	34.5	37	6	AX147162 Sequence
C 13	15.2	34.5	47	6	AX081593 Sequence
C 14	15.2	34.5	47	6	AX374774 Sequence
C 15	15	34.1	31	6	AX248444 Sequence
C 16	15	34.1	50	10	MMU41925 Sequence
C 17	14.8	33.6	31	6	AX582316 Sequence
C 18	14.8	33.6	33	6	I03806 Sequence
C 19	14.8	33.6	36	6	AR429930 Sequence

C 20	14.8	33.6	36	6	AX099684 Sequence
C 21	14.8	33.6	37	6	I03802 Sequence
C 22	14.8	33.6	47	6	AR288505 Sequence
C 23	14.8	33.6	47	6	AR289990 Sequence
C 24	14.8	33.6	50	6	AR032973 Sequence
C 25	14.8	33.6	50	6	I29713 Sequence
C 26	14.8	33.6	50	6	I19187 Sequence
C 27	14.8	33.6	50	6	AR209637 Sequence
C 28	14.6	33.2	32	6	CQ68809 Sequence
C 29	14.6	33.2	33	6	AR365650 Sequence
C 30	14.6	33.2	34	6	AR365637 Sequence
C 31	14.6	33.2	35	6	AX739899 Sequence
C 32	14.6	33.2	39	6	AR365666 Sequence
C 33	14.6	33.2	45	6	AX642259 Sequence
C 34	14.6	33.2	46	6	I13724 Sequence
C 35	14.6	33.2	47	6	AR291680 Sequence
C 36	14.4	32.7	20	6	AX462584 Sequence
C 37	14.4	32.7	32	6	BD061913 Sequence
C 38	14.4	32.7	34	6	AX574343 Sequence
C 39	14.4	32.7	40	6	BD235752 Sequence
C 40	14.4	32.7	40	6	BD235803 Sequence
C 41	14.4	32.7	47	6	AR291235 Sequence
C 42	14.4	32.7	50	5	XELRG73 Sequence
C 43	14.4	32.7	50	6	AX057065 Sequence
C 44	14.2	32.3	20	6	AR316182 Sequence
C 45	14.2	32.3	21	6	AR337058 Sequence
C 46	14.2	32.3	21	6	AR529926 Sequence
C 47	14.2	32.3	21	6	AX095951 Sequence
C 48	14.2	32.3	25	6	AX304716 Sequence
C 49	14.2	32.3	25	6	AX615111 Sequence
C 50	14.2	32.3	33	6	AX280063 Sequence
C 51	14.2	32.3	36	6	I18300 Sequence
C 52	14.2	32.3	38	6	AR089801 Sequence
C 53	14.2	32.3	48	8	AR383268 Sequence
C 54	14.2	32.3	48	8	AR383276 Sequence
C 55	14.2	32.3	49	6	AR239848 Sequence
C 56	14.2	32.3	49	6	AX279650 Sequence
C 57	14.2	32.3	50	6	AX190235 Sequence
C 58	14.2	32.3	50	10	MMU41975 Sequence
C 59	14	31.8	24	6	AX1608 Sequence
C 60	14	31.8	24	6	AX5670 Sequence
C 61	14	31.8	24	6	AX5712 Sequence
C 62	14	31.8	24	6	AX5754 Sequence
C 63	14	31.8	24	6	AX5796 Sequence
C 64	14	31.8	24	6	AR116287 Sequence
C 65	14	31.8	32	6	AR534294 Sequence
C 66	14	31.8	32	6	AR544580 Sequence
C 67	14	31.8	35	6	AR534275 Sequence
C 68	14	31.8	35	6	AR544561 Sequence
C 69	14	31.8	38	6	AB6752 Sequence
C 70	14	31.8	38	6	BD062648 Sequence
C 71	14	31.8	41	6	AR305163 Sequence
C 72	14	31.8	41	6	AR309267 Sequence
C 73	14	31.8	41	6	BD106074 Sequence
C 74	14	31.8	45	6	AR634370 Sequence
C 75	14	31.8	47	6	AR032638 Sequence
C 76	14	31.8	47	6	I29378 Sequence
C 77	14	31.8	47	6	I21052 Sequence
C 78	14	31.8	47	6	AR209302 Sequence
C 79	14	31.4	47	6	AR289255 Sequence
C 80	13.8	31.4	24	6	AX445527 Sequence
C 81	13.8	31.4	25	6	AX115688 Sequence
C 82	13.8	31.4	26	6	I21917 Sequence
C 83	13.8	31.4	26	6	AX134798 Sequence
C 84	13.8	31.4	26	6	AX137764 Sequence
C 85	13.8	31.4	29	6	AR160337 Sequence
C 86	13.8	31.4	34	6	AR157567 Sequence
C 87	13.8	31.4	34	6	AR12616 Sequence
C 88	13.8	31.4	34	6	AR430014 Sequence
C 89	13.8	31.4	34	6	AR533433 Sequence
C 90	13.8	31.4	35	6	I03808 Sequence
C 91	13.8	31.4	37	6	AX800567 Sequence
C 92	13.8	31.4	38	6	AR272268 Sequence

AX099684 Sequence
I03802 Sequence 5
AR288505 Sequence
AR289990 Sequence
AR032973 Sequence
I29713 Sequence 58
I19187 Sequence 58
AR209637 Sequence
CQ68809 Sequence
AR365650 Sequence
AR365637 Sequence
AX739899 Sequence
AR365666 Sequence
AX642259 Sequence
I13724 Sequence 30
AR291680 Sequence
AX462584 Sequence
BD061913 Antigenic
AX574343 Sequence
BD235752 Strengthe
BD235803 Method of
AR291235 Sequence
M13248 X laevis ri
AX057065 Sequence
AR316182 Sequence
AR337058 Sequence
AR529926 Sequence
AX095951 Sequence
AX304716 Sequence
AX615111 Sequence
AX280063 Sequence
I18300 Sequence 3
AR089801 Sequence
AR383268 Arbidops
AR383276 Arbidops
AR239848 Sequence
AX279650 Sequence
AX190235 Sequence
U41975 Mus musculu
AX1608 Sequence 17
AX5670 Sequence 17
AX5712 Sequence 17
AX5754 Sequence 17
AX5796 Sequence 17
AR116287 Sequence
AR534294 Sequence
AR544580 Sequence
AR534275 Sequence
AR544561 Sequence
AB6752 Sequence 12
BD062648 Interacti
AR305163 Sequence
AR309267 Sequence
BD106074 Novel LDL
AR634370 Sequence
AR032638 Sequence
I29378 Sequence 25
I21052 Sequence 25
AR209302 Sequence
AR289255 Sequence
AX445527 Sequence
AX115688 Sequence
I21917 Sequence 2
AX134798 Sequence
AX137764 Sequence
AR160337 Sequence
AR157567 Sequence
AR12616 Sequence
AR430014 Sequence
AR533433 Sequence
I03808 Sequence 11
AX800567 Sequence
AR272268 Sequence

C 93 13.8 31.4 42 6 CQ767048 Sequence
94 13.8 31.4 45 6 E05105
95 13.8 31.4 45 11 AL834120
C 96 13.8 31.4 47 6 AR382719 Sequence
97 13.8 31.4 48 6 BD263286 Compositi
98 13.8 31.4 48 6 BD263298 Compositi
99 13.8 31.4 48 6 BD263303 Compositi
100 13.8 31.4 48 6 BD263304 Compositi

ALIGNMENTS

RESULT 1
AX468571/c 32 bp DNA linear PAT 16-JUL-2002
LOCUS Sequence 12 from Patent W00238745.
DEFINITION AX468571
ACCESSION AX468571 GI:21901398
VERSION
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Mesikene, I., Hirt, H. and Jonak, C.
TITLE Regulation of mitogen-activated protein kinase (mapk)
JOURNAL Patent: WO 0238745-A 12 16-MAY-2002;
Oesterreichisches Forschungszentrum Selbstdorf GmbH (AT)
FEATURES
source
1..32
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"
ORIGIN

Query Match 36.8%; Score 16.2; DB 6; Length 32;
Best Local Similarity 85.7%; Pred. No. 8e+04; 3; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 23 AACCGTCGCGTTATTAGA 43
Db 31 AACATGTCGCGTTATTAGA 11

RESULT 2
AX338903/c 27 bp DNA linear PAT 09-JAN-2002
LOCUS Sequence 8 from Patent W00185971.
DEFINITION AX338903
ACCESSION AX338903 GI:18129070
VERSION
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Alberte, R.S. and Smith, R.D.
TITLE Transgenic plants incorporating traits of Zostera marina
JOURNAL Patent: WO 0185971-A 8 15-NOV-2001;
Phycogen, Inc. (US)
FEATURES
source
1..27
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"
ORIGIN

Query Match 36.4%; Score 16; DB 6; Length 27;
Best Local Similarity 79.2%; Pred. No. 9.9e+04; 5; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Oy 20 AATAACCGTCGCGTTATTAGA 43

Db 25 AATAACTTGTGCGGTTAATCAGA 2

RESULT 3
AX338904 27 bp DNA linear PAT 09-JAN-2002
LOCUS Sequence 9 from Patent W00185971.
DEFINITION AX338904
ACCESSION AX338904 GI:18129071
VERSION
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Alberte, R.S. and Smith, R.D.
TITLE Transgenic plants incorporating traits of Zostera marina
JOURNAL Patent: WO 0185971-A 9 15-NOV-2001;
Phycogen, Inc. (US)
FEATURES
source
1..27
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"
ORIGIN

Query Match 36.4%; Score 16; DB 6; Length 27;
Best Local Similarity 79.2%; Pred. No. 9.9e+04; 5; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Oy 20 AATAACCGTCGCGGTTATTAGA 43
Db 3 AATAACTTGTGCGGTTAATCAGA 26

RESULT 4
A09534 38 bp DNA linear PAT 02-SEP-2002
LOCUS A09534
DEFINITION Oligonucleotide.
ACCESSION A09534
VERSION A09534.1 GI:411963
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 38)
AUTHORS Flier, R., Fukushima, H. and Yeh, P.
TITLE Method for the microbiological preparation of human serum albumin
JOURNAL Patent: EP 0361991-A 5 04-APR-1990;
RHONE-POULENC SANTE
FEATURES
source
1..38
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
ORIGIN

Query Match 36.4%; Score 16; DB 6; Length 38;
Best Local Similarity 68.8%; Pred. No. 9.8e+04; 10; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Oy 11 TTCCTTTTATTAAACCGTCGCGTTATTAG 42
Db 7 TTCCTTCGATAGCGCGCGGCTTTAG 38

RESULT 5
A09567 38 bp DNA linear PAT 02-SEP-2002
LOCUS A09567
DEFINITION Oligonucleotide.
ACCESSION A09567

VERSION A09567.1 GI:411995
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 38)
AUTHORS Fleer, R., Fukuhara, H. and Yeh, P.
TITLE Method for the microbiological preparation of human serum albumin
JOURNAL and other heterologous proteins from a yeast
Patent: EP 0361991-A 39 04-APR-1990;
Rhone-Poulenc Sante
FEATURES
SOURCE
1..38
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

ORIGIN
Query Match 36.4%; Score 16; DB 6; Length 38;
Best Local Similarity 68.8%; Pred. No. 9.8e+04;
Matches 22; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 11 TTCCTCTTATACCGCGCGGTATTAG 42
Db 7 TTCTTTCGATAGCGCGCGCTTATG 38,

RESULT 6
LOCUS SYNRA3/C 50 bp ss-RNA linear SYN 27-APR-1993
DEFINITION Synthetic Bromo mosaic virus (BMV) RNA 3' end/CAT gene from
PB3CA42, partial cds.
-ACCESSION M19550
VERSION M19550.1 GI:209273
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 50)
AUTHORS French, R., Janda, M. and Ahlquist, P. G.
TITLE Bacterial gene inserted in an engineered RNA virus: Efficient
JOURNAL expression in monocotyledonous plant cells
COMMENT Science 231, 1294-1297 (1986)
FEATURES
SOURCE Original source text: Bromo mosaic virus and plasmid PB3CA42 RNA.
location/Qualifiers
1..50
/organism="synthetic construct"
/mol_type="genomic RNA"
/db_xref="taxon:32630"
10..>50
/note="coat protein"
/codon_start=1
/transl_table=11
/protein_id="AA072637.1"
/db_xref="GI:554572"
/translation="MSTRFSGAKKAKM"

ORIGIN
Query Match 36.4%; Score 16; DB 12; Length 50;
Best Local Similarity 62.5%; Pred. No. 9.8e+04;
Matches 25; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 4 GTCCTCTTCTTATACCGCGCGGTATTAGA 43
Db 41 GCTTCTTACCTCTCGAAATCTGTCGACATATTATA 2

RESULT 7
LOCUS A17381/c 38 bp DNA linear PAT 27-APR-1994
DEFINITION Nucleotide sequence 6 from patent number EP0481502.
ACCESSION A17381
VERSION A17381.1 GI:513877

KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 38)
AUTHORS Weidle, U. H. and Kaluza, B.
TITLE Process for the production of chimeric antibodies
JOURNAL Patent: EP 0481502-A 6 22-APR-1992;
BOEHRINGER MANNHEIM GMBH
FEATURES
SOURCE
1..38
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

ORIGIN
Query Match 35.9%; Score 15.8; DB 6; Length 38;
Best Local Similarity 65.7%; Pred. No. 1.2e+05;
Matches 23; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 1 GCGGATCCCGTTCCTTATACCGGCGCGGT 35
Db 36 GCTTCTCAGGCTTTATTTTAAGCGCGCGCT 2

RESULT 8
LOCUS AX515653 41 bp DNA linear PAT 05-OCT-2002
DEFINITION Sequence 1851 from Patent WO02052044.
ACCESSION AX515653
VERSION AX515653.1 GI:23562954
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.
TITLE Detection of genetic polymorphisms
JOURNAL Patent: WO 02052044-A 1851 04-JUL-2002;
Riken (JP)
FEATURES
SOURCE
1..41
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 35.9%; Score 15.8; DB 6; Length 41;
Best Local Similarity 81.0%; Pred. No. 1.2e+05;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 5 GTCCCGTTCCTTCTTATTAAC 25
Db 16 GTCCCTTCCTTCATTAATC 36

RESULT 9
LOCUS AX518248 41 bp DNA linear PAT 05-OCT-2002
DEFINITION Sequence 4446 from Patent WO02052044.
ACCESSION AX518248
VERSION AX518248.1 GI:23567646
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Nakamura, Y., Sekine, A., Iida, A. and Saito, S.
TITLE Detection of genetic polymorphisms
JOURNAL Patent: WO 02052044-A 4446 04-JUL-2002;
Riken (JP)

FEATURES
source
Location/Qualifiers
1. .41
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 35.9%; Score 15.8; DB 6; Length 41;
Best Local Similarity 81.0%; Pred. No. 1.2e+05;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 5 GTCCCGTCTCTTAATAC 25
|||||
16 GTCCCTTCCTCATATATC 36

RESULT 10
DROPRDM1 50 bp DNA linear INV 26-APR-1993
LOCUS D.melanogaster paired (prd) gene with a 1.1 kb insertion in exon 2,
DEFINITION 5', recombination site.
ACCESSION K03518.1 GI:158175
KEYWORDS insertion sequence; segmentation gene.
SEGMENT 1 OF 2
SOURCE Drosophila melanogaster (fruit fly)
ORGANISM Drosophila melanogaster
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
Ephydroidea; Drosophilidae; Drosophila.
REFERENCE 1 (bases 1 to 50)
AUTHORS Frigerio,G., Burri,M., Bopp,D., Baumgartner,S. and No1,M.
TITLE Structure of the segmentation gene paired and the Drosophila PRD
JOURNAL Cell 47 (5), 735-746 (1986)
MEDLINE 87051745
PUBMED 2877746
COMMENT Original source text: D.melanogaster (X-ray induced mutant strain
PRD-2.45.17) DNA, library of C.Nueslehn-Volhard.
The insert in mutant Drosophila exon 2, described in [1], causes
the prd mRNA to increase in size by 1.1 kb. The process also
deletes five base pairs from the wild-type prd gene, starting at
position 1065.
Location/Qualifiers
1. .50
/organism="Drosophila melanogaster"
/mol_type="genomic DNA"
/db_xref="taxon:7227"
<1. .>50
/note="pseudoprd cds"
/pseudo
/codon_start=1

ORIGIN
Chromosome 2 band 33C1.2.

Query Match 35.9%; Score 15.8; DB 3; Length 50;
Best Local Similarity 74.1%; Pred. No. 1.2e+05;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 12 TCCTTCTTAATACCGTGGCGTAT 38
|||||
17 TGCATCCGATACCGTGGCTGTCAT 43

RESULT 11
LOCUS AR365669 33 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 36 from patent US 5519127.
ACCESSION AR365669
VERSION AR365669.1 GI:34429581
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 33)
AUTHORS Shah,J., Bunarhin,A. and Iane,D.J.
TITLE Nucleic acid probes for the detection of Pneumocystis carinii
JOURNAL Patent: US 5519127-A 36 21-MAY-1996;
FEATURES Location/Qualifiers
source 1. .33
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 34.5%; Score 15.2; DB 6; Length 33;
Best Local Similarity 77.3%; Pred. No. 2.2e+05;
Matches 17; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 8 CCGTTCCTCTTAATACCGGT 29
:|||||
3 YCCTTCCTTCGATTAACCGGT 24

RESULT 12
LOCUS AX147162 37 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 4 from Patent WO0136457.
ACCESSION AX147162
VERSION AX147162.1 GI:14346333
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Mardin,A.D., Oomen,R.P., Wang,J. and Dunn,P.
TITLE Chlamydia antigens and corresponding dna fragments and uses thereof
JOURNAL Patent: WO 0136457-A 4 25-MAY-2001;
Aventis Pasteur Limited (CA)
FEATURES Location/Qualifiers
source 1. .37
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="3' PCR primer"

ORIGIN
Query Match 34.5%; Score 15.2; DB 6; Length 37;
Best Local Similarity 71.4%; Pred. No. 2.2e+05;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 CGGATCCGCTCTTAAATACCGGT 29
|||||
5 CGGATCCGCTCTTAAATACCGGT 32

RESULT 13
LOCUS AX081593 47 bp DNA linear PAT 27-FEB-2001
DEFINITION Sequence 98 from Patent WO0109350.
ACCESSION AX081593
VERSION AX081593.1 GI:13170418
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Berthet,F.X., Dalemans,W.L., Denoel,P., Deguesne,G.S., Feron,C.S.,
Lobet,Y.S., Poolman,J.S., Thiry,G.S., Ihonnard,J.S. and Voet,P.S.
TITLE Genetically engineered b1eb vaccine
JOURNAL Patent: WO 0109350-A 98 08-FEB-2001;
SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE)
FEATURES Location/Qualifiers
source 1. .47
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PNS4 primer"

ORIGIN

Query Match 34.5%; Score 15.2; DB 6; Length 47;
Best Local Similarity 71.4%; Pred. No. 2.2e+05;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 17 CTTAATACCGGTCGGTATTAGAA 44
41 CATATTTCCGACGCGTTAATTAAGA 14

RESULT 14
LOCUS AX374774 47 bp DNA linear PAT 01-MAR-2002
DEFINITION Sequence 98 from Patent WO209746.
ACCESSION AX374774
VERSION AX374774.1 GI:19169676
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 other sequences; artificial sequences.

AUTHORS Berthet, J.G., Dalemans, W.G., Denoel, P.G., Deguesne, G.G.,
Reton, C.G., Garcon, N.G., Lobet, Y.G., Poolman, J.G., Thiry, G.G.,
Thomard, J.G., and Voet, P.G.
TITLE Vaccine composition
JOURNAL Patent: WO 0209746-A 98 07-FEB-2002;
SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE)

FEATURES
SOURCE location/Qualifiers
1. .47
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PMS4 primer"

ORIGIN

Query Match 34.5%; Score 15.2; DB 6; Length 47;
Best Local Similarity 71.4%; Pred. No. 2.2e+05;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 17 CTTAATACCGGTCGGTATTAGAA 44
41 CATATTTCCGACGCGTTAATTAAGA 14

RESULT 15
LOCUS AX248444 31 bp DNA linear PAT 28-SEP-2001
DEFINITION Sequence 523 from Patent WO0166800.
ACCESSION AX248444
VERSION AX248444.1 GI:15863067
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Cargill, M., Ireland, J.S. and Lander, E.S.
TITLE Human single nucleotide polymorphisms
JOURNAL Patent: WO 0166800-A 523 13-SEP-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US)

FEATURES
SOURCE location/Qualifiers
1. .31
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 34.1%; Score 15; DB 6; Length 31;
Best Local Similarity 73.3%; Pred. No. 2.7e+05;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 12 TCCTTCTTAATACCGGTCGGC 34

Db 29 TCTTTCTTAATGACCTGCGGG 7

RESULT 16
LOCUS MMU41925 50 bp DNA linear ROD 05-JAN-1996
DEFINITION Mus musculus recombination between immunoglobulin heavy chain and
C-myc.
ACCESSION U41925
VERSION U41925
KEYWORDS U41925.1 GI:1147659
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS Muller, J.R.
TITLE Direct Submission
JOURNAL Submitted (05-DEC-1995) Jurgen R. Muller, Lab of Genetics, NIH/NCI,
Bldg. 37, Room 2B09, 37 Convent Dr., Bethesda, MD 20892-4255, USA

FEATURES
SOURCE location/Qualifiers
1. .50
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="BALB/cAn"
/db_xref="taxon:10090"
/chromosome="12(15)"
/map="1(12F1,15d2)"
/tissue_type="oil granuloma 7 days post pristane"
/dev_stage="7 days post pristane"

ORIGIN

Query Match 34.1%; Score 15; DB 10; Length 50;
Best Local Similarity 67.7%; Pred. No. 2.7e+05;
Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 4 GGTCCGTCCTTCTTAATACCGGTCGG 34
11 GGCACAGTCCTTCTGACTTACCACTCTC 41

RESULT 17
LOCUS AX582316 31 bp DNA linear PAT 10-JAN-2003
DEFINITION Sequence 4154 from Patent WO0211674.
ACCESSION AX582316
VERSION AX582316.1 GI:27654126
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 other sequences; artificial sequences.
AUTHORS Thompson, J., Mcwigsen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 4154 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)

FEATURES
SOURCE location/Qualifiers
1. .31
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Enzymatic Nucleic Acid"

ORIGIN

Query Match 33.6%; Score 14.8; DB 6; Length 31;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 5 GTCCGTCCTTCTTAATACCGGTC 30

|||||
Db 30 GTCCGTTCTGTTAGTACGCCCGTC 5

RESULT 18
103806/c 33 bp DNA linear PAT 02-DEC-1994

LOCUS Sequence 9 from Patent EP 0055942.
ACCESSION 103806
VERSION 103806.1 GI:592012

KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 33)
AUTHORS Inouye,M. and Nakamura,K.
TITLE Plasmid cloning vehicles
JOURNAL Patent: EP 0055942-A2 9 14-JUL-1982;
FEATURES Location/Qualifiers
1..33
source /organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 33.6%; Score 14.8; DB 6; Length 33;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 6 TCCGCTTCTTATTAACCGGTGCG 31
29 TCCCTTCATTATTAATACCTCTAG 4

RESULT 19
AR429930 36 bp DNA linear PAT 18-DEC-2003

LOCUS Sequence 40 from patent US 6645765.
ACCESSION AR429930
VERSION AR429930.1 GI:40190357

KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 36)
AUTHORS Anderson,H.M., Chay,C.A., Chen,G. and Conner,T.W.
TITLE Plant regulatory sequences for control of gene expression
JOURNAL Patent: US 6645765-A 40 11-NOV-2003;
FEATURES Location/Qualifiers
1..36
source /organism="unknown"
/mol_type="genomic DNA"

ORIGIN

Query Match 33.6%; Score 14.8; DB 6; Length 36;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTATTAACCGGTGCGG 34
6 CTTTCTTCTCACTCAGCGGTTCGG 31

Db 6 CTTTCTTCTCACTCAGCGGTTCGG 31

RESULT 20
AX099684 36 bp DNA linear PAT 02-APR-2001

LOCUS Sequence 40 from Patent WO0119976.
ACCESSION AX099684
VERSION AX099684.1 GI:13538738

KEYWORDS

SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE other sequences; artificial sequences.
1

AUTHORS Anderson,H.M., Chay,C.A., Chen,G. and Conner,T.W.
TITLE Plant regulatory sequences for control of gene expression
JOURNAL Patent: WO 0119976-A 40 22-MAR-2001;
FEATURES Location/Qualifiers
1..36
source /organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"

ORIGIN

Query Match 33.6%; Score 14.8; DB 6; Length 36;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTATTAACCGGTGCGG 34
6 CTTTCTTCTCACTCAGCGGTTCGG 31

Db 6 CTTTCTTCTCACTCAGCGGTTCGG 31

RESULT 21
103802/c 37 bp DNA linear PAT 02-DEC-1994

LOCUS Sequence 5 from Patent EP 0055942.
ACCESSION 103802
VERSION 103802.1 GI:592010

KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 37)
AUTHORS Inouye,M. and Nakamura,K.
TITLE Plasmid cloning vehicles
JOURNAL Patent: EP 0055942-A2 5 14-JUL-1982;
FEATURES Location/Qualifiers
1..37
source /organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 33.6%; Score 14.8; DB 6; Length 37;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 6 TCCGCTTCTTCTTATTAACCGGTGCG 31
29 TCCCTTCATTATTAATACCTCTAG 4

Db 29 TCCCTTCATTATTAATACCTCTAG 4

RESULT 22
AR288505/c 47 bp DNA linear PAT 12-JUN-2003

LOCUS Sequence 240 from patent US 6537751.
ACCESSION AR288505
VERSION AR288505.1 GI:31675789

KEYWORDS

SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 47)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 240 25-MAR-2003;
FEATURES Location/Qualifiers
1..47
source /organism="unknown"
/mol_type="genomic DNA"

ORIGIN

Query Match 33.6%; Score 14.8; DB 6; Length 47;
Best Local Similarity 61.1%; Pred. No. 3.3e+05;

Matches 22; Conservative 1; Mismatches 13; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATACCGGTCGGTATTATTAAGA 44
Db 46 CATTAAATTTAATACATGCTCCTGTTTGAAGAAA 11

RESULT 23
LOCUS AR289990 47 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 1725 from patent US 6537751.
ACCESSION AR289990
VERSION AR289990.1 GI:31677274
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 47)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
JOURNAL disequilibrium map of the human genome
FEATURES Patent: US 6537751-A 1725 25-MAR-2003;
Location/Qualifiers
source 1..47
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 47;
Best Local Similarity 59.5%; Pred. No. 3.3e+05;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 3 GGGTCCCGCTCTCTTATTAACCGGTCGGTATTATTAAGA 44
Db 46 GGTCCCATCTCTCTTATTAATTAAGACCACTTAATTAATA 5

RESULT 24
LOCUS AR032973 50 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 585 from patent US 5869241.
ACCESSION AR032973
VERSION AR032973.1 GI:5948578
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 50)
TITLE Edwards,C.A., Cantor,C.R., Andrews,B.M., Turin,L.M. and Fry,K.E.
JOURNAL Method of determining DNA sequence preference of a DNA-binding
FEATURES molecule
Patent: US 5869241-A 585 09-FEB-1999;
Location/Qualifiers
source 1..50
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 50;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCCTTCTTAATACCGGTCGGGTT 36
Db 27 TGCCTTTATCTACACCGGTTTCGGTT 2

RESULT 25
LOCUS I29713 50 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 585 from patent US 5578444.
ACCESSION I29713
VERSION I29713.1 GI:1820504

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 50)
TITLE Edwards,C.A., Cantor,C.R., Andrews,B.M., Turin,L.M. and Fry,K.E.
JOURNAL Sequence-directed DNA-binding molecules compositions and methods
FEATURES Patent: US 5578444-A 585 26-NOV-1996;
Location/Qualifiers
source 1..50
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 50;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCCTTCTTAATACCGGTCGGGTT 36
Db 27 TGCCTTTATCTACACCGGTTTCGGTT 2

RESULT 26
LOCUS I91387 50 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 585 from patent US 5726014.
ACCESSION I91387
VERSION I91387.1 GI:3935857
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 50)
TITLE Edwards,C.A., Cantor,C.R., Andrews,B.M. and Turin,L.M.
JOURNAL Screening assay for the detection of DNA-binding molecules
FEATURES Patent: US 5726014-A 585 10-MAR-1998;
Location/Qualifiers
source 1..50
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 50;
Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCCTTCTTAATACCGGTCGGGTT 36
Db 27 TGCCTTTATCTACACCGGTTTCGGTT 2

RESULT 27
LOCUS AR209637 50 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 585 from patent US 6384208.
ACCESSION AR209637
VERSION AR209637.1 GI:21511114
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 50)
TITLE Edwards,C.A., Cantor,C.R., Andrews,B.M., Turin,L.M. and Fry,K.E.
JOURNAL Sequence directed DNA binding molecules compositions and methods
FEATURES Patent: US 6384208-A 585 07-MAY-2002;
Location/Qualifiers
source 1..50
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 33.6%; Score 14.8; DB 6; Length 50;

Best Local Similarity 73.1%; Pred. No. 3.3e+05;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCTCTTAATACCGGTCGGGTT 36
27 TGCTTTATACTACCGGTTCCGGT 2

Db

RESULT 28
LOCUS CO868809 32 bp DNA linear PAT 13-SEP-2004
DEFINITION Sequence 20 from Patent WO2004073728.
ACCESSION CO868809
VERSION CO868809.1 GI:51998743
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 other sequences; artificial sequences.
AUTHORS Westphal,O., Waelli,T., Gorczynski,R., Mueller,S., Mach,J.P.,
Hattmann,A., Bessler,W., Hofmann,P., Zaehringer,U., Alexander,C.,
vor dem Esche,U., Uimer,A. and Verdini,A.
TITLE Compositions comprising fetal hemoglobin and bacterial endotoxin
and optionally additional fetal liver components
JOURNAL Patent: WO 2004073728-A 20 02-SEP-2004;
Clinique La Prairie Research SA (LU)
FEATURES Location/Qualifiers
source 1..32
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

ORIGIN
Query Match 33.2%; Score 14.6; DB 6; Length 32;
Best Local Similarity 81.0%; Pred. No. 4.1e+05;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 19 TAATPACCGGTCGGGTTAATT 39
1 TAATPACCGGTTAGGTCATT 21

Db

RESULT 29
LOCUS AR365650 33 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 17 from patent US 5519127.
ACCESSION AR365650
VERSION AR365650.1 GI:34429562
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 Unclassified.
AUTHORS 1 (bases 1 to 33)
Shah,J., Buharin,A. and Lane,D.J.
TITLE Nucleic acid probes for the detection of Pneumocystis carinii
JOURNAL Patent: US 5519127-A 17 21-MAY-1996;
FEATURES Location/Qualifiers
source 1..33
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 33.2%; Score 14.6; DB 6; Length 33;
Best Local Similarity 81.0%; Pred. No. 4.1e+05;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATACCGGT 29
4 CCTTCCTTCTGATATACCGGT 24

Db

RESULT 30
LOCUS AR365637/c

LOCUS AR365637 34 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 4 from patent US 5519127.
ACCESSION AR365637
VERSION AR365637.1 GI:34429549
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 Unclassified.
AUTHORS 1 (bases 1 to 34)
Shah,J., Buharin,A. and Lane,D.J.
TITLE Nucleic acid probes for the detection of Pneumocystis carinii
JOURNAL Patent: US 5519127-A 4 21-MAY-1996;
FEATURES Location/Qualifiers
source 1..34
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 33.2%; Score 14.6; DB 6; Length 34;
Best Local Similarity 81.0%; Pred. No. 4.1e+05;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATACCGGT 29
31 CCTTCCTTCTGATATACCGGT 11

Db

RESULT 31
LOCUS AX739899/c 35 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 7 from Patent WO03025016.
ACCESSION AX739899
VERSION AX739899.1 GI:30519182
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 other sequences; artificial sequences.
AUTHORS 1
Dawbarn,D., Allen,S.J. and Robertson,A.G.
TITLE Polypeptide purification method
JOURNAL Patent: WO 03025016-A 7 27-MAR-2003;
The University of Bristol (GB)
FEATURES Location/Qualifiers
source 1..35
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

ORIGIN
Query Match 33.2%; Score 14.6; DB 6; Length 35;
Best Local Similarity 73.9%; Pred. No. 4.1e+05;
Matches 17; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy 21 ATAACCGGTCGGGTTATTAGA 43
32 AAACCGGTCGGGTCATTATA 10

Db

RESULT 32
LOCUS AR365666 39 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 33 from patent US 5519127.
ACCESSION AR365666
VERSION AR365666.1 GI:34429578
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 Unclassified.
AUTHORS 1 (bases 1 to 39)
Shah,J., Buharin,A. and Lane,D.J.
TITLE Nucleic acid probes for the detection of Pneumocystis carinii
JOURNAL Patent: US 5519127-A 33 21-MAY-1996;
FEATURES Location/Qualifiers

ACCESSION BD061913
VERSION BD061913.1 GI:22607518
KEYWORDS JP 2001517091-A/247.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 32)
AUTHORS Chow,T.P., Fry,K.E., Lim,M.Y. and Mcatee,C.P.
TITLE Antigenic composition and method of detection for Helicobacter
JOURNAL Patent: JP 2001517091-A 247 02-OCT-2001;
GENELABS TECHNOLOGIES INC
COMMENT PN JP 2001517091-A/247
PD 02-OCT-2001
PF 25-APR-1998 JP 1998547263
PR 25-APR-1997 US 60/045107,14-OCT-1997 US 60/061958 PI
THERESA P CHOW KIRK B FRY, MOON Y LIM, C P MCATEE PC
C12N15/31,C07K14/205,C07K16/12,A61K39/106
CC Strandedness: Single;
Topology: Linear;
FH Key Location/Qualifiers.
FEATURES
source 1..32
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
ORIGIN
Query Match 32.7%; Score 14.4; DB 6; Length 32;
Best Local Similarity 75.0%; Pred. No. 5e+05; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 6;
Qy 1 GCGGATCCGCTTCTTTAATAA 24
Db 4 GCGATCCCATTCACCTATATAA 27
RESULT 38
AX574343 34 bp DNA linear PAT 07-JAN-2003
LOCUS AX574343
DEFINITION Sequence 7 from Patent WO0250545.
ACCESSION AX574343
VERSION AX574343.1 GI:27551693
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Pelletier,J., Gros,P. and Dubow,M.
TITLE Compositions and methods involving Staphylococcus aureus protein
JOURNAL steau-19
Patent: WO 0250545-A 7 27-JUN-2002;
Phagotech Inc. (CA)
FEATURES
source 1..34
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="synthetic oligonucleotide"
ORIGIN
Query Match 32.7%; Score 14.4; DB 6; Length 34;
Best Local Similarity 75.0%; Pred. No. 5e+05; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 6;
Qy 1 GCGGATCCGCTTCTTTAATAA 24
Db 2 GCGATCCCATTCCTTTTCAATTA 25
RESULT 39
BD235752 40 bp DNA linear PAT 17-JUL-2003
LOCUS BD235752
DEFINITION Strengthened functional expression of heterogenous G

protein-coupled receptor.
ACCESSION BD235752
VERSION BD235752.1 GI:33045522
KEYWORDS JP 2002523090-A/5.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 40)
AUTHORS Pausch,M.H., Lai,M., Silverman,S., Birsan,C., Baumbauch,W.,
Teeng,E., Kajakowski,E.M. and Ozenberger,B.A.
TITLE Strengthened functional expression of heterogenous G
JOURNAL Protein-coupled receptor
Patent: JP 2002523090-A 5 30-JUL-2002;
BASF AG
COMMENT OS Artificial Sequence
PN JP 2002523090-A/5
PD 30-JUL-2002
PF 01-SEP-1998 JP 2000567691
PR 01-SEP-1998 US 60/098704
PI MARK HENRY PAUSCH,MARGARET LAI,SANFORD SILVERMAN,CAMELIA PI
BIRSAN,
PI WILLIAM BAUMBAUCH,EUGENE TSENG,EILEEN MARIE KAJKOWSKI, PI
BRADLEY ALTON OZENBERGER
PC C12N1/19,C07K14/72,C12N15/09,C12P21/02,C12Q1/02,G01N33/15, PC
G01N33/50,
PC G01N33/566/(C12N1/19,C12R1:865),(C12P21/02,C12R1:865),C12N15/
PC 00
CC Description of Artificial Sequence:oligonucleotide FH Key
FH source 1..40
Location/Qualifiers
/organism="Artificial Sequence".
FEATURES
source 1..40
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
ORIGIN
Query Match 32.7%; Score 14.4; DB 6; Length 40;
Best Local Similarity 65.6%; Pred. No. 5e+05; Indels 11; Gaps 0;
Matches 21; Conservative 0; Mismatches 11;
Qy 9 CGTTCCTTTAATACCGGTCGGGTATTA 40
Db 5 CGTGCCTTTACTTACCGGTACCATCATGA 36
RESULT 40
BD235803 40 bp DNA linear PAT 17-JUL-2003
LOCUS BD235803
DEFINITION Method of modifying function of heterogenous G protein-coupled
receptor.
ACCESSION BD235803
VERSION BD235803.1 GI:33045573
KEYWORDS JP 2002523091-A/5.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 40)
AUTHORS Pausch,M.H. and Wees,J.
TITLE Method of modifying function of heterogenous G protein-coupled
JOURNAL Patent: JP 2002523091-A 5 30-JUL-2002;
BASF AG
COMMENT OS Artificial Sequence
PN JP 2002523091-A/5
PD 30-JUL-2002
PF 01-SEP-1998 JP 2000567692
PR 01-SEP-1998 US 60/098704
PI MARK HENRY PAUSCH,JURGEN WEES
PC C12N15/09,C07K14/72,C12N1/19,C12Q1/02,G01N33/15,G01N33/50, PC
G01N33/566,
PC G01N33/58/(C12N1/19,C12R1:865),C12N15/00
CC Description of Artificial Sequence:oligonucleotide FH Key

This Page Blank (usps)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 08:29:04 ; Search time 258 Seconds
(without alignment)
1009.568 Million cell updates/sec

Title: US-10-673-063-3_COPY_900_943

Perfect score: 1 gcgggtccgcgtccctctta.....ccggtcgcggtatttaagaa 44

Sequence: 1 gcgggtccgcgtccctctta.....ccggtcgcggtatttaagaa 44

Scoring table: IDENTITY NUC
Gapop 10'-0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

4167226

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : N_Geneseq_16Dec04:*

1: geneseq1980s:*\n2: geneseq1990s:*\n3: geneseq2000s:*\n4: geneseq2001as:*\n5: geneseq2001bs:*\n6: geneseq2002as:*\n7: geneseq2002bs:*\n8: geneseq2003as:*\n9: geneseq2003bs:*\n10: geneseq2003cs:*\n11: geneseq2003ds:*\n12: geneseq2004as:*\n13: geneseq2004bs:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	17.4	39.5	39	13	AdS87007 PCR prime
2	16.2	36.8	32	6	AA143407 SIMK muta
3	16	36.4	27	6	AA520859 Gene-spec
4	16	36.4	27	6	AA520860 Gene-spec
5	16	36.4	33	12	AdB85746
6	16	36.4	33	12	AdL27336 BphA2 inv
7	15.8	35.9	45	2	AAQ87806 Primer us
8	15.6	35.5	33	6	ABK89998 Human hea
9	15.4	35.0	34	2	AA527543 C. Pneumo
10	15.2	34.5	37	5	AA527543 Staphyloc
11	15.2	34.5	38	9	AdB81046 LINE retr
12	15.2	34.5	47	3	AA265893 Human map
13	15.2	34.5	47	4	AA591472 N. mening
14	15.2	34.5	47	4	ABK37852 PCMK(+)-C
15	15.2	34.1	31	4	AA130035 Human sin
16	15	34.1	47	3	AA269059 Human map
17	15	34.1	50	6	AB202614 Human leu
18	15	34.1	50	6	AB207725 Human leu
19	14.8	33.6	31	6	ABK59783 Human CTC
20	14.8	33.6	36	4	AA581443 PCR prime

21	14.8	33.6	39	6	AA243960	Ad443960 DI228 oli
22	14.8	33.6	47	3	AA267378	AA267378 Human map
23	14.8	33.6	50	2	AAQ69835	AAQ69835 Human pap
24	14.8	33.6	50	2	AA264297	AA264297 HPV type
25	14.8	33.6	50	2	AA517585	AA517585 Test sequ
26	14.8	33.6	50	6	ABK93076	ABK93076 DNA bindi
27	14.8	33.6	50	6	AB202818	AB202818 Human leu
28	14.8	33.6	50	12	AD80615	AD80615 Duplex ol
29	14.8	33.6	50	13	AD591869	AD591869 Nematode
30	14.6	33.2	25	9	AC197514	AC197514 Human mic
31	14.6	33.2	34	2	AAQ10823	AAQ10823 Pneumocys
32	14.6	33.2	34	2	AA242447	AA242447 Probe 148
33	14.6	33.2	35	10	AD135720	AD135720 Human tyr
34	14.6	33.2	38	2	AAV06323	AAV06323 Human Col
35	14.6	33.2	41	6	AB247662	AB247662 Human ATP
36	14.6	33.2	41	6	AB245067	AB245067 Human ATP
37	14.6	33.2	41	12	ADL60971	ADL60971 Human org
38	14.6	33.2	45	6	ABN84317	ABN84317 Rhinoviru
39	14.6	33.2	47	12	AD018016	AD018016 Primer of
40	14.6	33.2	47	12	AD018088	AD018088 Primer of
41	14.4	32.7	20	6	ABQ93060	ABQ93060 T. tausch
42	14.4	32.7	25	9	AC188894	AC188894 Human mic
43	14.4	32.7	29	10	ADK65726	ADK65726 Glucokina
44	14.4	32.7	29	10	ADL09096	ADL09096 Staphyloc
45	14.4	32.7	32	2	AAV90788	AAV90788 Primer Y1
46	14.4	32.7	34	6	ABK87091	ABK87091 S. aureus
47	14.4	32.7	40	3	AA294303	AA294303 Rat M3 mu
48	14.4	32.7	40	3	AA518580	AA518580 Rat musca
49	14.4	32.7	41	12	ADL60971	ADL60971 Human org
50	14.4	32.7	47	3	AA266643	AA266643 Human map
51	14.4	32.7	50	5	AA266643	AA266643 SIV gene
52	14.4	32.7	50	10	ADL31889	ADL31889 Butterfly
53	14.4	32.7	50	10	ADL31920	ADL31920 Human ret
54	14.4	32.3	20	8	AA267393	AA267393 Primer us
55	14.2	32.3	20	8	AB281133	AB281133 Dual spec
56	14.2	32.3	25	6	AB292866	AB292866 Human eos
57	14.2	32.3	25	6	ABV75348	ABV75348 Human BCP
58	14.2	32.3	31	6	AB222006	AB222006 Helicobac
59	14.2	32.3	31	6	AB222037	AB222037 Helicobac
60	14.2	32.3	32	12	ADL70702	ADL70702 Human tra
61	14.2	32.3	33	6	AAH77221	AAH77221 Becherich
62	14.2	32.3	33	13	AD573809	AD573809 E. coli n
63	14.2	32.3	34	2	AAV33572	AAV33572 Leukocyte
64	14.2	32.3	36	2	AAQ62183	AAQ62183 Tryptoph
65	14.2	32.3	36	2	AAQ61847	AAQ61847 PDI promo
66	14.2	32.3	38	3	AAZ43342	AAZ43342 Mutine ty
67	14.2	32.3	38	3	AA505327	AA505327 PCR prime
68	14.2	32.3	39	10	ADP54788	ADP54788 Influenza
69	14.2	32.3	41	6	ABL40260	ABL40260 Human pro
70	14.2	32.3	41	10	AD53158	AD53158 Thernus t
71	14.2	32.3	45	6	AA146572	AA146572 Human PAP
72	14.2	32.3	45	6	AA146580	AA146580 Human PAP
73	14.2	32.3	48	10	ACF04958	ACF04958 Hair papi
74	14.2	32.3	49	5	ABAI0693	ABAI0693 Tail adap
75	14.2	32.3	50	4	AAH90534	AAH90534 Human clo
76	14.2	32.3	50	6	AB204787	AB204787 Human leu
77	14.2	32.3	50	10	ADG33460	ADG33460 Human DNA
78	14.2	32.3	50	12	ADH74736	ADH74736 LIC Cloni
79	14.2	32.3	24	4	AAQ24974	AAQ24974 PCR prime
80	14	31.8	24	4	AAQ09446	AAQ09446 Sense PCR
81	14	31.8	30	4	AAH84364	AAH84364 Human cel
82	14	31.8	32	3	AAZ36904	AAZ36904 PCR prime
83	14	31.8	35	3	AAZ36906	AAZ36906 PCR prime
84	14	31.8	38	2	AAV34694	AAV34694 TRK2 gene
85	14	31.8	38	2	AAZ31019	AAZ31019 Upstream
86	14	31.8	38	2	AA54760	AA54760 PCR prime
87	14	31.8	38	10	AA562934	AA562934 S. aureus
88	14	31.8	41	2	AAV85621	AAV85621 LRP5 exon
89	14	31.8	42	11	ADM79708	ADM79708 Group B S
90	14	31.8	45	10	ACCT8190	ACCT8190 DNA seque
91	14	31.8	47	2	AAQ69500	AAQ69500 Human nuc
92	14	31.8	47	2	AA263962	AA263962 Human nuc
93	14	31.8	47	2	AA263962	AA263962 Human nuc

94 14 31.8 47 2 AAX17250 Test sequ
95 14 31.8 47 6 ABR82741 DNA bindi
96 14 31.8 47 12 ADE80280
c 97 13.8 31.4 24 6 ABQ07869
c 98 13.8 31.4 24 6 ABQ01975
c 99 13.8 31.4 24 6 ABQ07910
c 100 13.8 31.4 25 4 AAH38015
AAH38015 SNP spect

ALIGNMENTS

RESULT 1

ADs87007/c
ID ADs87007 standard; DNA; 39 BP.

AC ADs87007;

DT 18-NOV-2004 (first entry)

DE PCR primer 1 used to amplify murine TRP-2 cDNA.

KW vaccine; ubiquitin; Ub; T-cell target; melanoma; sarcoma;
KW Hodgkins lymphoma; non-Hodgkins; leukaemia; neuroblastoma; myeloma;
KW lung cancer; stomach; skin; thyroid; ovary; prostate; womb; pancreas;
KW colon; bladder; breast; oesophagus; kidney; brain; mouse; murine; ss;
KW PCR; primer; TRP-2.

OS Mus sp.

XX WO2004035085-A1.

FN 29-APR-2004.

PD 16-OCT-2003; 2003WO-JP013279.

PF 17-OCT-2002; 2002JP-00302816.

XX (KYUS-) KYUSHU TLO CO LTD.

PI Himeno K, Furue M, Maehara Y;

XX WPI; 2004-357144/33.

PT Gene vaccine containing cancer antigen genes ligated to ubiquitin genes
or cytokine genes for prevention and treatment of cancer.

PS Example 6; SEQ ID NO 23; 266pp; Japanese.

XX The invention relates to a novel genetic vaccine containing the ubiquitin
CC gene together with a gene encoding an antigenic protein containing a T-
CC cell target sequence. The vaccine of the invention may be useful for
CC prevention and treatment of cancers including melanoma, sarcoma, lymphoma
CC (Hodgkins or non-Hodgkins), leukaemia, neuroblastoma, myeloma and cancer
CC of the lung, stomach, skin, thyroid, ovary, prostate, womb, pancreas,
CC colon, bladder, breast, oesophagus, kidney or brain. The current sequence
CC is that of a genetic vaccine/ubiquitin (Ub)-related PCR primer of the
CC invention.

XX Sequence 39 BP; 11 A; 10 C; 12 G; 6 T; 0 U; 0 Other;

Query Match 39.5%; Score 17.4; DB 13; Length 39;

Best Local Similarity 68.6%; Pred. No. 1.4e+03;

Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 5 GTCCGCTTCCTTAAATACCGGTGCGGTTATT 39

DB 36 GGCCCATGCTCTTAATTGGCGCGCTTGATT 2

RESULT 2

AA143407/c
ID AA143407 standard; DNA; 32 BP.

XX AA143407;

AC 02-SEP-2002 (first entry)

DT SIMK mutagenic PCR primer (SIMKLOF).

XX Salt stress-induced mitogen activated-protein kinase kinase; SIMK; ss;
KW stress tolerance; salt tolerance; plant cell; PCR; primer; SIMK; SIMKLOF.

XX Undifferent.

OS Synthetic.

XX WO200238745-A2.

FN 16-MAY-2002.

PD 06-NOV-2001; 2001WO-EP012800.

PP 07-NOV-2000; 2000AT-00001880.

XX (OSTP) OESTERR FORSCH SEIBERSDORF.

PI Meeklene I, Hirt H, Jonak C;

XX WPI; 2002-490077/52.

PT Salt stress-induced mitogen-activated protein kinase, useful for
improving stress tolerance, especially salt tolerance in eukaryotic
cells, particularly in plant cells.

PS Example; Page 17; 42pp; English.

XX The invention comprises the amino acid and coding sequence of a salt
CC stress-induced mitogen-activated protein kinase kinase (SIMK). The SIMK
CC DNA and protein sequences of the invention are useful for improving
CC stress tolerance (i.e. salt tolerance) in eukaryotic cells - particularly
CC in plant cells. The present DNA sequence represents a stress-induced
CC mitogen-activated protein kinase (SIMK) mutagenic PCR primer
XX

XX Sequence 32 BP; 8 A; 9 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 36.8%; Score 16.2; DB 6; Length 32;

Best Local Similarity 85.7%; Pred. No. 4.4e+03;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 23 AACCGTCCGGTATTAGAGA 43

DB 31 AACATGTCGCGGTTATGAGA 11

AA520859/c

ID AA520859 standard; DNA; 27 BP.

AC AA520859;

DT 09-APR-2002 (first entry)

DE Gene-specific PCR primer Z-ST-P18 for cloning Z. marina sulfotransferase.

XX Plant; transgenic; marine eelgrass; zosteric acid biosynthesis;
KW saline-resistance; anoxia-resistance; anti-fouling genetic trait;
KW marine vascular plant; sulphated phenolic compound; Zostera marina;
KW sulfotransferase; ST; enzyme; PCR; primer; ss.

OS Zostera marina.

XX WO200185971-A2.

PN 15-NOV-2001.

XX 10-MAY-2001; 2001WO-US015412.

XX 10-MAY-2000; 2000US-0202529P.
XX (PHYC-) PHYCOGEN INC.
XX Alberce RS, Smith RD;
XX WPI; 2002-121947/16.
XX
XX New transgenic plants comprising a zosteric acid biosynthetic gene, a
XX saline resistance gene or a hypoxia resistance gene derived from *Zostera*
XX marina, useful for producing plants with antifouling traits.
XX
XX Example; Fig 3; 117pp; English.
XX
XX The present invention relates to a new transgenic plant comprising a
XX heterologous gene derived from the marine eelgrass *Zostera marina* or at
XX least one heterologous nucleotide sequence encoding a zosteric acid
XX biosynthetic function, a saline-resistance function, or a anoxia-
XX transgenic plant possessing an anti-fouling genetic trait by providing a
XX cDNA population derived from a marine vascular plant, isolating from the
XX cDNA population a nucleic acid species which hybridises to a nucleic acid
XX that encodes a sulfoltransferase (ST), an alcohol dehydrogenase (ADH), and
XX phenylalanine ammonia lyase (PAL) or a cinnamate-4-hydroxylase (CH), and
XX transforming a target host plant with the isolated nucleic acid. The
XX plant is useful in the genetic engineering of plant species having
XX desirable genetic traits such as antifouling traits, salt and anoxia
XX resistance, and pathogen defence strategy. The expression of such
XX biosynthetic enzymes are sufficient to support the production of zosteric
XX acid and other sulphated phenolic compounds in a target plant. AAS20856-
XX AAS20862 represent degenerate or gene-specific PCR primers for cloning *Z.*
XX marina sulfoltransferase
XX
SQ Sequence 27 BP; 8 A; 6 C; 5 G; 8 T; 0 U; 0 Other;
Query Match 36.4%; Score 16; DB 6; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.2e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
CY 20 AATAACGGTGGCGTTATTAGA 43
DB 25 AATAACTTGTGGGGTTATCAGA 2
RESULT 4
AAS20860
ID AAS20860 standard; DNA; 27 BP.
XX
XX AAS20860;
XX
XX 09-APR-2002 (first entry)
XX
XX Gene-specific PCR primer Z-ST-P19 for cloning *Z. marina* sulfoltransferase.
XX
XX Plant; transgenic; marine eelgrass; zosteric acid biosynthesis;
XX saline-resistance; anoxia-resistance; anti-fouling genetic trait;
XX marine vascular plant; sulphated phenolic compound; *Zostera marina*;
XX sulfoltransferase; ST; enzyme; PCR; primer; ss.
XX
XX *Zostera marina*.
XX
XX WO200185971-A2.
XX
XX 15-NOV-2001.
XX
XX 10-MAY-2001; 2001WO-US015412.
XX
XX 10-MAY-2000; 2000US-0202529P.
XX
XX (PHYC-) PHYCOGEN INC.
XX
XX Alberce RS, Smith RD;
XX
PI

XX WPI; 2002-121947/16.
XX
XX New transgenic plants comprising a zosteric acid biosynthetic gene, a
XX saline resistance gene or a hypoxia resistance gene derived from *Zostera*
XX marina, useful for producing plants with antifouling traits.
XX
XX Example; Fig 3; 117pp; English.
XX
XX The present invention relates to a new transgenic plant comprising a
XX heterologous gene derived from the marine eelgrass *Zostera marina* or at
XX least one heterologous nucleotide sequence encoding a zosteric acid
XX biosynthetic function, a saline-resistance function, or a anoxia-
XX transgenic plant possessing an anti-fouling genetic trait by providing a
XX cDNA population derived from a marine vascular plant, isolating from the
XX cDNA population a nucleic acid species which hybridises to a nucleic acid
XX that encodes a sulfoltransferase (ST), an alcohol dehydrogenase (ADH), and
XX phenylalanine ammonia lyase (PAL) or a cinnamate-4-hydroxylase (CH), and
XX transforming a target host plant with the isolated nucleic acid. The
XX plant is useful in the genetic engineering of plant species having
XX desirable genetic traits such as antifouling traits, salt and anoxia
XX resistance, and pathogen defence strategy. The expression of such
XX biosynthetic enzymes are sufficient to support the production of zosteric
XX acid and other sulphated phenolic compounds in a target plant. AAS20856-
XX AAS20862 represent degenerate or gene-specific PCR primers for cloning *Z.*
XX marina sulfoltransferase
XX
SQ Sequence 27 BP; 8 A; 5 C; 6 G; 8 T; 0 U; 0 Other;
Query Match 36.4%; Score 16; DB 6; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.2e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
CY 20 AATAACGGTGGCGTTATTAGA 43
DB 3 AATAACTTGTGGGGTTATCAGA 26
RESULT 5
ADE85746
ID ADE85746 standard; DNA; 30 BP.
XX
XX ADE85746;
XX
XX 12-FEB-2004 (first entry)
XX
XX BphA2 inverted antisense oligonucleotide control SEQ ID NO:50.
XX
XX cancer; hyperproliferative cell disease; BphA2 antibody;
XX BphA2 agonistic antibody; cytostatic; antiproliferative;
XX antiinflammatory; vasotropic; respiratory; gene therapy;
XX metastatic cancer; asthma; psoriasis; inflammatory bowel disease;
XX smooth muscle restenosis; endothelial restenosis; Crohn's disease;
XX chronic obstructive pulmonary disease; human; control; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX WO2003094859-A2.
XX
XX 20-NOV-2003.
XX
XX 12-MAY-2003; 2003WO-US015044.
XX
XX 10-MAY-2002; 2002US-0379322P.
XX
XX 14-OCT-2002; 2002US-0418213P.
XX
XX 03-APR-2003; 2003US-0460507P.
XX
XX (MEDI-) MEDIMUNE INC.
XX
XX Kinch MS, Carles-Kinch K, Kiener P, Langermann S;
XX
XX

DR WPI; 2004-012002/01.
XX Treating cancer or a non-cancer hyperproliferative cell disease (e.g.
PT asthma, psoriasis, inflammatory bowel disease or restenosis) in a patient
PT comprises administering to the patient a therapeutic amount of an EphA2
PT antibody.
XX
PS Example; SEQ ID NO 50; 173bp; English.
XX
CC The present invention describes a method for treating cancer or a non-
CC cancer hyperproliferative cell disease or disorder in a patient, which
CC comprises administering to the patient a therapeutic amount of an EphA2
CC antibody (1) that is an EphA2 agonistic antibody, an EphA2 cancer cell
CC phenotype inhibiting antibody, an exposed EphA2 epitope antibody, or an
CC antibody that binds EphA2 with a K-off of less than 3×10^{-3} s⁻¹. Also
CC described: (1) a pharmaceutical composition comprising a therapeutic
CC amount of (1) and a pharmaceutical carrier; (2) a cell line that produces
CC (1); (3) a hybridoma deposited with the ATCC accession number PTA-4572,
CC PTA-4573 or PTA-4574; (4) an isolated nucleic acid comprising a
CC nucleotide sequence encoding a light chain variable domain or a heavy
CC chain variable domain of the EphA2 antibody; (5) a vector comprising the
CC nucleic acid described above; (6) a host cell comprising the vector; (7)
CC methods of identifying the EphA2 agonistic antibody or the EphA2 antibody
CC that inhibits a cancer cell phenotype, that kills cancer cells having a
CC cancer cell phenotype or that preferentially binds an EphA2 epitope
CC exposed on cancer cells; and (8) a method of diagnosing, prognosing or
CC monitoring the efficacy of therapy for cancer in a patient known to or
CC suspected to have cancer. (1) has cytostatic, antiproliferative,
CC antiproliferative, antiinflammatory, vasotropic and respiratory activities,
CC and can be used in gene therapy. The composition and methods are useful
CC in managing, diagnosing, preventing or treating hyperproliferative cell
CC diseases (i.e., metastatic cancer) or non-cancer hyperproliferative cell
CC diseases or disorders, such as asthma, psoriasis, inflammatory bowel
CC disease, smooth muscle restenosis, endothelial restenosis, Crohn's
CC disease or chronic obstructive pulmonary disease. They may also be used
CC for monitoring the efficacy of therapy for cancer in a patient known to
CC or suspected to have cancer, and in screening for anti-cancer drugs. The
CC present sequence is used in the exemplification of the present invention.
CC
XX
SQ Sequence 30 BP; 4 A; 14 C; 6 G; 6 T; 0 U; 0 Other;
OY
DB
Query Match 36.4%; Score 16; DB 12; Length 30;
Best Local Similarity 79.2%; Pred. No. 5.3e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
OY 2 CGGGTCCGTCCTTAAATAC 25
DB 3 CGCGTCCGTCCTTACCATGAC 26
RESULT 6
ADL27336/C
XX ADL27336 standard; DNA; 33 BP.
XX AC
XX ADL27336;
XX DT
XX 03-JUN-2004 (first entry)
XX DE Forward primer for amplifying prethrombin for cloning into pSectag2A.
XX KW adzyme; catalytic domain; allergic disease; inflammatory disease;
XX KW inflammatory disorder; allergic disorder; inflammatory cytokine; PCR;
XX KW primer; ss.
XX OS Synthetic.
XX WO2004019878-A2.
XX EN
XX 11-MAR-2004.
XX PD
XX 27-AUG-2003; 2003WO-US026937.
XX PF
XX 27-AUG-2002; 2002US-0406517P.
XX PR

PR 05-NOV-2002; 2002US-0423754P.
PR 27-NOV-2002; 2002US-0430001P.
XX
XX (COMP-) COMPOUND THERAPEUTICS INC.
PA (AFEVY/) AFEVYAN N B.
XX
XX Afeyan NB, Baynes B, Dasgupta R, Lee PD, Wong GG;
XX WPI; 2004-239110/22.
XX
XX New adzyme for enzymatically altering a substrate, useful for preparing a
PT composition for treating diseases associated with a soluble or membrane
PT bound molecule, e.g., allergic or inflammatory diseases.
XX
PS Example 2; Page 143; 202pp; English.
XX
CC The specification describes an adzyme for enzymatically altering a
CC substrate. The adzyme comprises a catalytic domain that catalyzes a
CC chemical reaction converting the substrate to one or more products, and a
CC targeting group that reversibly binds with an address site on the
CC substrate or with an address site on a second molecule that occurs in
CC functional proximity to the substrate (the targeting moiety and the
CC catalytic domain are heterologous with respect to each other). The adzyme
CC is useful for preparing a composition for treating diseases associated
CC with a soluble or membrane bound molecule, e.g., allergic or inflammatory
CC disease. Adzymes of the invention can be used to treat an inflammatory or
CC allergic disorder, where the substrate of the adzyme is an inflammatory
CC cytokine. PCR primers ADL77334-ADL27341 were used in overlap/recombinant
CC PCR to assemble prethrombin(G4S)3scFvAlphahA and scHA(G4S)3prethrombin,
CC which are adzymes of the invention.
XX
SQ Sequence 33 BP; 9 A; 11 C; 8 G; 5 T; 0 U; 0 Other;
OY
DB
Query Match 36.4%; Score 16; DB 12; Length 33;
Best Local Similarity 79.2%; Pred. No. 5.4e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
OY 19 TAAATACCGTCGCGGTATTAA 42
DB 32 TACTCACTGTCGCGGTCAATTA 9
RESULT 7
AAQ87806/C
XX AAQ87806 standard; DNA; 45 BP.
XX AC
XX AAQ87806;
XX DT
XX 25-MAR-2003 (revised)
XX DT 14-NOV-1995 (first entry)
XX DE
XX Primer used to amplify IGE receptor gene mRNA.
XX KW Probe; immunoglobulin; IGE; receptor; beta; allergic disease; detection;
XX KW screening; diagnosis; ss.
XX OS Synthetic.
XX PN
XX EP649910-A1.
XX PD
XX 26-APR-1995.
XX PF
XX 21-OCT-1994; 94EP-00307751.
XX PR
XX 22-OCT-1993; 93JP-00265144.
XX PA (SOME) SUMITOMO ELECTRIC IND CO.
XX PI
XX Osogawa M, Miyabe Y, Nakata M, Ra C, Suzuki K;
XX WPI; 1995-156760/21.
XX
XX Probes for mutation(s) in beta chain gene of a high affinity IGE receptor
PT

PT - for the diagnosis of allergic disease, esp. in neonate(s).
XX
PS Example 3; Page 9; 17pp; English.
XX
CC DNA probes (See AA087799-803) having sequences identical or complementary
CC to parts of the immunoglobulin E (IgE) receptor, are used to detect genes
CC associated with allergic disease (diseases involving mutations in the
CC beta chain gene). They may be used in neonatal screening, prenatal
CC diagnosis etc. Two primers (AA087805, AA087806) were used to amplify mRNA
CC in blood samples transcribed from the IgE receptor gene to produce cDNA.
CC The cDNA is then conjugated with a probe and an IgE ligand (See AA087804)
CC which is immobilised on a support is then used to bind to probe/IgE
CC receptor gene conjugates. The probe is then eluted by a gradual rise in
CC temperature. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 45 BP; 13 A; 11 C; 11 G; 10 T; 0 U; 0 Other;
Query Match 35.9%; Score 15.8; DB 2; Length 45;
Best Local Similarity 74.1%; Pred. No. 6.9e+03;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
OY 6 TCCCGTCTCTTATATACGGTGC 32
Db 31 TCCATTGATTATTATAGCGCGCC 5
RESULT 8
ID AAK89998 standard; DNA; 33 BP.
XX AAK89998;
XX
DT 21-OCT-2002 (first entry)
XX
DE Human heavy chain CDR3 variable region, PCR primer eUT.
XX
KW Human; immune response; chronic B-lymphoproliferative disorder; CDR3;
KW complementarity determining region 3; hypervariable region; B-cell;
KW immunoglobulin heavy chain; VH-CDR3; idiotypic immunoglobulin;
KW cytosstatic; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN MO200255559-A1.
XX
PD 18-JUL-2002.
XX
PF 15-JAN-2001; 2001WO-IT000014.
XX
PR 15-JAN-2001; 2001WO-IT000014.
XX
PA (FAZI/) FAZIO V M.
PA (SAGL/) SAGLIO G.
XX
PI Fazio VM, Saglio G;
XX
DR WPI; 2002-583654/62.
XX
PT Use of DNA sequences coding for hypervariable region (VH- complementarity
PT determining region 3 (CDR3)) of idiotypic immunoglobulin expressed on B-
PT cells of chronic B- lymphoproliferative disorders, as therapeutic
PT vaccine.
XX
PS Example 2; Fig 1B; 30pp; English.
XX
CC The present invention relates to a method for inducing an immune response
CC against B-lymphoproliferative disorders. The method comprises DNA
CC sequences encoding for the complementarity determining region 3 (CDR3)
CC hypervariable region of immunoglobulin heavy chain (VH-CDR3) alone or in
CC combination with at least another immunomodulating sequence. The DNA
CC sequences are useful as therapeutic vaccines for chronic B-
CC lymphoproliferative disorders in mammals, preferably humans. A
CC recombinant plasmid expression vector containing a DNA sequence of the

CC invention is useful as a therapeutic vaccine or for the manufacture of a
CC vaccine effective against chronic B-lymphoproliferative disorders
CC expressing the surface idiotypic immunoglobulin on B-cells in mammals,
CC preferably humans. An efficient, safe and easily reproducible DNA-based
CC immune response against B-lymphoproliferative pathologies can be
CC achieved. The present sequence represents a PCR primer used to amplify
CC human heavy chain CDR3 variable region in the examples of the present
CC invention
XX
SQ Sequence 33 BP; 7 A; 7 C; 11 G; 8 T; 0 U; 0 Other;
Query Match 35.5%; Score 15.6; DB 6; Length 33;
Best Local Similarity 70.0%; Pred. No. 8e+03;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
OY 3 GGGTCCGCTCTTATATACGGTGC 32
Db 33 GGTACCGTCTCTCATATATAGCGCGCC 4
RESULT 9
ID AAX27543 standard; DNA; 34 BP.
XX AAX27543;
XX
DT 27-MAY-1999 (first entry)
XX
DE Staphylokinase (Sak) encoding DNA amplifying primer 2.
XX
KW Staphylokinase; Sak; recombinant; myocardial infarction; cerebral;
KW thrombembolia disease; arterial thrombosis; pulmonary thrombosis;
KW hydrolytic; fibrin; PCR primer; ss.
XX
OS Synthetic.
XX
PN Staphylococcus aureus.
XX
PN MO9904017-A1.
XX
PD 28-JAN-1999.
XX
PF 17-JUL-1998; 98WO-CN000129.
XX
PR 19-JUL-1997; 97CN-00105988.
XX
PA (BAIH/) BAI H.
XX
PI Zhang Q, Zhang G, Xu G, Qu G, Bie L, Xu W, Wu Y;
XX
DR WPI; 1999-132261/11.
XX
PT Highly safe, novel recombinant staphylokinase (Sak) produced from high-
PT expression engineered strain - as plasminogen activator, with very high
PT hydrolytic activity to human fibrin, useful in treating thrombembolia
PT diseases e.g. myocardial infarction.
XX
PS Claim 12; Page 26; 51pp; Chinese.
XX
CC Sequences AAX27542-43 represent PCR primers for the amplification of the
CC DNA encoding a recombinant staphylokinase (Sak). The Sak-producing
CC Staphylococcus aureus SL1.063 is deposited as CGMCC No.0353. The
CC invention provides a method for constructing a Sak-producing engineered
CC strain which comprises (a) screening Sak-producing Staphylococcus aureus;
CC obtaining a regulated Sak gene by PCR (polymerase chain reaction)
CC amplification with chromosomal DNA of Sak-producing S. aureus as
CC template, with primers (AAX27542-43) (b) introduction of the obtained DNA
CC fragment into a plasmid selected from pUC19 and pBV220; and (c)
CC transferring the recombinant plasmid into a host cell such as E. coli of
CC DHS alpha. Tc1 or Tc2 strains. The staphylokinase can be applied in
CC treatment of myocardial infarction, thrombembolia diseases and arterial
CC thrombosis including cerebral and pulmonary thrombi. Hydrolytic activity
CC of the staphylokinase to human fibrin is very high
XX

SQ Sequence 34 BP; 8 A; 9 C; 4 G; 13 T; 0 U; 0 Other;

Query Match 35.0%; Score 15.4; DB 2; Length 34;

Best Local Similarity 76.0%; Pred. No. 9.8e+03;

Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 GCGGATCCGCTTCTTAAATAC 25
 |||||
 DB 2 GCGGATCCGCTTCTTCAATAC 26

RESULT 10

AAF83844
 ID AAF83844 standard; DNA; 37 BP.

XX AAF83844;

XX 11-SEP-2003 (revised)

DT 06-AUG-2001 (first entry)

XX C. pneumoniae amino acid transporter DNA amplifying 3' primer.

XX Amino acid transporter; Chlamydia; infection; chronic bronchitis;

XX sinusitis; antibacterial; vaccine; gene therapy; PCR primer; ss.

XX Chlamydia pneumoniae.

XX MO200136457-A2.

XX 25-MAY-2001.

XX 10-NOV-2000; 2000WO-CA001346.

XX 15-NOV-1999; 99US-016561SP.

XX (AVERT) AVENTIS PASTEUR LTD.

XX Murdin AD, Oomen RP, Wang J, Dunn P;

DR WPI; 2001-343797/36.

XX A Chlamydia polypeptide, an amino acid transporter gene, for the

PT treatment and prevention of Chlamydia infection.

XX Claim 32; Page 52; 80pp; English.

XX Sequences AAF83843-844 represent PCR primers for amplifying the genomic

CC DNA encoding a Chlamydia pneumoniae amino acid transporter protein. The

CC amino acid transporter is useful for the treatment, prevention and

CC diagnosis of Chlamydia infection, preferably Chlamydia pneumoniae

CC infection, in human and veterinary applications. A protective vaccine

CC against Chlamydia pneumoniae is useful to prevent infection which leads

CC to chronic bronchitis and sinusitis. (Updated on 11-SEP-2003 to

CC standardise OS field)

XX Sequence 37 BP; 6 A; 10 C; 9 G; 12 T; 0 U; 0 Other;

Query Match 34.5%; Score 15.2; DB 5; Length 37;

Best Local Similarity 71.4%; Pred. No. 1.2e+04;

Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 CCGGATCCGCTTCTTAAATACCGGT 29
 |||||
 DB 5 CCGGATCCGCTTCTTAAATACCGGT 32

RESULT 11

ADBB1046/c
 ID ADBB1046 standard; DNA; 38 BP.

XX ADBB1046;

DT 04-DEC-2003 (first entry)

XX LINE retro-position related primer, SEQ ID No 6.

XX RNA retro-position; 3' UTR; LINE; APB domain; retro-transposition;

XX endonuclease domain; chromosome; gene therapy; gene transfer; PCR;

XX primer; ss.

XX Unidentified.

XX MO2003064644-A1.

XX 07-AUG-2003.

XX 26-NOV-2002; 2002WO-JP012317.

XX 31-JAN-2002; 2002JP-00024226.

XX (DNAV-) DNAVEC RES INC.

XX Fujiwara H, Takahashi H, Hasegawa M;

DR WPI; 2003-627609/59.

XX LINE retro-position by trans-complementation for transferring targeted,

XX specific gene or nucleic acid of e.g. endonuclease domain via

XX substitution to chromosome using virus vector, applicable in gene

XX Example 1; Page 35; 96pp; Japanese.

XX The invention relates to a novel RNA retro-position comprising the

XX transcription of an RNA containing a 3' UTR fragment of a LINE in cells;

XX and trans-positioning the ORF protein of such LINE after expressing from

XX other than the RNA. The invention further comprises a similar method in

XX which the transcription of an RNA containing a 3' UTR fragment of an APB

XX domain-carrying type site-specific LINE in cells, and expressing the ORF

XX protein of the LINE in such cells; or transcription of an RNA containing

XX 3' UTR fragment of a LINE in cells, and expressing ORF protein in such

XX cells thereby modifying a retro-transposition target site of a LINE by

XX substituting the endonuclease domain of the LINE by that of another LINE

XX via ORF protein of such LINE. The invention also includes a retro-

XX transposition vector with RNA encoding the 3' UTR fragment of a LINE but

XX not expressing the encoded ORF of the LINE; a vector encoding a protein in

XX for substitution of the endonuclease domain of an encoded ORF protein in

XX the site-specific LINE by the endonuclease domain of the encoded ORF

XX protein in another LINE; and a kit for gene transfer through retro-

XX transposition of an RNA. The method is useful for transferring targeted,

XX specific genes or nucleic acids of an endonuclease domain via

XX substitution to a chromosome using a virus vector, which is applicable in

XX gene therapy. The retro-transposition in the host is highly efficient by

XX targeting specifically at LINE, and with little damage to the host due to

XX the gene transfer. This polynucleotide sequence represents a PCR primer

XX used in the exemplification of the invention.

SQ Sequence 38 BP; 18 A; 7 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 34.5%; Score 15.2; DB 9; Length 38;

Best Local Similarity 71.4%; Pred. No. 1.2e+04;

Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 12 TCCTCTTAATACCGGTGCGGTATT 39
 |||||
 DB 29 TCCTCTTAATACGCGCATGTTT 2

RESULT 12

AAZ65893/c
 ID AAZ65893 standard; DNA; 47 BP.

XX AAZ65893;

DT 11-SEP-2001 (first entry)

DE Human map-related biallelic marker SEQ ID NO:240.
 XX Human genome, biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW genotyping; hybridisation; identification; characterisation; diagnosis;
 KW single nucleotide polymorphism; SNP; ds.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH variation replace(24,T)
 FT /tag=a
 FT /standard_name="single nucleotide polymorphism"
 XX
 FN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 XX 21-APR-1999; 99WO-IB000822.
 XX
 XX 21-APR-1998; 98US-0082614P.
 PR 23-NOV-1998; 98US-0109732P.
 XX
 XX (GBST) GENSET.
 PA
 P1 Cohen D, Blumenfeld M, Chumakov I;
 PI WPI, 2000-013267/01.
 DR
 XX Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX
 PS Claim 1; Page 281; 2745pp; English.
 XX
 CC AA65654 to AA69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AA69579 to AA77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 CC
 XX
 SQ Sequence 47 BP; 18 A; 6 C; 7 G; 16 T; 0 U; 0 Other;
 Qy Query Match 34.5%; Score 15.2; DB 3; Length 47;
 Best Local Similarity 63.9%; Pred. No. 1.3e+04;
 Matches 23; Conservative 0; Mismatches 13; Indels 0; Gaps 0;
 9 CGTTCCTTAATACCGGCGGTTATTAGAA 44
 46 CATTTAATTTAATACATGCTGCTTTGAAAA 11
 Db
 RESULT 13
 ID AAF91472/c
 AAF91472 standard; DNA; 47 BP.
 AC AAF91472;
 XX
 DT 04-MAY-2001 (first entry)
 XX
 XX N. meningitidis Nspa upstream sequence inverse PCR primer PNS4.
 DE Modified Gram-negative bacterium; outer membrane vesicle; bleb; vaccine;
 XX genetically modified; protective antigen expression; LPS detoxification;
 KW

KW LPS; lipid A; homologous recombination vector; immunisation;
 KW immunoprotective; non-toxic; paediatric; plasmid construction;
 KW modified Neisseria meningitidis; PCR primer; ss.
 XX
 OS Neisseria meningitidis.
 XX
 FN WO200109350-A2.
 XX
 PD 08-FEB-2001.
 XX
 XX 31-JUL-2000; 2000WO-EP007424.
 PF
 XX 03-AUG-1999; 99GB-00018319.
 PR
 XX (SMK) SMITHKLINE BEECHAM BIOLOGICALS.
 PA
 P1 Berthet FJ, Dalemans WLJ, Denoel P, Deguesne G, Feron C, Lobet Y;
 PI Poolman J, Thiry G, Thonnard J, Voet P;
 XX WPI, 2001-138654/14.
 DR
 XX
 PT New isolated polynucleotide useful for outer membrane vesicle preparation
 PT from Gram-negative bacterial strain for vaccination of microbial
 PT infections.
 XX
 PS Example 6; Page 47; 128pp; English.
 XX
 CC The invention relates to a genetically-engineered outer membrane vesicle
 CC (bleb) preparation from a Gram-negative bacterium for use as a vaccine.
 CC The blebs of the invention are improved with respect to their
 CC immunogenicity and toxicity by the introduction of one or more genetic
 CC changes to the chromosome of the bacterium from which the blebs are
 CC derived. The changes made include the upregulation of protective antigen
 CC expression, the downregulation of immunodominant non-protective antigen
 CC expression, and genetic changes which result in detoxification of the
 CC lipid A moiety of lipopolysaccharide (LPS). The invention also
 CC encompasses modified Gram-negative bacterial strains from which the bleb
 CC preparations are made, a vector suitable for performing recombination
 CC events (for the generation of the modified bacterial strains),
 CC bacterially-derived nucleic acid sequences used in such a vector, and an
 CC immunoprotective and non-toxic Gram-negative bleb, ghost, or killed whole
 CC cell vaccine suitable for paediatric use. The bleb preparation is useful
 CC in the manufacture of a medicament for immunising a human host against a
 CC disease caused by infection of one or more of the following: Neisseria
 CC meningitidis, Neisseria gonorrhoeae, Haemophilus influenza, Moraxella
 CC catarrhalis, Pseudomonas aeruginosa, Chlamydia trachomatis, and Chlamydia
 CC pneumoniae. The invention may also be used to provide immunisation against
 CC the influenza virus. Bacterially derived nucleotide sequences of the
 CC invention are used in the performance of homologous recombination events
 CC up to 1000 bp upstream of a bacterial chromosomal gene in order to either
 CC increase or decrease expression of that gene. Immunoprotective and non-
 CC toxic Gram-negative bleb, ghost, or killed whole cell vaccines are more
 CC immunogenic, less toxic and safer, and are particularly useful for
 CC paediatric use. The present sequence represents a PCR primer used in the
 CC production of a plasmid used in the generation of a modified Neisseria
 CC meningitidis strain
 CC
 XX
 SQ Sequence 47 BP; 15 A; 9 C; 6 G; 17 T; 0 U; 0 Other;
 Qy Query Match 34.5%; Score 15.2; DB 4; Length 47;
 Best Local Similarity 71.4%; Pred. No. 1.3e+04;
 Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
 17 CTTAATACCGGCGGTTATTAGAA 44
 41 CATATTTCCGACCGGTTATTAGCA 14
 Db
 RESULT 14
 ID ABK37852/c
 ABK37852 standard; DNA; 47 BP.
 AC ABK37852;
 XX

```

XX 08-MAY-2002 (first entry)
DT
XX pCMK(+) construction PCR primer #17.
DE
XX pCMK(+), ss; PCR, primer; antibacterial; vaccine; bleb;
XX Gram-negative bacteria; outer membrane; LPS; lipopolysaccharide;
XX meningitis; bacteraemia; otitis media; pneumonia; chronic bronchitis;
XX sinusitis.
XX Neisseria meningitidis.
OS
XX WO200209746-A2.
XX
XX 07-FEB-2002.
XX
XX 31-JUL-2001; 2001WO-EP008857.
XX
XX 31-JUL-2000; 2000WO-EP007424.
XX
XX 08-FEB-2001; 2001GB-00003170.
XX
XX (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Berthet FJ, Dalemans W, Denoel P, Dequesne G, Feron C, Garcon N;
XX Lopet Y, Poolman J, Thiry G, Thomard J, Voet P;
XX WPI; 2002-188688/24.
XX
XX New immunogenic composition comprising an antigen derived from a pathogen
XX and a blep preparation from Neisseria meningitidis, useful as a vaccine
XX for treating or preventing disease caused by the pathogen.
XX
XX Example 2; Page 49; 125pp; English.
XX
XX The invention relates to an immunogenic composition comprising an antigen
XX derived from a pathogen capable of protecting a host against the
XX pathogen, mixed with an adjuvant comprising a bleb preparation derived
XX from a Gram-negative bacterial strain. The immunogenic composition
XX consists of N. meningitidis B blebs or N. meningitidis C polysaccharide
XX antigen. The blebs (derived from the outer membrane) may also have their
XX toxic lipopolysaccharide (LPS) content reduced using heterologous down
XX regulating sequences for LPS pathway genes or by up regulating genes
XX involved in LPS synthesis suppression. By a promoter replacement
XX technique. The immunogenic preparation is useful in the manufacture of a
XX medicament for the treatment of a disease caused by the pathogen from
XX which the antigen is derived (e.g. from Neisseria, meningitis and
XX bacteraemia, from Moraxella, otitis media and pneumonia, and from H.
XX influenzae chronic bronchitis, sinusitis, pneumonia and otitis media).
XX The bleb derived from M. catarrhalis or from a non-typable H. influenzae
XX is useful as an adjuvant in an immunogenic composition comprising one or
XX more pneumococcal capsular polysaccharides or protein antigens. The
XX present sequence is a PCR primer used to construct the gene delivery
XX vector pCMK(+) for producing N. meningitidis strains producing
XX recombinant blebs
XX
XX Sequence 47 BP; 15 A; 9 C; 6 G; 17 T; 0 U; 0 Other;
SQ
Query Match 34.5%; Score 15.2; DB 6; Length 47;
Best Local Similarity 71.4%; Pred. No. 1.3e+04;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY 17 CTTAATTAACCGGTCGCGTTATTAAAGA 44
DB 41 CATATTTCGCGACGCGTTAATTAAGA 14

```

```

DT 18-OCT-2001 (first entry)
XX
XX Human single nucleotide polymorphism (SNP) 72.
DE
XX Human; resequence; genotype; disease; forensic; paternity testing;
XX single nucleotide polymorphism; SNP; ss.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX variation 16
XX FT /**tag = a
XX FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200166800-A2.
XX
XX 13-SEP-2001.
XX
XX 07-MAR-2001; 2001WO-US007268.
XX
XX 07-MAR-2000; 2000US-0187510P.
XX
XX 22-MAY-2000; 2000US-0206129P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Cargill M, Ireland JS, Lander ES;
XX WPI; 2001-522952/57.
XX
XX Nucleic acid molecules from the human genome which include polymorphic
XX sites, useful in methods for predicting the presence, absence or severity
XX of a particular phenotype or disorder (e.g. diabetes) associated with a
XX particular genotype.
XX
XX Claim 1; Page 64; 145pp; English.
XX
XX The invention relates to the identification of nucleic acid molecules
XX (AA129513-AA13134) from the human genome which include polymorphic sites
XX which can predispose individuals to disease. Various genes from a number
XX of individuals were resequenced and single nucleotide polymorphisms
XX (SNPs) in these genes were discovered. The method is useful for predicting the
XX presence, absence or severity of a particular phenotype or disorder (e.g.
XX diabetes) associated with a particular genotype. The nucleic acids
XX containing the polymorphic sites may be useful in forensics and paternity
XX testing
XX
XX Revised record issued on 04-NOV-2004 : Correction to Feature Table Key
XX
XX Sequence 31 BP; 12 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 34.1%; Score 15; DB 4; Length 31;
Best Local Similarity 78.3%; Pred. No. 1.4e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 12 TCCTTTTAATTAACCGGTCGCGG 34
DB 29 TCTTCTTAATGAGCTGCGGAG 7

```

```

RESULT 15
AA130035/C
ID AA130035 standard; DNA; 31 BP.
XX
XX AA130035;
AC
XX
DT 04-NOV-2004 (revised)

```

```

RESULT 16
AA269059
ID AA269059 standard; DNA; 47 BP.
XX
XX AA269059;
AC
XX
XX 10-SEP-2001 (first entry)
XX
XX Human map-related biallelic marker SEQ ID NO:3415.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation; diagnosis;
XX single nucleotide polymorphism; SNP; ds.

```

```
XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX Variation replace(24,G)
XX FT /*tag=a
XX FT /standard_name="single nucleotide polymorphism"
XX
XX WO954500-A2.
XX
XX PD 28-OCT-1999.
XX
XX PF 21-APR-1999; 99WO-IB000822.
XX
XX PR 21-APR-1998; 98US-0082614P.
XX PR 23-NOV-1998; 98US-0109732P.
XX
XX PA (GEST ) GENSET.
XX
XX PI Cohen D, Blumenfeld M, Chumakov I;
XX
XX DR WPI; 2000-013267/01.
XX
XX PT Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX PS Claim 3; Page 959; 2745pp; English.
XX
XX CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses; they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX Compositions and methods of the invention can also be useful for the
XX identification of the targets for the development of pharmaceutical
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX pharmaceutical agents acting on a disease as well as other treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX 3367, are not actually given a sequence in the Sequence Listing from the
XX present invention
XX
XX SQ Sequence 47 BP; 16 A; 13 C; 5 G; 13 T; 0 U; 0 Other;
XX
XX Query Match 34.1%; Score 15; DB 3; Length 47;
XX Best Local Similarity 67.7%; Pred. No. 1.6e+04;
XX Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
XX
XX QY 10 GTTCCTCTTAATACCGGTCGGGTATTA 40
XX ||||| ||||| ||||| |||||
XX 16 GTTCATCTTAATAAACATTCCTCAGCTCTA 46
XX
XX RESULT 17
XX ABZ02614
XX ID ABZ02614 standard; DNA, 50 BP.
XX
XX AC ABZ02614;
XX
XX DT 09-JAN-2003 (first entry)
XX
XX DE Human leukocyte gene expression profiling probe SEQ ID NO 2605.
XX
XX XX T7; leukocyte; gene expression profiling; allograft rejection;
XX KM atherosclerosis; congestive heart failure; systemic lupus erythematosus;
XX KM rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
XX ss.
XX
XX OS Homo sapiens.
XX
XX XX WO200257414-A2.
XX
XX PN
```

```
XX PD 25-JUL-2002.
XX
XX XX 22-OCT-2001; 2001WO-US047856.
XX
XX PF 20-OCT-2000; 2000US-0241994P.
XX PR 08-JUN-2001; 2001US-0296764P.
XX
XX PA (BIOC-) BIOCARDIA INC.
XX
XX PI Wohlgemuth J, Fry K, Marcuk G, Altman P, Prentice J, Phillips J;
XX PI Ly N, Woodward R, Quartermous T, Johnson F;
XX
XX DR WPI; 2002-636525/68.
XX
XX XX New system for leukocyte expression profiling, diagnosing a disease, or
XX PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
XX FT or congestive heart failure, comprises diagnostic oligonucleotides.
XX
XX PS Claim 1; Page 410; 0pp; English.
XX
XX CC The invention relates to a system for detecting gene expression, which
XX comprises one or two isolated DNA molecules that detect expression of a
XX gene, where the gene corresponds to any of 8143 oligonucleotides
XX (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
XX for leukocyte expression profiling. It is particularly useful for
XX diagnosing a disease, monitoring (rate of) progression of a disease,
XX predicting therapeutic outcome, determining prognosis for a patient,
XX predicting disease complications in an individual or monitoring response
XX to treatment in an individual. The diseases include cardiac allograft
XX rejection, kidney allograft rejection, liver allograft rejection,
XX atherosclerosis, congestive heart failure, systemic lupus erythematosus,
XX rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
XX
XX SQ Sequence 50 BP; 9 A; 8 C; 8 G; 25 T; 0 U; 0 Other;
XX
XX Query Match 34.1%; Score 15; DB 6; Length 50;
XX Best Local Similarity 67.7%; Pred. No. 1.6e+04;
XX Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
XX
XX QY 14 CTCTTAATACCGGTCGGGTATTAAGA 44
XX ||||| ||||| ||||| |||||
XX 2 CTGCTCATCTCTTTGCGCTATTGGAA 32
XX
XX RESULT 18
XX ABZ07725/C
XX ID ABZ07725 standard; DNA, 50 BP.
XX
XX AC ABZ07725;
XX
XX DT 09-JAN-2003 (first entry)
XX
XX DE Human leukocyte gene expression profiling probe SEQ ID NO 7716.
XX
XX XX T7; leukocyte; gene expression profiling; allograft rejection;
XX KM atherosclerosis; congestive heart failure; systemic lupus erythematosus;
XX KM rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
XX ss.
XX
XX OS Homo sapiens.
XX
XX XX WO200257414-A2.
XX
XX PN 25-JUL-2002.
XX
XX PD 22-OCT-2001; 2001WO-US047856.
XX
XX PF 20-OCT-2000; 2000US-0241994P.
XX PR 08-JUN-2001; 2001US-0296764P.
XX
XX PA (BIOC-) BIOCARDIA INC.
XX
XX XX
```

PS Claim 5; Page 105; 152pp; English.

CC The invention relates to enzymatic nucleic acid molecules that down
XX regulate expression of chloride channel calcium activated 1 (ClCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of ClCA1 in a cell or
CC tissue. The sequences are useful for reducing ClCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of ClCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of ClCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention

SQ Sequence 31 BP, 9 A; 7 C; 11 G; 4 T; 0 U; 0 Other;

QY Query Match 33.6%; Score 14.8; DB 6; Length 31;
Best Local Similarity 73.1%; Pred. No. 1.8e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Db 5 GTCCCGTTCTTCTTAATACCGGTC 30
30 GTCCCGTTCTTGTAGCTAGCCCGTC 5

RESULT 20

ID AAF81443 standard; DNA; 36 BP.
XX AAF81443
AC AAF81443;
DT 08-JUN-2001 (first entry)
XX PCR primer GSP2 for corn promoter clone #700343485.
KW Corn; promoter; transgenic plant; herbicide resistance; PCR primer; ss.
OS Zea mays.
PN WO200119976-A2.
PD 22-MAR-2001.
PF 13-SEP-2000; 2000WO-USO25078.
PR 16-SEP-1999; 99US-0154182P.
XX (MONS) MONSANTO CO.
PI Anderson HM, Chay CA, Chen G, Conner TW;
DR WPI; 2001-244796/25.
XX Novel promoter nucleic acid sequences useful for regulating heterologous
PT gene expression in plants, comprising regulatory sequences located
PT upstream to plant DNA structural coding sequences.
XX Example 3; Page 87; 101pp; English.

CC The present invention relates to novel corn promoter sequences (see
CC AAF81456-AAF81478). The promoter sequences are useful for conferring
CC expression of a second polynucleotide molecule in a transgenic plant
CC tissue. In addition, the promoter sequences are useful for providing
CC plants with herbicide resistance. The promoter sequences are suitable for
CC selectively modulating expression of any operatively linked gene and
CC provide additional regulatory element diversity in a plant expression

CC vector in gene stacking approaches. The present sequence is a PCR primer
CC used in the present invention
XX
SQ Sequence 36 BP; 6 A; 11 C; 9 G; 10 T; 0 U; 0 Other;
Query Match 33.6%; Score 14.8; DB 4; Length 36;
Best Local Similarity 73.1%; Pred. No. 1.8e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Qy 9 CGTTCCTTCTTAATTAACCGGTGCGG 34
Db 6 CTTTCTTCTCACTCAGCGGTGCGG 31
RESULT 21
AAD43960/C
ID AAD43960 standard; DNA; 39 BP.
XX
AC AAD43960;
XX
DT 14-NOV-2002 (first entry)
XX
DE D1228 oligo used to assemble beta-amyloid gene subfragment.
XX
KW Amyloidogenic protein; Alzheimer's disease; Huntington's disease;
KW spongiform encephalopathy; familial amyloid cardiomyopathy; amyloidosis;
KW Gerstmann-Strauszler-Scheinker syndrome; spongiform encephalopathy; GSS;
KW Creutzfeldt-Jacob disease; insulinoma; diabetes; body myocytis; myeloma;
KW C_β beta-amyloid; ss.
XX
OS Unidentified.
XX
PN MO20242462-A2.
XX
PD 30-MAY-2002.
XX
PF 27-NOV-2001; 2001WO-US044581.
XX
PR 27-NOV-2000; 2000US-0253302P.
PR 29-NOV-2000; 2000US-0250198P.
PR 20-DEC-2000; 2000US-0257186P.
XX
PA (PRAE-) PRAECIS PHARM INC.
PI Gafter ML, Israel DI, Joyal JL, Gosselin M;
XX
DR WPI; 2002-636427/68.
XX
PT Novel therapeutic agent useful for treating an amyloidogenic disorder,
PT e.g. Alzheimer's disease, comprises an immunoglobulin heavy chain
PT constant region linked to a peptide capable of binding amyloidogenic
PT protein.
XX
PS Example 4; Fig 7A; 79pp; English.
XX
CC The invention relates to a compound comprising an immunoglobulin (Ig)
CC heavy chain constant region or its fragment that retains the ability to
CC bind an Fc receptor linked by a linker group or a direct bond to a
CC peptide capable of binding an amyloidogenic protein. The invention is
CC useful for clearing an amyloidogenic protein such as beta-amyloid,
CC transthyretin (TTR), prion protein (PrP), islet amyloid polypeptide
CC (IAPP), artrial natriuretic factor (ANF), kappa light chain, lambda light
CC chain, amyloid A, procollagen, cystatin C, beta2-microglobulin, Apol-I,
CC gelsolin, calcitonin, fibrinogen, huntington, alpha-synuclein and
CC lysozyme from a subject and for treating an amyloidogenic disorder such
CC as Alzheimer's disease and spongiform encephalopathy. Disorders treatable
CC include those caused or characterised by deposits of TTR (eg. familial
CC amyloid cardiomyopathy), PrP (eg. spongiform encephalopathies, including
CC scrapie in sheep, bovine spongiform encephalopathy in cows and
CC Creutzfeldt-Jacob disease (CJ) and Gerstmann-Strauszler-Scheinker
CC syndrome (GSS) in humans), IAPP (eg. insulinoma, adult onset diabetes),
CC ANF (eg. isolated atrial amyloid), kappa or lambda light chain (eg.
CC idiopathic amyloidosis, myeloma), amyloid A (eg. amyloidosis), Apo A-I

CC (eg. hereditary non-neuropathic systemic amyloidosis), gelsolin (eg.
CC familial amyloidosis of Finnish type), fibrinogen (eg. hereditary renal
CC amyloidosis), lysozyme (eg. hereditary systemic amyloidosis). Other
CC examples of amyloidogenic disorders include Huntington's disease and
CC inclusion body myocytis. The present sequence is an oligonucleotide used
CC to assemble beta amyloid gene subfragment
XX
SQ Sequence 39 BP; 14 A; 10 C; 8 G; 7 T; 0 U; 0 Other;
Query Match 33.6%; Score 14.8; DB 6; Length 39;
Best Local Similarity 73.1%; Pred. No. 1.8e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Qy 9 CGTTCCTTCTTAATTAACCGGTGCGG 34
Db 36 CATTCTTCTTAATGTTCTGTCGCGG 11
RESULT 22
AAZ67378/C
ID AAZ67378 standard; DNA; 47 BP.
XX
AC AAZ67378;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human map-related biallelic marker SEQ ID NO:1725.
XX
KW Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation; diagnosis;
KW single nucleotide polymorphism; SNP; ds.
XX
OS Homo sapiens.
XX
FH Key
FH Location/Qualifiers
FT variation
FT replace(24,T)
FT /tag= a
FT /standard_name= "single nucleotide polymorphism"
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (G8ST) GENSET.
PI Cohen D, Blumenfeld M, Chumakov I;
XX
DR WPI; 2000-013267/01.
XX
PT Novel biallelic markers used to construct a high density disequilibrium
PT map of the human genome.
XX
PS Claim 1; Page 598; 2745pp; English.
XX
CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AAZ6579 to AAZ77440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the invention
CC have a variety of uses: they can be used for high density mapping of the
CC human genome, and in complex association studies and haplotyping studies
CC which are useful in determining the genetic basis for disease states.
CC Compositions and methods of the invention can also be useful for the
CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and

CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX
 SQ Sequence 47 BP; 18 A; 4 C; 13 G; 12 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 3; Length 47;
 Best Local Similarity 59.5%; Pred. No. 1.9e+04;
 Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 3 GGGTCCGGTCTTATACCGTGGCGTTATTAGAA 44
 |||||
 Db 46 GGCTCCCATCTCTTTATAGTTAGCACCATTATTATA 5

RESULT 23
 AAQ69835/c
 ID AAQ69835 standard; DNA; 50 BP.
 XX
 AC AAQ69835;

XX 25-MAR-2003 (revised)
 DT 06-MAR-1995 (first entry)
 XX

DE Human papilloma virus type-16 E6/E7 (start site 97), target region.

XX DNA protein-binding assay; test sequence; screening sequence; promoter;
 KW target; TATA box; Herpes Simplex Virus; HSV; origin of replication; U9;
 KW transcription factor; TFIID: ds.

XX Synthetic.

XX MO9414980-A1.

XX 07-JUN-1994.

XX 20-DEC-1993; 93WO-US012388.

XX 23-DEC-1992; 92US-00996783.

XX 17-SEP-1993; 93US-00123936.

XX (GENE-) GENELABS TECHNOLOGIES INC.

XX Edwards CA, Cantor CR, Andrews BM, Turin LM, Fry KE;
 PI WPI, 1994-234711/28.

PT Sequence-directed DNA-binding molecules - useful in pharmaceuticals and
 PT as molecular reagents.

PS Claim 28; Page 504; 587PD; English.

XX A DNA protein-binding assay is provided, useful for screening libraries
 CC of synthetic or biological cpds. for their ability to bind DNA test
 CC sequences. The assay is versatile in that any number of test sequences
 CC can be tested by placing the test sequence adjacent to a defined protein-
 CC binding screening sequence. Binding of mols. to these test sequences
 CC changes the binding characteristics of the protein mol. to its cognate
 CC binding sequence. When such a mol. binds the test sequence, the
 CC equilibrium of the DNA:protein complexes is disturbed, generating changes
 CC in the concentration of free DNA probe. One application of this method is
 CC to eucaryotic general transcription factors (e.g. TFIID), where the
 CC target region is typically selected from DNA sequences adjacent to the
 CC binding site for the eucaryotic transcription factor. Numerous exemplary
 CC test sequences are given: the sequences in AAQ69251-731 and AAQ69850
 CC correspond to promoter targets (typically, TATA box-contg. sites) for
 CC human genes and the sequences in AAQ69732-849 correspond to promoter
 CC targets for viral genes. The test sequences may also be randomly
 CC generated. DNA:protein interaction may be used for screening purposes,
 CC e.g. the Herpes Simplex Virus (HSV) origin of replication and U9 (see
 CC AAQ69851-52, AAQ69865 and AAQ69891). (Updated on 25-MAR-2003 to correct
 CC PN field.)
 XX
 SQ Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 2; Length 50;
 Best Local Similarity 73.1%; Pred. No. 1.9e+04;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCTTCTTATACCGTGGCGTT 36
 |||||
 Db 27 TGCTTTATACTACCGTTCGGTT 2

RESULT 24
 AAT64297/c
 ID AAT64297 standard; DNA; 50 BP.
 XX
 AC AAT64297;

XX 25-MAR-2003 (revised)
 DT 17-MAR-1997 (first entry)
 XX

DE HPV type 16 E6/E7 gene (start site 97) TFIID binding site.

XX Duplex DNA; target region; binding characteristic; DNA binding protein;
 KW TFIID; transcription factor; binding site; inhibition; enhance; cancer;
 KW inherited genetic disorder; ds.

XX Human papillomavirus.

XX US5578444-A.

XX 26-NOV-1996.

XX 20-DEC-1993; 93US-00171389.

XX 27-JUN-1991; 91US-00723618.

XX 23-DEC-1992; 92US-00996783.

XX 17-SEP-1993; 93US-00123936.

XX (GENE-) GENELABS TECHNOLOGIES INC.

XX Fry KB, Turin LM, Andrews BM, Cantor CR, Edwards CA;
 PI WPI, 1997-020402/02.

PT Altering binding characteristics of DNA binding proteins to duplex DNA -
 PT by attaching specific small cpd. to target region close to the protein's
 PT binding site, useful in treatment of viral disease, cancer etc.

PS Claim 6; Col 399; 264pp; English.

XX The sequences given in AAT63713-4312 represent duplex DNA's which act as
 CC target regions in the method of the invention. The method for altering
 CC the binding characteristics of a DNA-binding protein to duplex DNA
 CC comprises contacting the duplex DNA with a small molecule which binds
 CC sequence-specifically to a target region, where, when the small molecule
 CC is bound to the target region, it is adjacent to, but not overlapping by
 CC more than 4 bp, a binding site for a DNA-binding protein. The small
 CC molecule is added at a concentration effective to alter the binding of
 CC the DNA binding protein, pref. TFIID, to its binding site on the duplex
 CC DNA. The binding of the small molecule may inhibit or enhance the binding
 CC of the DNA-binding protein to its binding site. The compounds isolated
 CC using this method are potentially useful as therapeutic agents for
 CC treatment of any disease which involves a specific DNA sequence, e.g.
 CC cancer, or inherited genetic disorders etc. The method is suitable for
 CC screening large biological or chemical libraries and allows determination
 CC of sequence-specific and relative affinities of known DNA-binding agents
 CC for different DNA sequences. The design of these duplex DNA's allows a
 CC single DNA:protein interaction to be used for screening sequence-
 CC specific, or preferential, DNA binding proteins that recognise almost any
 CC possible sequence (see also AAT49539-74). (Updated on 25-MAR-2003 to
 CC correct PF field.)
 XX
 SQ Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 2; Length 50;
 Best Local Similarity 73.1%; Pred. No. 1.9e+04;
 Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

11 TTCCTTTTAAATACCGGTCGGGTT 36
 27 TGCCTTTTAACTACCGGTTTCGGTT 2

RESULT 25
 AAX17585/c
 ID AAX17585 standard; DNA; 50 BP.

XX AAX17585;

DT 06-MAY-1999 (first entry)

DE Test sequence from human papilloma virus type-16 E6/E7 (start site 97).

KW Test sequence; DNA-binding molecule; screening sequence; human;
 KM nucleic acid amplification; target; viral; ds.

XX Human papillomavirus.

OS US5869241-A.

PN US5869241-A.

PD 09-FEB-1999.

XX 07-JUN-1995; 95US-00475228.

XX 27-JUN-1991; 91US-00723618.

PR 23-DEC-1992; 92US-0096783.

PR 17-SEP-1993; 93US-00123936.

PR 20-DEC-1993; 93US-00171389.

XX (GENE-) GENELABS TECHNOLOGIES INC.

PA Fry KE, Turin LM, Andrews BM, Cantor CR, Edwards CA;

PI WPI; 1999-152755/13.

DR WPI; 1999-152755/13.

XX Determination of DNA sequence preference of a DNA-binding molecule -

PT based on inhibition of binding of protein to oligonucleotide sequence

PT attached to test sequence.

XX Claim 3; Col 399-400; 270pp; English.

PS Sequences AAX17001 to AAX17600 represent specifically claimed target test

XX sequences that are used in the method of the invention of determining the

CC DNA sequence preference of a DNA-binding molecule. The method comprises:

CC (i) adding a test molecule and a DNA-binding protein to a mixture of

CC duplex DNA test oligonucleotides, each of the test oligonucleotides

CC having a test sequence adjacent to a screening sequence, where the

CC screening sequence binds to the DNA-binding protein with a binding

CC affinity that is independent of the DNA sequence of the test sequence,

CC and where the mixture of duplex DNA test oligonucleotides includes

CC several test sequences; (ii) incubating the test molecule, the mixture of

CC duplex DNA test oligonucleotides and the DNA-binding protein for a time

CC sufficient to permit binding of the test molecule to test sequences in

CC the duplex DNA; (iii) separating unbound test oligonucleotides from test

CC oligonucleotides bound to binding protein; (iv) amplifying the unbound

CC test oligonucleotides; (v) repeating steps (ii) to (iv); (vi) isolating

CC the amplified test oligonucleotides; and (vii) sequencing the isolated

CC test oligonucleotides. Test sequences AAX17001-X17481 and AAX17600

CC correspond to promoter targets for human genes and test sequences

CC AAX17482-X17595 correspond to promoter targets for viral genes

XX Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;

SQ Query Match 33.6%; Score 14.8; DB 2; Length 50;

Best Local Similarity 73.1%; Pred. No. 1.9e+04;

Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

11 TTCCTTTTAAATACCGGTCGGGTT 36
 27 TGCCTTTTAACTACCGGTTTCGGTT 2

RESULT 26
 ABR83076/c
 ID ABR83076 standard; DNA; 50 BP.

XX ABR83076;

DT 27-AUG-2002 (first entry)

DE DNA binding molecule screening method test sequence #585.

KW DNA binding molecule screening; inhibition of transcription; infection;

KW human immunodeficiency virus; HIV; parasite; cancer; cardiovascular;

KW respiratory; gastrointestinal; endocrine; metabolic; rheumatic;

KW immunological; haematological; neurological; psychiatric; dermatological;

XX ophthalmological; musculo-skeletal; urogenital disorder; ss.

OS Synthetic.

PN US6384208-B1.

PD 07-MAY-2002.

XX 15-JUL-1999; 99US-00354947.

XX 27-JUN-1991; 91US-00723618.

PR 23-DEC-1992; 92US-0096783.

PR 17-SEP-1993; 93US-00123936.

PR 20-DEC-1993; 93US-00171389.

XX 07-JUN-1995; 95US-00482080.

XX (GENE-) GENELABS TECHNOLOGIES INC.

PA Edwards CA, Cantor CR, Andrews BM, Turin LM, Fry KE;

PI WPI; 2002-442819/47.

DR WPI; 2002-442819/47.

XX Decreasing transcriptional activity of genes for treating infections or

PT cancer, by administration of an agent that binds to two non-overlapping

PT regions of the gene.

XX Example 15; SEQ ID NO 585; 98pp; English.

PS The invention relates to a method of decreasing transcriptional activity

XX in a duplex deoxyribonucleic acid (DNA) template (T1) comprising

CC contacting (T1) with a binding agent comprising at least one small duplex

CC DNA-binding molecule (T2) coupled to at least one other small duplex-

CC binding molecule that binds to a non-overlapping region of target

CC sequence (TS). The method is useful for inhibiting transcription of a

CC range of disease-related genes for treating infections (by viruses,

CC including human immunodeficiency virus, bacteria, fungi, protozoa and

CC parasites), cancer, cardiovascular, respiratory, gastrointestinal,

CC endocrine/metabolic, rheumatic/immunological, haematological,

CC neurological, psychiatric, dermatological, ophthalmological, musculo-

CC skeletal, genetic or urogenital disorders. The method provides sequence-

CC specific inhibition of transcription of pathological genes without

CC affecting transcription of cellular genes regulated by the same

CC transcription factor, and can be applied to regulation of any gene.

CC ABR82492-ABR83155 represent DNA binding molecule test sequences used in

CC the method of the invention

XX Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;

SQ Query Match 33.6%; Score 14.8; DB 6; Length 50;

Best Local Similarity 73.1%; Pred. No. 1.9e+04;

Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

11 TTCCTTTTAAATACCGGTCGGGTT 36

Db 27 TGCCTTTACTAACCGGTTGCGTT 2

RESULT 27
ABZ02818
ID ABZ02818 standard; DNA; 50 BP.
XX
AC ABZ02818;
XX
DT 09-JAN-2003 (first entry)
XX
DE Human leukocyte gene expression profiling probe SEQ ID NO 2809.
XX
XX T7; leukocyte; gene expression profiling; allograft rejection;
KM atherosclerosis; congestive heart failure; systemic lupus erythematosus;
KM rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
KM ss.
XX Homo sapiens.
OS
PN M020257414-A2.
XX
PD 25-JUL-2002.
XX
PF 22-OCT-2001; 2001WO-US047856.
XX
PR 20-OCT-2000; 2000US-0241994P.
PR 08-JUN-2001; 2001US-0296764P.
XX
PA (BIOC-) BIOCARDIA INC.
XX
XX Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;
PI Ly N, Woodward R, Quenterous T, Johnson F;
XX
XX MPI; 2002-636525/68.
DR
XX
XX New system for leukocyte expression profiling, diagnosing a disease, or
PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
or congestive heart failure, comprises diagnostic oligonucleotides.
XX
XX Claim 1; Page 417; 0pp; English.
XX
XX The invention relates to a system for detecting gene expression, which
CC comprises one or two isolated DNA molecules that detect expression of a
CC gene, where the gene corresponds to any of 8143 oligonucleotides
CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
CC for leukocyte expression profiling. It is particularly useful for
CC diagnosing a disease, monitoring (rate of) progression of a disease,
CC predicting therapeutic outcome, determining prognosis for a patient,
CC predicting disease complications in an individual or monitoring response
CC to treatment in an individual. The diseases include cardiac allograft
CC rejection, kidney allograft rejection, liver allograft rejection,
CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
XX
XX Sequence 50 BP; 19 A; 6 C; 9 G; 16 T; 0 U; 0 Other;
SQ

Query Match 33.6%; Score 14.8; DB 6; Length 50;
Best Local Similarity 64.7%; Pred. No. 1.9e+04;
Matches 22; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 11 TTCTCTTTAATACCGGTCGGCTTATTAAGA 44
DB 10 TTCTCGAGCATTAAGCTGGCGCTTAATTAAGA 43

RESULT 28
ADE80615/C
ID ADE80615 standard; DNA; 50 BP.
XX
AC ADE80615;
XX
DT 29-JAN-2004 (first entry)

XX
DE Duplex oligonucleotide for DNA protein binding assay seq id 585.
XX
XX DNA-binding; duplex DNA test oligonucleotide; DNA protein binding;
KM library screening; promoter target; virus; ds.
XX
XX Human papillomavirus.
OS
PN US2003124530-A1.
XX
XX
PD 03-JUL-2003.
XX
XX 13-NOV-2001; 2001US-00993346.
XX
XX 27-JUN-1991; 91US-00723618.
PR 23-DEC-1992; 92US-00996783.
PR 17-SEP-1993; 93US-00123936.
PR 20-DEC-1993; 93US-00171389.
PR 07-JUN-1995; 95US-00482080.
PR 15-JUL-1999; 99US-00354947.
XX
XX (GENE-) GENELABS TECHNOLOGIES INC.
XX
XX Edwards CA, Cantor CR, Andrews BM, Turin LM, Fry KE;
PI
DR MPI; 2004-031270/03.
XX
XX
XX Screening for sequence-directed DNA-binding molecules comprises adding a
PT test molecule to a test system composed of a DNA-binding protein and a
PT duplex DNA test oligonucleotide having adjacent screening and test
PT sequences.
XX
XX
XX Claim 2; SEQ ID NO 585; 283pp; English.
XX
XX The invention describes a method for screening for molecules capable of
CC binding to a selected test sequence in a duplex DNA. The above method
CC comprises: constructing a duplex DNA test oligonucleotide having a
CC screening sequence adjacent to a selected test sequence, where a DNA-
CC binding protein is effective to bind to the screening sequence with a
CC binding affinity that is substantially independent of such test sequence,
CC but where DNA protein binding to the screening sequence is sensitive to
CC binding of test molecules to such test sequence; adding a test molecule
CC to be screened to a test system composed of the DNA-binding protein and
CC the duplex DNA test oligonucleotide having the screening and test
CC sequences adjacent one another; incubating the molecule in the test
CC system for a period sufficient to permit binding of the molecule being
CC tested to the test sequence in the duplex DNA; and comparing the amount
CC of binding protein bound to the duplex DNA before and after the adding.
CC The method is useful in screening libraries of synthetic or biological
CC compounds for their ability to bind DNA test sequences. The method may
CC also be used in characterizing the preferred binding sequences of any
CC selected DNA-binding molecule. This sequence represents a test sequence
CC corresponding to a promoter target of a viral gene.
XX
XX Sequence 50 BP; 22 A; 9 C; 10 G; 9 T; 0 U; 0 Other;
SQ

Query Match 33.6%; Score 14.8; DB 12; Length 50;
Best Local Similarity 73.1%; Pred. No. 1.9e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCTCTTTAATACCGGTCGGCTT 36
DB 27 TGCCTTTACTAACCGGTTTTCGTT 2

RESULT 29
ADS91869/C
ID ADS91869 standard; DNA; 50 BP.
XX
AC ADS91869;
XX
XX
DT 02-DEC-2004 (first entry)

DE Nematode LNA-modified oligo capture probe #212.
XX locked nucleic acid; LNA; biostability; cancer; cyrostatic;
KM diagnostic microarray; ss; probe; nematode.
XX
OS Caenorhabditis elegans.
XX
FH Key
FT modified_base
FT Location/Qualifiers
FT 1
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= Locked nucleic acid (LNA). All LNA
FT cytosines are methyl cytosines."
FT 2..49
FT modified_base
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Locked nucleic acid (LNA) exists at every
FT third position (LNA-3). All LNA cytosines are methyl
FT cytosines."
FN WO2004035819-A2.
PN
PD 29-APR-2004.
PP
PR 21-OCT-2003; 2003WO-DK000715.
XX
XX 21-OCT-2003; 2002US-0420278P.
PR 19-MAY-2003; 2003DK-00000752.
XX
PA (EXIQ-) EXIQON AS.
PA (MORK/) MORK S.
PI Kauppinen S, Alebo C, Nielsen PS, Jeffares DC, Mourier T;
PI Arctander P, Tommerup N, Tolstrup N, Vissing H;
DR WPI; 2004-357224/33.

New non-naturally-occurring nucleic acid having a melting temperature and capture efficiency higher than a control nucleic acid, useful for detecting and amplifying target nucleic acid, for alternative mRNA splice variant detection.

Example 8; Page 102; 400pp; English.

This invention relates to novel non-naturally occurring nucleic acids that exhibit enhanced biostability and capture efficiency i.e., hybridisation. Specifically, it refers to locked nucleic acid (LNA) oligos that have restricted flexibility in the ribofuranose ring of the nucleoside due to the presence of a 2'-O-, 4'-C methylene bridge. The present invention describes these oligos as useful for detecting target nucleic acids and in particular for profiling mRNA splice variants, detecting mutations, deletions or duplications that may be associated with onset or increased risk of diseases such as cancer. Accordingly, CC such oligos exhibit cytostatic activities. Furthermore, these LNA CC containing oligos can be used as fluorescent in situ hybridisation (FISH) probes or on diagnostic microarrays to detect splice isoform signatures, CC as well as antisense oligos that can modulate or silence sense nucleic CC acid agents. This oligonucleotide sequence is a nematode LNA-modified oligo capture probe of the invention.

Sequence 50 BP; 13 A; 13 C; 13 G; 11 T; 0 U; 0 Other;

Query Match 33.6%; Score 14.8; DB 13; Length 50;
Beet local Similarity 59.5%; Pred. No. 1.9e+04;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

1 GCGGATCCGTCCTTAAATAACGGAGCGCGGTATTATTAAG 42
||| ||| ||| ||| ||| ||| ||| ||| ||| |||
42 GCGTGCCACGTTCTGTATCCTTAAGAAGCGATTGAAG 1

RESULT 30

ACI97514	
ID	ACI97514 standard; DNA; 25 BP.
XX	
AC	ACT97514;
XX	
DT	14-OCT-2003 (first entry)
XX	
DE	Human microarray DNA oligonucleotide SEQ ID NO 97505.
XX	
EST; ss;	probe; expressed sequence tag; microarray; gene expression;
KW	genetic variation; diallelic marker; polymorphism; human;
KW	cross-species comparison.
XX	
OS	Homo sapiens.
XX	
PN	US2003104410-A1.
XX	
PD	05-JUN-2003.
XX	
PF	15-MAR-2002; 2002US-00098263.
XX	
PR	16-MAR-2001; 2001US-0276759P.
XX	
PA	(AFFY-) AFFYMETRIX INC.
XX	
PI	Mittmann MP;
XX	
DR	WPI; 2003-567953/53.
XX	
PT	New array of nucleic acid probes, useful for in situ hybridization, in
PT	Southern, Northern or dot-blot hybridization to identify or detect the
PT	sequence or specific mutations of any gene.
XX	
Claim 1;	SEQ ID NO 97505; 9pp; English.

	CC	The invention discloses a microarray comprising a plurality of nucleic acid probes including one of 2,018,500 fully defined sequences, or its
	CC	perfect match, perfect mismatch, antisense match or antisense mismatch.
	CC	Also disclosed is a method of gene expression analysis. The array is used
	CC	in monitoring gene expression levels by hybridisation to a DNA library,
	CC	in analysis of genetic variation or in hybridisation of tag-labelled
	CC	compounds. The nucleic acid probes are specifically designed for analysis
	CC	of at least one target sequence. The method of analysis comprises
	CC	hybridising at least one or more nucleic acids to at least two or more
	CC	nucleic acid probes and detecting the hybridisation. The nucleic acid
	CC	probes are attached to a solid support. The analysis comprises monitoring
	CC	gene expression levels, identifying allelic markers or polymorphisms,
	CC	or family members of a gene and a cross-species comparison. Each of the
	CC	nucleic acids further comprises a tag sequence. The array of nucleic acid
	CC	probes is useful in situ hybridisation, in Southern, Northern or dot-
	CC	blot hybridisation to identify or detect the sequence or specific
	CC	mutations of any gene, in mapping the 5' terminus of mRNA molecules by
	CC	primer extensions or in screening cDNA or genomic libraries or subclones
	CC	for additional subclones containing segments of DNA that have been
	CC	isolated and previously sequenced. The sequence presented is one of the
	CC	nucleic acid probes incorporated in the microarray. Note: The sequence
	CC	data for this patent can also be obtained in electronic format directly
	CC	from USPTO at seqdata.uspto.gov/sequence.html
	XX	
SQ	Sequence 25 BP; 2 A; 9 C; 5 G; 9 T; 0 U; 0 Other;	
Query Match	33.2%; Score 14.6; DB 9; Length 25;	
Best Local Similarity	81.0%; Pred. NO. 2.1e+04;	
Matches 17; Conservative	0; Mismatches 4; Indels 0; Gaps 0	
Dy	2 CGGGTCCCCTTCCTTTAAT 22 	
Db	3 CGGGTCCCCTTCCTTTACT 23 	
RESULT 31		
AAQ10823/c		
ID AAQ10823 standard; DNA; 34 BP.		

receptor-related polypeptides comprising expressing a tyrosine kinase receptor-related polypeptide in a recombinant expression system. separating the expressed monomeric tyrosine kinase receptor-related polypeptide from multimeric form(s) of the expressed polypeptide, and allowing refolding of the expressed tyrosine kinase receptor-related polypeptide into a biologically active form. Also described: (1) purifying recombinant TrkA1g2, TrkA1g2.6, TrkB1g4, or TrkC1g4 from inclusion bodies in a bacterial expression system in which monomeric TrkA1g2, TrkA1g2.6, TrkB1g4, or TrkC1g4 is separated from a mixture including monomeric, and multimeric TrkA1g2.6, TrkB1g4, or TrkC1g4 by a gel filtration step, and allowed to refold into an active form; (2) preparations of TrkA1g2, TrkA1g2.6, TrkB1g2 or TrkC1g2 obtained by a method above comprising less than 20% TrkA1g2, TrkA1g2.6, TrkB1g2 or TrkC1g2 dimer or dimer aggregate; and (3) preparations of TrkA1g2, TrkA1g2.6, TrkB1g2 or TrkC1g2 obtained by a method above comprising more than 80-99% TrkA1g2, TrkA1g2.6, TrkB1g2 or TrkC1g2, or comprising 100% TrkA1g2, TrkA1g2.6, TrkB1g2 or TrkC1g2 monomer. The method is useful for producing tyrosine kinase receptor-related polypeptides which can be used as biosensors. Compared with previous methods, the present method provides improved yields, has improved stability, does not require a separate dialysis-based refolding step, is much quicker than processes involving dialysis, produces product at higher concentrations without strand swap dimers, and since product is not in contact with urea for the length periods required during a dialysis procedure, it is less likely to be amidated. The present sequence represents a PCR primer for TrkB1g26His, which is used in the exemplification of the present invention.

Sequence 35 BP; 6 A; 10 C; 7 G; 10 T; 0 U; 2 Other;

Query Match 33.2%; Score 14.6; DB 10; Length 35;
Best Local Similarity 73.9%; Pred. No. 2.2e+04;
Matches 17; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

21 ATAACCGTCCGCGTTATTAGA 43
32 AAAACGGTGGGTCATTATA 10

RESULT 34
AAV06323/c
ID AAV06323 standard; DNA; 38 BP.
AC AAV06323;
XX
DT 06-MAY-1998 (first entry)
XX
DE Human Col III gene 3' end synthesising 3' primer.
XX
KW Collagen; Col III; recombinant; post-translational enzyme; human;
KW procollagen; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9738710-A1.
XX
PD 23-OCT-1997.
XX
PE 11-APR-1997; 97WO-US007300.
XX
PR 12-APR-1996; 96US-0061336.
XX
PA (FIBR-) FIBROGEN INC.
PA (FIFI-) ACAD FINLAND.
XX
PI Kivirikki KI, Pihlajaniemi T;
XX
DR WPI; 1997-526203/48.
XX
PT Recombinant production of (pro)collagen having correct folding - using
PT vectors encoding collagen sub:unit and collagen post-translational enzyme
PT respectively.

Example 11; Page 67; 90pp; English.

This primer is used to synthesise the 3' end of the human Col III gene by PCR amplification. This is used in the construction of recombinant vectors containing collagen genes. A novel method for producing a (pro)collagen polypeptide comprises culturing a host cell, where the host cell has been infected, transfected or transformed with a first expression vector comprising a polynucleotide molecule having a nucleic acid sequence which encodes a (pro)collagen subunit and a second expression vector comprising a polynucleotide molecule having a nucleic acid sequence which encodes at least one (pro)collagen post-translational enzyme or enzyme subunit. The (pro)collagen polypeptide is then purified from the cultured cell. The (pro)collagen polypeptide is selected from collagen types IV, V, VI, VII, VIII, IX, X, XI, XII, XIV, XV, XVI, XVII, XVIII, and XIX. The methods can be used for the production of collagens such as human collagens which can be used in therapeutic applications. The method provides for the synthesis of correctly folded proteins so that they exhibit the normal triple-helical conformation characteristic of procollagens and collagens. Purification of the collagens is greatly facilitated

Sequence 38 BP; 12 A; 10 C; 11 G; 5 T; 0 U; 0 Other;

Query Match 33.2%; Score 14.6; DB 2; Length 38;
Best Local Similarity 69.0%; Pred. No. 2.2e+04;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

4 GATCCGTTCCCTTATTAAACCGGTGCG 32
38 GACCTGTTCCTTTATTAAACGCGCGC 10

RESULT 35
ABZ47662
ID ABZ47662 standard; DNA; 41 BP.
AC ABZ47662;
XX
DT 26-JUN-2003 (first entry)
XX
DE Human ATP-binding cassette ABC7/CFTR gene polymorphic site, #4446.
XX
KW Human; drug metabolising enzyme; gene; drug metabolism; chromosome 7;
KW polymorphic site; drug evaluation; drug screening; genotyping;
KW genetic profiling; therapeutic customisation; adverse reaction;
KW clinical trial; drug approval; single nucleotide polymorphism; SNP; ds.
XX
OS Homo sapiens.
OS
FH Key Location/Qualifiers
FH variation replace(21,G)
FT /*tag=a
FT /standard_name= "Single nucleotide polymorphism (SNP)"
XX
PN WO200252044-A2.
XX
PD 04-JUL-2002.
XX
PE 27-DEC-2001; 2001WO-JP011592.
XX
PR 27-DEC-2000; 2000JP-00399443.
PR 02-MAY-2001; 2001JP-00135256.
PR 27-AUG-2001; 2001JP-00256862.
XX
PA (RIKE) RIKEN KK.
XX
PI Nakamura Y, Sekine A, Iida A, Satto S;
XX
DR WPI; 2002-583571/62.
XX
PT Identifying individuals having a polymorphism, useful for determining the
PT effectiveness or side effect of a drug or treatment protocol, comprises

DT 01-JUL-2004 (first entry)
 XX Human organic anion transport protein SNP region #680.
 DE
 XX
 XX gene therapy; human; OATP2; cMOAT; hepatic disease; metabolic disease;
 KM inflammatory disease; cardiovascular disease; hyperproliferative disease;
 KM neurological disease; infectious disease; liver disease;
 KM high cholesterol; hypertension; congestive heart failure;
 KM coronary heart disease; cancer; wound healing; ds; SNP;
 KM single nucleotide polymorphism.
 XX
 OS Homo sapiens.
 XX
 XX US2004068096-A1.
 PN
 XX
 XX 08-APR-2004.
 PD
 XX
 XX 20-SEP-2002; 2002US-00252155.
 PE
 XX 21-SEP-2001; 2001US-0324172P.
 PR
 XX 27-NOV-2001; 2001US-0333700P.
 XX
 XX (TSUC/) TSUCHIHASHI Z.
 PA (HUI/) HUI L.
 PA (KIRC/) KIRCHGESNER T.
 XX
 XX Tsuchihashi Z, Hui L, Kirchgessner T;
 PI
 XX WPI: 2004-304621/28.
 DR
 XX
 XX New nucleic acid encoding human OATP2 or cMOAT protein, useful in
 PT diagnosing, treating or preventing diseases or disorders, e.g.
 PT inflammatory, cardiovascular, hyperproliferative, neurological or
 PT infectious diseases.
 XX
 XX Disclosures; SEQ ID NO 747; 296pp; English.
 PS
 XX The invention relates to an isolated nucleic acid derived from a human
 CC gene encoding a protein, i.e. human OATP2 protein or human cMOAT protein,
 CC where the nucleic acid comprises at least one polymorphic position. The
 CC nucleic acid and the encoded protein, kits and composition are useful in
 CC diagnosing, treating or preventing diseases or disorders, e.g. hepatic,
 CC metabolic, inflammatory, cardiovascular, hyperproliferative,
 CC neurological, infectious diseases, liver disease, high cholesterol,
 CC hypertension, congestive heart failure or coronary heart disease and
 CC cancer and promotes wound healing. The present sequence represents the
 CC amino acid sequence of a human organic anion transport protein.
 CC
 XX
 SQ Sequence 41 BP; 16 A; 6 C; 14 G; 5 T; 0 U; 0 Other;
 Query Match 33.2%; Score 14.6; DB 12; Length 41;
 Best Local Similarity 69.0%; Pred. No. 2.3e+04;
 Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;
 QY 10 GTTCCTTCTTAATACCGGCGCGATTAT 38
 Db 41 GCTCCTCTTTTAACCTCTACCGGTAT 13
 RESULT 38
 ID ABBN84317 standard; DNA; 45 BP.
 XX
 XX ABBN84317;
 AC
 XX
 XX 29-AUG-2003 (revised)
 DT 01-OCT-2002 (first entry)
 XX
 XX Rhinovirus specific PCR primer rhLD.R1.
 DE
 KM CM985; pertubagen; viral infection; virucide; human; gene therapy; PCR;
 KM primer; ss.
 XX

OS Human rhinovirus sp.
 XX
 XX WO200255697-A2.
 PN
 XX
 XX 18-JUL-2002.
 PD
 XX
 XX 16-NOV-2001; 2001WO-US043486.
 PF
 XX 27-NOV-2000; 2000US-0253333P.
 PR
 XX 28-FEB-2001; 2001US-0272026P.
 XX
 XX (DELTA-) DELTAGEN PROTEOMICS INC.
 PA
 XX
 XX Kamb CA, Poritz MA, Teng DH;
 PI
 XX WPI: 2002-557822/59.
 DR
 XX
 XX New CM985 pertubagen polypeptides and polynucleotides useful for
 PT treating viral infections by the picornaviridae class, in chromosomal
 PT mapping, tissue typing, forensic biology, or viral serotyping.
 PT
 XX
 XX Example 6; Fig 17; 117pp; English.
 PS
 XX The present sequence is of PCR primer rhLD.R1, which was used in an
 CC example from the invention describing methods for identifying the targets
 CC of viral-neutralising pertubagens. In order to construct a viral target
 CC library, 10 of the polypeptides encoded by the human rhinovirus-14 genome
 CC were RT-PCR amplified from viral RNA using the viral-specific
 CC oligonucleotides given in ABBN84310-29. These include the present primer
 CC which, in addition to the viral sequence, includes a 5' restriction site.
 CC PCR products were cloned into pVT725 (HIS+) in-frame with the LexA
 CC binding domain. The polynucleotide sequence (see ABBN84303) encoding novel
 CC pertubagen CM985 (see ABBN9541) was cloned into pVT578 such that the 53
 CC amino acids of CM985 were fused in-frame with the C-terminus of the LexA
 CC activating domain. The pVT578-W985 and pVT725-viral library constructs
 CC were introduced into a yeast strain, and viral proteins that interacted
 CC with the W985 pertubagen were identified. The invention provides host
 CC cells, vectors and gene therapy vectors comprising polynucleotides
 CC encoding CM985. The host cells provide for methods for producing
 CC polypeptides having viral-related activity, which in turn can be used to
 CC identify potential therapeutics. The invention also provides methods for
 CC identifying a cellular target that interacts with the pertubagen, and
 CC for using such targets to screen for viral therapeutics. (Updated on 29-
 CC AUG-2003 to standardise OS field)
 XX
 XX
 SQ Sequence 45 BP; 11 A; 12 C; 7 G; 15 T; 0 U; 0 Other;
 Query Match 33.2%; Score 14.6; DB 6; Length 45;
 Best Local Similarity 62.2%; Pred. No. 2.3e+04;
 Matches 23; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
 QY 4 GGTCCCGTCTTCTTAATACCGGCGCGTTATTA 40
 Db 37 GGTGACATTAATCTTAATTAAGCGCGCTGTATTGA 1
 RESULT 39
 ID ADO18016 standard; DNA; 47 BP.
 XX
 XX ADO18016;
 AC
 XX
 XX 01-JUL-2004 (first entry)
 DT
 XX
 XX Primer of the invention #242.
 DE
 XX single nucleotide polymorphism; primer; ss.
 KM
 XX Synthetic.
 OS
 XX WO2004003220-A2.
 PN
 XX
 XX 08-JAN-2004.
 PD

XX 26-JUN-2003; 2003WO-US020150.
XX
XX 28-JUN-2002; 2002US-0392504P.
XX
XX (ORCH-) ORCHID BIOSCIENCES INC.
XX
XX Giles R, Baisch JM, McKeown B, Stolorow M;
XX WPI; 2004-091088/09.
XX
XX New panel of single nucleotide polymorphisms comprising two or more
XX single nucleotide polymorphisms, useful for analyzing compromised nucleic
XX acid samples.
XX
XX Claim 2; SEQ ID NO 243; 76pp; English.
XX
XX The present invention relates to a panel of two or more single nucleotide
XX polymorphisms, where each of the polymorphisms of the panel are selected
XX from single nucleotide polymorphisms that are not genetically linked with
XX respect to one another, and where each of the polymorphisms of the panel
XX are selected from single nucleotide polymorphisms that are located
XX outside tandem repeat nucleic acid sequences. The known sample and the
XX unknown sample are from the same individual. The known sample is from a
XX family member. The compromised nucleic acid sample comprises nucleic acid
XX fragments from 10-100 nucleotides in length. The identity of the one or
XX more single nucleotide polymorphisms is determined using a single base
XX primer extension reaction. The present sequence represents a primer of
XX the invention.
XX
XX Sequence 47 BP; 6 A; 12 C; 17 G; 11 T; 0 U; 1 Other;

Query Match 33.2%; Score 14.6; DB 12; Length 47;
Best Local Similarity 66.7%; Pred. No. 2.3e+04;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
Qy 3 GGGTCCGTTCTTCTTAATACCGTGC 32
Db 1 GGATGGGTTCCGTCCTATATCTGGCNC 30

RESULT 40
ADO18088
ID ADO18088 standard; DNA; 47 BP.
XX
XX ADO18088;
XX
XX 01-JUL-2004 (first entry)
XX
XX Primer of the invention #314.
XX
XX single nucleotide polymorphism; primer; ss.
XX
XX Synthetic.
XX
XX WO2004003220-A2.
XX
XX 08-JAN-2004.
XX
XX 26-JUN-2003; 2003WO-US020150.
XX
XX 28-JUN-2002; 2002US-0392504P.
XX
XX (ORCH-) ORCHID BIOSCIENCES INC.
XX
XX Giles R, Baisch JM, McKeown B, Stolorow M;
XX WPI; 2004-091088/09.
XX
XX New panel of single nucleotide polymorphisms comprising two or more
XX single nucleotide polymorphisms, useful for analyzing compromised nucleic
XX acid samples.

PS Claim 2; SEQ ID NO 315; 76pp; English.
XX
XX The present invention relates to a panel of two or more single nucleotide
XX polymorphisms, where each of the polymorphisms of the panel are selected
XX from single nucleotide polymorphisms that are not genetically linked with
XX respect to one another, and where each of the polymorphisms of the panel
XX are selected from single nucleotide polymorphisms that are located
XX outside tandem repeat nucleic acid sequences. The known sample and the
XX unknown sample are from the same individual. The known sample is from a
XX family member. The compromised nucleic acid sample comprises nucleic acid
XX fragments from 10-100 nucleotides in length. The identity of the one or
XX more single nucleotide polymorphisms is determined using a single base
XX primer extension reaction. The present sequence represents a primer of
XX the invention.
XX
XX Sequence 47 BP; 6 A; 12 C; 17 G; 11 T; 0 U; 1 Other;

Query Match 33.2%; Score 14.6; DB 12; Length 47;
Best Local Similarity 66.7%; Pred. No. 2.3e+04;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
Qy 3 GGGTCCGTTCTTCTTAATACCGTGC 32
Db 1 GGATGGGTTCCGTCCTATATCTGGCNC 30

Search completed: May 24, 2005, 12:14:32
Job time : 271 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 11:49:09 ; Search time 98 Seconds
(without alignments)
734.655 Million cell updates/sec

Title: US-10-673-063-3_COPY_900_943
Perfect score: 44
Sequence: 1 ggcgggtccgcgttcctctta.....ccggtcgcggttataagaa 44

Scoring table: IDENTITY NUC
Gapop 10'-0 , Gapexc 1.0

Searched: 1202784 seqs, 818138359 residues
Total number of hits satisfying chosen parameters: 1209694

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : Issued_Patents.NA.*
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PTUS.COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfile1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	15.8	35.9	25	4	US-09-396-196G-29372
C 2	15.2	34.5	33	6	5519127-36
C 3	15.2	34.5	33	6	5519127-36
C 4	14.8	33.6	25	4	US-09-396-196G-29373
C 5	14.8	33.6	36	4	US-09-665-189A-40
C 6	14.8	33.6	47	4	US-09-422-978-1725
C 7	14.8	33.6	47	4	US-09-422-978-1725
C 8	14.8	33.6	50	1	US-08-171-389-585
C 9	14.8	33.6	50	1	US-08-123-936-585
C 10	14.8	33.6	50	2	US-08-475-228A-585
C 11	14.8	33.6	50	3	US-08-482-080A-585
C 12	14.8	33.6	50	3	US-09-354-947-585
C 13	14.8	33.6	50	5	PCT-US93-12388-585
C 14	14.6	33.2	33	6	5519127-17
C 15	14.6	33.2	33	6	5519127-17
C 16	14.6	33.2	34	6	5519127-4
C 17	14.6	33.2	34	6	5519127-4
C 18	14.6	33.2	39	6	5519127-33
C 19	14.6	33.2	39	6	5519127-33
C 20	14.6	33.2	46	1	US-07-826-928A-30
C 21	14.6	33.2	47	4	US-09-422-978-415
C 22	14.6	33.2	49	3	US-08-889-502-34
C 23	14.4	32.7	47	4	US-09-422-978-2970
C 24	14.2	32.3	20	4	US-09-198-452A-6719
C 25	14.2	32.3	20	4	US-09-922-146-31
C 26	14.2	32.3	21	4	US-09-657-472-1129
C 27	14.2	32.3	36	1	US-07-956-697B-3

C 28	14.2	32.3	C 36	1	US-08-263-098-3	Sequence 3, Appli
C 29	14.2	32.3	C 38	2	US-08-857-946-83	Sequence 83, Appli
C 30	14.2	32.3	C 38	3	US-08-970-740-83	Sequence 83, Appli
C 31	14.2	32.3	C 49	3	US-09-538-709-983	Sequence 983, App
C 32	14	31.8	C 24	3	US-08-379-452-17	Sequence 17, Appli
C 33	14	31.8	C 24	3	US-09-409-670-17	Sequence 17, Appli
C 34	14	31.8	C 30	3	US-09-461-667-456	Sequence 456, App
C 35	14	31.8	C 32	4	US-09-709-103-34	Sequence 34, Appli
C 36	14	31.8	C 32	4	US-09-439-410A-34	Sequence 8, Appli
C 37	14	31.8	C 35	4	US-09-709-103-8	Sequence 8, Appli
C 38	14	31.8	C 35	4	US-09-439-410A-8	Sequence 8, Appli
C 39	14	31.8	C 41	4	US-09-060-229-117	Sequence 117, App
C 40	14	31.8	C 41	4	US-09-402-923A-117	Sequence 117, App
C 41	14	31.8	C 47	1	US-08-171-389-585	Sequence 250, App
C 42	14	31.8	C 47	1	US-08-123-936-250	Sequence 250, App
C 43	14	31.8	C 47	2	US-08-475-228A-250	Sequence 250, App
C 44	14	31.8	C 47	3	US-08-482-080A-250	Sequence 250, App
C 45	14	31.8	C 47	3	US-09-354-947-250	Sequence 250, App
C 46	14	31.8	C 47	4	US-09-422-978-990	Sequence 990, App
C 47	14	31.8	C 47	5	PCT-US93-12388-250	Sequence 250, App
C 48	13.8	31.4	C 25	4	US-09-396-196G-50594	Sequence 50594, A
C 49	13.8	31.4	C 26	1	US-08-218-933-2	Sequence 2, Appli
C 50	13.8	31.4	C 26	5	PCT-US95-03918-2	Sequence 2, Appli
C 51	13.8	31.4	C 29	3	US-08-194-560-7	Sequence 7, Appli
C 52	13.8	31.4	C 34	3	US-08-510-133A-7	Sequence 7, Appli
C 53	13.8	31.4	C 34	3	US-08-585-895-7	Sequence 7, Appli
C 54	13.8	31.4	C 34	3	US-08-601-132-7	Sequence 7, Appli
C 55	13.8	31.4	C 34	4	US-08-671-573B-7	Sequence 7, Appli
C 56	13.8	31.4	C 34	4	US-09-631-092B-7	Sequence 7, Appli
C 57	13.8	31.4	C 38	3	US-08-718-904-124	Sequence 124, App
C 58	13.8	31.4	C 38	4	US-09-449-249-124	Sequence 124, App
C 59	13.8	31.4	C 47	4	US-09-516-667-73	Sequence 73, Appli
C 60	13.8	31.4	C 48	4	US-09-516-667-35	Sequence 35, Appli
C 61	13.8	31.4	C 48	4	US-09-516-667-74	Sequence 74, Appli
C 62	13.8	31.4	C 48	4	US-09-516-667-75	Sequence 75, Appli
C 63	13.6	30.9	C 25	4	US-09-396-196G-84468	Sequence 84468, A
C 64	13.6	30.9	C 25	4	US-09-396-196G-84469	Sequence 84469, A
C 65	13.6	30.9	C 38	4	US-09-060-299-249	Sequence 249, App
C 66	13.6	30.9	C 38	4	US-09-402-923A-249	Sequence 249, App
C 67	13.6	30.9	C 40	2	US-08-628-422-25	Sequence 25, Appli
C 68	13.6	30.9	C 40	4	US-09-763-550-14	Sequence 14, Appli
C 69	13.6	30.9	C 42	4	US-09-408-020-88	Sequence 88, Appli
C 70	13.6	30.9	C 42	6	5177307-5	Patent No. 5177307
C 71	13.6	30.9	C 42	6	5177307-5	Patent No. 5177307
C 72	13.4	30.5	C 33	1	US-08-449-311A-5	Sequence 5, Appli
C 73	13.4	30.5	C 33	1	PCT-US95-17106A-5	Sequence 5, Appli
C 74	13.4	30.5	C 36	1	US-08-121-202-21	Sequence 21, Appli
C 75	13.4	30.5	C 36	1	US-08-121-202-22	Sequence 22, Appli
C 76	13.4	30.5	C 36	3	US-08-822-516-8	Sequence 8, Appli
C 77	13.4	30.5	C 36	3	US-09-131-684-8	Sequence 8, Appli
C 78	13.4	30.5	C 39	6	5519127-31	Patent No. 5519127
C 79	13.4	30.5	C 39	6	5519127-31	Patent No. 5519127
C 80	13.4	30.5	C 40	2	US-08-124-961A-20	Sequence 20, Appli
C 81	13.4	30.5	C 40	3	US-09-037-190-18	Sequence 18, Appli
C 82	13.4	30.5	C 40	3	US-09-037-192-18	Sequence 18, Appli
C 83	13.4	30.5	C 40	3	US-09-037-143-18	Sequence 18, Appli
C 84	13.4	30.5	C 40	3	US-09-049-671-18	Sequence 18, Appli
C 85	13.4	30.5	C 40	3	US-08-260-174-18	Sequence 18, Appli
C 86	13.4	30.5	C 40	3	US-09-338-128A-18	Sequence 18, Appli
C 87	13.4	30.5	C 40	3	US-09-232-346-18	Sequence 18, Appli
C 88	13.4	30.5	C 45	3	US-09-037-192-18	Sequence 18, Appli
C 89	13.4	30.5	C 45	3	US-08-358-627F-3	Sequence 3, Appli
C 90	13.4	30.5	C 45	3	US-08-465-712C-3	Sequence 3, Appli
C 91	13.4	30.5	C 45	3	US-09-552-733-3	Sequence 3, Appli
C 92	13.4	30.5	C 45	4	US-09-349-925-3	Sequence 3, Appli
C 93	13.4	30.5	C 49	3	US-08-782-480-57	Sequence 57, Appli
C 94	13.4	30.5	C 49	3	US-08-954-211-57	Sequence 57, Appli
C 95	13.4	30.5	C 49	3	US-09-005-167A-57	Sequence 57, Appli
C 96	13.4	30.5	C 49	3	US-09-176-741B-57	Sequence 57, Appli
C 97	13.4	30.5	C 50	1	US-07-750-080A-21	Sequence 21, Appli
C 98	13.4	30.5	C 50	1	US-07-750-080A-42	Sequence 42, Appli
C 99	13.4	30.5	C 50	1	US-08-651-472-21	Sequence 21, Appli
C 100	13.4	30.5	C 50	3	US-08-651-472-42	Sequence 42, Appli

ALIGNMENTS

RESULT 1

```

1  Sequence 29372, Application US/09396196G
2  Patent No. 6621724
3  GENERAL INFORMATION:
4  APPLICANT: Michael Mitmann
5  APPLICANT: David Mack
6  APPLICANT: David Lockhart
7  APPLICANT: Affymetrix, Inc.
8  TITLE OF INVENTION: Methods of Genetic Analysis
9  FILE REFERENCE: 3101.1
10 CURRENT APPLICATION NUMBER: US/09/396,196G
11 CURRENT FILING DATE: 1999-09-15
12 PRIOR APPLICATION NUMBER: 60/100,678
13 PRIOR FILING DATE: 1998-09-17
14 NUMBER OF SEQ ID NOS: 127806
15 SOFTWARE: FASTSEQ for Windows Version 4.0
16 SEQ ID NO 29372
17 LENGTH: 25
18 TYPE: DNA
19 ORGANISM: Mus musculus
20 US-09-396-196G-29372

```

Query Match	35.9%	Score 15.8;	DB 4;	Length 25;
Best Local Similarity	89.5%;	Pred. No.1.5e+03;		
Matches 17;	Conservative	0;	Mismatches 2;	Indels 0;
				Gaps 0

QY	26	CGTCGCGGTATTAGAA	44
Db	19	CAGTCGCGGTATTAGAA	1

RESULT

```

5519127-36
; Patent No. 5519127
; APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
; PNEUMOCOCCUS CARINII
; NUMBER OF SEQUENCES: 57
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US//07/826,657
; FILING DATE: 21-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 392,679
; FILING DATE: 11-AUG-1989
; SEQ ID NO:36:
; LENGTH: 33
5519127-36

```

Query Match	34.5%	Score 15.2;	DB 6;	Length 33;
Best Local Similarity	45.5%;	Pred. No. 3e+03;		
Matches 10; Conservative	8;	Mismatches 4;	Indels 0;	Gaps 0

QY 8 CCGTTCCTTCTAATAACCGGT 23
:|::||::|:|::|||:
Db 3 YCCUUCCTUCUGAUAACCGGU 24

RESULT

; PATENT NO. 5519127
 ; APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
 ; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
 ; PNEUMOCOCCUS CARINII
 ; NUMBER OF SEQUENCES: 57
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/07/826,657
 ; FILING DATE: 21-JAN-1992

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 392,679
; FILING DATE: 11-AUG-1989
; SEQ ID NO:36
; LENGTH: 33
5519127-36

```

Query Match	34.5%	Score 15.2;	DB 6;	Length 33;
Best Local Similarity	45.5%	Pred. No. 3e+03;		
Matches 10;	Conservative	8;	Mismatches 4;	Indels 0;
			Gaps	0;

QY 8 CCGTTCCTTCTAATAACCGGT 23
 :|::||::|:|:|||||:
 Db 3 YCCUUCUUCUGAUAACCGGU 24

RESULT 4

```

Sequence 29373, Application US/09396196G
Patent No. 6621724
GENERAL INFORMATION:
APPLICANT: Michael Miltmann
APPLICANT: David Mack
APPLICANT: David Lockhart
APPLICANT: Affymetrix, Inc.
TITLE OF INVENTION: Methods of Genetic Analysis
FILE REFERENCE: 3101.1
CURRENT APPLICATION NUMBER: US/09/396,196G
CURRENT FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: 60/100,678
PRIOR FILING DATE: 1998-09-17
NUMBER OF SEQ ID NOS: 127806
SOFTWARE: FASTSEQ for Windows Version 4.0
SEQ ID NO 29373
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-09-396-196G-29373

```

Query Match	33.6%	Score 14.8	DB 4	Length 25
Best Local Similarity	88.9%	Pred. No. 4.1e+03		
Matches 16; Conservative	0	Mismatches 2	Indels 0	Gaps 0

QY	26	CGTCCGGTTATTAGA	43
Db	18	CAGTCGGTAATTAGA	1

RESULT

```

US-09-665-189A, Application US/09665189A
Sequence 40,
Patent No. 6645765
GENERAL INFORMATION:
APPLICANT: Anderson, Heather
APPLICANT: Chay, Catherine
APPLICANT: Chen, Guilan
APPLICANT: Comer, Timothy
TITLE OF INVENTION: Plant Regulatory Sequences for Control of Gene Expression
FILE REFERENCE: 38-211 (15674) B
CURRENT APPLICATION NUMBER: US/09/665,189A
CURRENT FILING DATE: 2000-09-15
PRIOR APPLICATION NUMBER: 09/665,189
PRIOR FILING DATE: 2000-09-15
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.0
SEQ ID NO 40
LENGTH: 36
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: misc.feature
LOCATION: (1)..(36)
OTHER INFORMATION: Synthetic primer sequence

```

US-09-665-189A-40

Query Match 33.6%; Score 14.8; DB 4; Length 36;
Best Local Similarity 73.1%; Pred. No. 4.5e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATACCGGTGCGG 34
Db 6 CTTTCTTCTCACTCAGCGTTGCGG 31

RESULT 6

US-09-422-978-240/C
; Sequence 240; Application US/094222978
; Patent No. 6537751

GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

FILE REFERENCE: GENSER.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 240

LENGTH: 47
; TYPE: DNA

ORGANISM: Homo Sapiens
; FEATURE:

NAME/KEY: allele
; LOCATION: 24

OTHER INFORMATION: 99-1368-299 : polymorphic base C or T
US-09-422-978-240

Query Match 33.6%; Score 14.8; DB 4; Length 47;
Best Local Similarity 61.1%; Pred. No. 4.8e+03;
Matches 22; Conservative 1; Mismatches 13; Indels 0; Gaps 0;

Qy 9 CGTTCCTTCTTAATACCGGTGCGGTATTATAGAA 44
Db 46 CATTTAATTATATATGATGCTCTCTGTTTGAATAA 11

RESULT 7

US-09-422-978-1725/C
; Sequence 1725; Application US/094222978
; Patent No. 6537751

GENERAL INFORMATION:

APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya

TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

FILE REFERENCE: GENSER.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20

EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21

EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23

EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21

NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 1725

LENGTH: 47
; TYPE: DNA

ORGANISM: Homo Sapiens
; FEATURE:

NAME/KEY: allele

LOCATION: 24

OTHER INFORMATION: 99-5951-438 : polymorphic base C or T
US-09-422-978-1725

Query Match 33.6%; Score 14.8; DB 4; Length 47;
Best Local Similarity 59.5%; Pred. No. 4.8e+03;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 3 GGGTCCGTCCTTCTTAATACCGGTGCGGTATTATAGAA 44
Db 46 GGTCTCCATCTCTTATTATTAATTAATTAATTAATTA 5

RESULT 8

US-08-171-389-585/C
; Sequence 585; Application US/08171389
; Patent No. 5578444

GENERAL INFORMATION:
; APPLICANT: Edwards, Cynthia A.
; APPLICANT: Cantor, Charles R.

APPLICANT: Andrews, Beth M.
; APPLICANT: Turin, Lisa M.

TITLE OF INVENTION: Sequence-Directed DNA Binding
; TITLE OF INVENTION: Molecules, Compositions and Methods

NUMBER OF SEQUENCES: 641
CORRESPONDENCE ADDRESS:

ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive

CITY: Redwood City
STATE: CA

COUNTRY: USA
ZIP: 94063

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/171,389
; FILING DATE:

CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/123,936
; FILING DATE: 17-SEP-1993

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/996,783

FILING DATE: 23-DEC-1992
; APPLICATION NUMBER: US 07/723,618

FILING DATE: 27-JUN-1991
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/081,070
; FILING DATE: 22-JUN-1993

ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.

REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-0175/G19P3

TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880

TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 585:

SEQUENCE CHARACTERISTICS:
; LENGTH: 50 base pairs

TYPE: nucleic acid
; STRANDEDNESS: double

TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: NO
; ORIGINAL SOURCE: Human papilloma virus type-16 E6/E7
; INDIVIDUAL ISOLATE: (start site 97)

US-08-171-389-585

Query Match 33.6%; Score 14.8; DB 1; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCCTTTAATAACCGGTCGGGTT 36
DB 27 TGCCTTTAATAACCGGTCGGGTT 2

RESULT 9

US-08-123-936-585/c
Sequence 585, Application US/08123936
Patent No. 5726014
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
TITLE OF INVENTION: Screening Assay for the Detection of
TITLE OF INVENTION: DNA-Binding Molecules
NUMBER OF SEQUENCES: 640
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/123,936
FILING DATE: 27-JUN-1991
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
ATTORNEY/AGENT INFORMATION:
NAME: Rabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0075.32/G19P2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 B6/E7
INDIVIDUAL ISOLATE: (start site 97)
US-08-123-936-585

Query Match 33.6%; Score 14.8; DB 1; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCCTTTAATAACCGGTCGGGTT 36
DB 27 TGCCTTTAATAACCGGTCGGGTT 2

RESULT 10

US-08-475-228A-585/c
Sequence 585, Application US/08475228A
Patent No. 5869241
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk B.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,228A
FILING DATE: 06-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Stratford, Carol A.
REGISTRATION NUMBER: 34,444
REFERENCE/DOCKET NUMBER: 4600-0175.21/G19P3D2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 B6/E7
INDIVIDUAL ISOLATE: (start site 97)
US-08-475-228A-585

Query Match 33.6%; Score 14.8; DB 2; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 11 TTCCTTTAATAACCGGTCGGGTT 36
DB 27 TGCCTTTAATAACCGGTCGGGTT 2

RESULT 11
US-08-482-080A-585/c
Sequence 585, Application US/08482080A

Patent No. 6010849
GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,080A
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/171,389
FILING DATE: 20-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Brady, John F.
REGISTRATION NUMBER: 39,118
REFERENCE/DOCKET NUMBER: 4600-0175.20/G19P3D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 324-0880
TELEFAX: (650) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 E6/E7
INDIVIDUAL ISOLATE: (start site 97)
US-08-482-080A-585
Query Match 33.6%; Score 14.8; DB 3; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 11 TTCCTTTTAATACCGGTCGGGTT 36
DB 27 TGCCTTTTACTAACCGGTTTCGGTT 2
RESULT 12
US-09-354-947-585/C
; Sequence 585, Application US/09354947
; Patent No. 6384208

GENERAL INFORMATION:
APPLICANT: Edwards, Cynthia A.
APPLICANT: Cantor, Charles R.
APPLICANT: Andrews, Beth M.
APPLICANT: Turin, Lisa M.
APPLICANT: Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/354,947
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/482,080
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: US 08/171,389
FILING DATE: 20-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Brady, John F.
REGISTRATION NUMBER: 39,118
REFERENCE/DOCKET NUMBER: 4600-0175.20/G19P3D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 324-0880
TELEFAX: (650) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 E6/E7
INDIVIDUAL ISOLATE: (start site 97)
US-09-354-947-585
Query Match 33.6%; Score 14.8; DB 3; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 11 TTCCTTTTAATACCGGTCGGGTT 36
DB 27 TGCCTTTTACTAACCGGTTTCGGTT 2
RESULT 13
PCT-US93-12388-585/C
; Sequence 585, Application PC/TUS9312388

GENERAL INFORMATION:
APPLICANT: Sequence-Directed DNA Binding
TITLE OF INVENTION: Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 641
CORRESPONDENCE ADDRESS:
ADDRESS: GeneLabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/12388
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0175.41/G19PCT2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 B6/E7
INDIVIDUAL ISOLATE: (start site 97)
PCT-US93-12388-585
Query Match 33.6%; Score 14.8; DB 5; Length 50;
Best Local Similarity 73.1%; Pred. No. 4.9e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 11 TTCCTTCTTAATACCGGTCGGGTT 36
DB 27 TGCTTTACTACCGGTTTCGGTT 2
RESULT 14
5519127-17
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
PNEUMOCYSTIS CARINII
NUMBER OF SEQUENCES: 57
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/826,657
FILING DATE: 21-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 392,679
FILING DATE: 11-AUG-1989
SEQ ID NO:17:
LENGTH: 33
5519127-17

Query Match 33.2%; Score 14.6; DB 6; Length 33;
Best Local Similarity 81.0%; Pred. No. 5.4e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 9 CGTTCCTTCTTAATACCGGT 29
DB 4 CCTTCCTTCGTGATTACCGGT 24
RESULT 15
5519127-17
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
PNEUMOCYSTIS CARINII
NUMBER OF SEQUENCES: 57
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/826,657
FILING DATE: 21-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 392,679
FILING DATE: 11-AUG-1989
SEQ ID NO:17:
LENGTH: 33
5519127-17
Query Match 33.2%; Score 14.6; DB 6; Length 33;
Best Local Similarity 81.0%; Pred. No. 5.4e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 9 CGTTCCTTCTTAATACCGGT 29
DB 4 CCTTCCTTCGTGATTACCGGT 24
RESULT 16
5519127-4/c
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
PNEUMOCYSTIS CARINII
NUMBER OF SEQUENCES: 57
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/826,657
FILING DATE: 21-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 392,679
FILING DATE: 11-AUG-1989
SEQ ID NO:4:
LENGTH: 34
5519127-4
Query Match 33.2%; Score 14.6; DB 6; Length 34;
Best Local Similarity 81.0%; Pred. No. 5.4e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 9 CGTTCCTTCTTAATACCGGT 29
DB 31 CCTTCCTTCGTGATTACCGGT 11
RESULT 17
5519127-4/c
Patent No. 5519127
APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
PNEUMOCYSTIS CARINII
NUMBER OF SEQUENCES: 57
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/826,657
FILING DATE: 21-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 392,679
5519127-17

```
; FILING DATE: 11-AUG-1989
; SEQ ID NO: 4
; LENGTH: 34
5519127-4

Query Match      33.2% Score 14.6; DB 6; Length 34;
Best Local Similarity 81.0%; Pred. No. 5.4e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      9 CGTTCCTTCTTAATAACCGGT 29
        |||||
Db      31 CTTCTCTTGATGATACCGGT 11

RESULT 18
5519127-33
; Patent No. 5519127
; APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
; PNEUMOCOCCUS CARINITI
; NUMBER OF SEQUENCES: 57
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/826,657
; FILING DATE: 21-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 392,679
; FILING DATE: 11-AUG-1989
; SEQ ID NO: 33
; LENGTH: 39
5519127-33

Query Match      33.2% Score 14.6; DB 6; Length 39;
Best Local Similarity 47.6%; Pred. No. 5.6e+03;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY      9 CGTTCCTTCTTAATAACCGGT 29
        |||||
Db      5 CCUCCUUCUGAUAUACCGGU 25

RESULT 19
5519127-33
; Patent No. 5519127
; APPLICANT: SHAH, JYOTSNA;BUHARIN, AMELIA;LANE, DAVID J.
; TITLE OF INVENTION: NUCLEIC ACID PROBES FOR THE DETECTION OF
; PNEUMOCOCCUS CARINITI
; NUMBER OF SEQUENCES: 57
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/826,657
; FILING DATE: 21-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 392,679
; FILING DATE: 11-AUG-1989
; SEQ ID NO: 33
; LENGTH: 39
5519127-33

Query Match      33.2% Score 14.6; DB 6; Length 39;
Best Local Similarity 47.6%; Pred. No. 5.6e+03;
Matches 10; Conservative 7; Mismatches 4; Indels 0; Gaps 0;

QY      9 CGTTCCTTCTTAATAACCGGT 29
        |||||
Db      5 CCUCCUUCUGAUAUACCGGU 25

RESULT 20
US-07-826-928A-30
; Sequence 30, Application US/07826928A
; Patent No. 5439829
; GENERAL INFORMATION:
; APPLICANT: Anderson, Leslie D.
; APPLICANT: Cook, James A.
```

```
; APPLICANT: David, Gary S.
; APPLICANT: Hochschwender, Susan M.
; APPLICANT: Kasher, Mary S.
; APPLICANT: Smith, Michele C.
; APPLICANT: Stemmer, Willem P.
; TITLE OF INVENTION: METHOD OF IMMOBILIZING AND CROSS LINKING
; TITLE OF INVENTION: PROTEINS AND OTHER MOLECULES AND USES THEREOF
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company
; STREET: Lilly Corporate Center
; CITY: Indianapolis
; STATE: IN
; COUNTRY: USA
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/826,928A
; FILING DATE: 19920124
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy, Richard B.
; REGISTRATION NUMBER: 35,296
; REFERENCE/DOCKET NUMBER: X8180A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 317-276-3589
; TELEFAX: 317-276-1294
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 46 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-07-826-928A-30

Query Match      33.2% Score 14.6; DB 1; Length 46;
Best Local Similarity 69.0%; Pred. No. 5.9e+03;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY      16 TCTTAATAACCGGTCGGGCTATTATGA 44
        |||||
Db      9 TATTAAATGATGCTGCTATTATGA 37

RESULT 21
US-09-422-978-3415
; Sequence 3415, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1998-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 3415
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
```

NAME/KEY: allele
LOCATION: 24
OTHER INFORMATION: 99-3812-243 : polymorphic base T or G
US-09-422-978-3415

Query Match 33.2%; Score 14.6; DB 4; Length 47;
Best Local Similarity 64.5%; Pred. No. 5.9e+03;
Matches 20; Conservative 1; Mismatches 10; Indels 0; Gaps 0;

QY 10 GTTCCTTCTAATACCGTGGCGTTATT 40
DB 16 GTTCATCCCTAATAACCTTCTCAGCTCTTA 46

RESULT 22
US-08-889-502-34
Sequence 34, Application US/08889502
Patent No. 6066726
GENERAL INFORMATION:
APPLICANT: Fair, David H
APPLICANT: Ruseak, Shelley J
TITLE OF INVENTION: GENE THERAPY VECTOR WITH TISSUE
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kevin M. Farrell
STREET: P.O. Box 999
CITY: York Harbor
STATE: ME
COUNTRY: USA
ZIP: 03911

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/889,502
FILING DATE: 08-JUL-1997
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Farrell, Kevin M
REGISTRATION NUMBER: 35,505
REFERENCE/DOCKET NUMBER: 0146-2008
TELECOMMUNICATION INFORMATION:
TELEPHONE: (207) 363-0558
TELEFAX: (207) 363-0528
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 49 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-889-502-34

Query Match 33.2%; Score 14.6; DB 3; Length 49;
Best Local Similarity 62.2%; Pred. No. 6e+03; 14; Indels 0; Gaps 0;
Matches 23; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 3 GGGTCCGCTTCCTTCTAATAACCGTGGCGTTATT 39
DB 10 GGTGCTTCTCTCTCTCACTTGTCAAGGGGCTCTTAGT 46

RESULT 23
US-09-422-978-2970
Sequence 2970, Application US/09422978
Patent No. 6537751
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Martha
APPLICANT: Chumakov, Ilya

TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/09/422,978
CURRENT FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 2970
LENGTH: 47
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: allele
LOCATION: 24
OTHER INFORMATION: 99-21307-370 : polymorphic base A or G
US-09-422-978-2970

Query Match 32.7%; Score 14.4; DB 4; Length 47;
Best Local Similarity 69.2%; Pred. No. 7.2e+03;
Matches 18; Conservative 1; Mismatches 7; Indels 0; Gaps 0;

QY 1 GCGGGTCCGCTTCCTTCTAATAAC 26
DB 22 GCRCTCTCTGTGGCTTCTAATAAGC 47

RESULT 24
US-09-198-452A-6719/C
Sequence 6719, Application US/09198452A
Patent No. 6559294
GENERAL INFORMATION:
APPLICANT: Grifais, R.
TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
FILE REFERENCE: 9710-003-999
CURRENT APPLICATION NUMBER: US/09/198,452A
CURRENT FILING DATE: 1998-11-24
NUMBER OF SEQ ID NOS: 6849
SEQ ID NO 6719
LENGTH: 20
TYPE: DNA
ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6719

Query Match 32.3%; Score 14.2; DB 4; Length 20;
Best Local Similarity 84.2%; Pred. No. 7.1e+03;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 10 GTTCCTTCTAATAACCG 28
DB 19 GTTCCTTCTGATACAG 1

RESULT 25
US-09-922-146-31/C
Sequence 31, Application US/09922146
Patent No. 6566133
GENERAL INFORMATION:
APPLICANT: Lex M. Cowser
APPLICANT: Brett P. Monia
TITLE OF INVENTION: ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 9 EXPRESSION
FILE REFERENCE: RTS-0252
CURRENT APPLICATION NUMBER: US/09/922,146
CURRENT FILING DATE: 2001-08-01
NUMBER OF SEQ ID NOS: 48
SEQ ID NO 31
LENGTH: 20
TYPE: DNA

US-09-422-978-2970
Sequence 2970, Application US/09422978
Patent No. 6537751
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Martha
APPLICANT: Chumakov, Ilya


```

: ORGANISM: Artificial Sequence
:
: FEATURE:
: OTHER INFORMATION: Antisense Oligonucleotide
US-09-922-146-31
:
Query Match      32.3%; Score 14.2; DB 4; Length 20;
Best Local Similarity 84.2%; Pred. No. 7.1e+03;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      21 ATACCGGTCCGGGTATT 39
Db      19 AGAACCTGTCCGGTCTT 1

RESULT 26
US-09-657-472-1129/C
: Sequence 1129, Application US/09657472
: Patent No. 6727063
: GENERAL INFORMATION:
: APPLICANT: Lander, Eric S.
: APPLICANT: Cargill, Michele
: APPLICANT: Ireland, James S.
: APPLICANT: Bolik, Stacey
: APPLICANT: Daley, George Q.
: APPLICANT: McCarthy, Jeanette J.
: TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
: FILE REFERENCE: 2825.1027-001
: CURRENT APPLICATION NUMBER: US/09/657,472
: PRIOR FILING DATE: 2000-09-07
: PRIOR APPLICATION NUMBER: US 60/153,357
: PRIOR FILING DATE: 1999-09-10
: PRIOR APPLICATION NUMBER: US 60/220,947
: PRIOR FILING DATE: 2000-07-26
: PRIOR APPLICATION NUMBER: US 60/225,724
: PRIOR FILING DATE: 2000-08-16
: NUMBER OF SEQ ID NOS: 2551
: SOFTWARE: FastSeq for Windows Version 4.0
: SEQ ID NO 1129
: LENGTH: 21
: TYPE: DNA
: ORGANISM: Homo sapiens
US-09-657-472-1129

Query Match      32.3%; Score 14.2; DB 4; Length 21;
Best Local Similarity 76.2%; Pred. No. 7.2e+03;
Matches 16; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY      13 CTTCTTAATRACCGGTGGC 33
Db      21 CTTCTTAATRACGTGCGG 1

RESULT 27
US-07-956-697B-3
: Sequence 3, Application US/07956697B
: Patent No. 5374543
: GENERAL INFORMATION:
: APPLICANT: Murdoch, Douglas Craig
: TITLE OF INVENTION: Enhanced Indole Biosynthesis
: NUMBER OF SEQUENCES: 5
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Amgen Inc.
: STREET: Amgen Center
: STREET: 1840 Dehavenland Drive
: CITY: Thousand Oaks
: STATE: California
: COUNTRY: USA
: ZIP: 91320-1789
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Microsoft Word Version 5.0
```

```

: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/07/956,697B
: FILING DATE: 02-OCT-1992
: CLASSIFICATION: 435
: INFORMATION FOR SEQ ID NO: 3:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 36 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: unknown
US-07-956-697B-3

Query Match      32.3%; Score 14.2; DB 1; Length 36;
Best Local Similarity 84.2%; Pred. No. 8.2e+03;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      25 CCGGTCCGGGTATTATAGA 43
Db      11 CCGGTCCGGCGCATTAAGA 29

RESULT 28
US-08-263-098-3
: Sequence 3, Application US/08263098
: Patent No. 5494816
: GENERAL INFORMATION:
: APPLICANT: Murdoch, Douglas Craig
: TITLE OF INVENTION: Enhanced Indole Biosynthesis
: NUMBER OF SEQUENCES: 5
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Amgen Inc.
: STREET: Amgen Center
: STREET: 1840 Dehavenland Drive
: CITY: Thousand Oaks
: STATE: California
: COUNTRY: USA
: ZIP: 91320-1789
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Microsoft Word Version 5.0
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/263,098
: FILING DATE: 21-JUN-1994
: CLASSIFICATION: 435
: INFORMATION FOR SEQ ID NO: 3:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 36 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: unknown
US-08-263-098-3

Query Match      32.3%; Score 14.2; DB 1; Length 36;
Best Local Similarity 84.2%; Pred. No. 8.2e+03;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      25 CCGGTCCGGGTATTATAGA 43
Db      11 CCGGTCCGGCGCATTAAGA 29

RESULT 29
US-08-857-946-83/C
: Sequence 83, Application US/08857946
: Patent No. 5994075
: GENERAL INFORMATION:
: APPLICANT: Goodfellow, P. N.
: TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
: NUMBER OF SEQUENCES: 162
: CORRESPONDENCE ADDRESS:
```

ADDRESSEE: Banner & Witcoff, Inc.
STREET: 75 State Street
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109-1807
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/857,946
FILING DATE: 16-MAY-1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/60/017,824
FILING DATE: 17-MAY-1996
ATTORNEY/AGENT INFORMATION:
NAME: Kathleen M. Williams
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3529/05573
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-345-9100
TELEFAX: 617-345-9111
INFORMATION FOR SEQ ID NO: 83:
SEQUENCE CHARACTERISTICS:
LENGTH: 38 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
FEATURE:
NAME/KEY: primer bmm160f
US-08-857-946-83

Query Match 32.3%; Score 14.2; DB 2; Length 38;
Best Local Similarity 62.9%; Pred. No. 8.3e+03;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 4 GGTCCCGTCTTCTTAATACCGGTGCGGTTAT 38
DB 38 GGTCCAGTAGTCTTCTTAACGTGCGCGTCTTT 4

RESULT 30
US-08-970-740-83/C
Sequence 83, Application US/08970740
GENERAL INFORMATION:
APPLICANT: Goodfellow, P.N.
TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
NUMBER OF SEQUENCES: 162
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Inc.
STREET: 28 State Street, 28th Floor
CITY: Boston
STATE: Massachusetts
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/970,740
FILING DATE: 14-NOV-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/857,946
FILING DATE: 16-MAY-1997
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/017,824
FILING DATE: 17-MAY-1996
ATTORNEY/AGENT INFORMATION:
NAME: Kathleen M. Williams
REGISTRATION NUMBER: 34,380
REFERENCE/DOCKET NUMBER: 3529/59829
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-227-7111
TELEFAX: 617-227-4399
INFORMATION FOR SEQ ID NO: 83:
SEQUENCE CHARACTERISTICS:
LENGTH: 38 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
FEATURE:
NAME/KEY: primer bmm160f
US-08-970-740-83

Query Match 32.3%; Score 14.2; DB 3; Length 38;
Best Local Similarity 62.9%; Pred. No. 8.3e+03;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 4 GGTCCCGTCTTCTTAATACCGGTGCGGTTAT 38
DB 38 GGTCCAGTAGTCTTCTTAACGTGCGCGTCTTT 4

RESULT 31
US-09-538-709-983/C
Sequence 983, Application US/09538709
Patent No. 6468749
GENERAL INFORMATION:
APPLICANT: Ulanovsky, et al
TITLE OF INVENTION: SEQUENCE-DEPENDENT GENE SORTING TECHNIQUES
FILE REFERENCE: 540579-2006
CURRENT APPLICATION NUMBER: US/09/538,709
CURRENT FILING DATE: 2001-06-08
NUMBER OF SEQ ID NOS: 1311
SOFTWARE: PatentIn version 3.0
SEQ ID NO 983
LENGTH: 49
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURES:
OTHER INFORMATION: Adaptor
US-09-538-709-983

Query Match 32.3%; Score 14.2; DB 3; Length 49;
Best Local Similarity 70.4%; Pred. No. 8.9e+03;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 9 CGTCCCTTCTTAATACCGGTGCGGCT 35
DB 44 CGTCCGATCGAATCGCGCGCGGT 18

RESULT 32
US-08-379-452-17
Sequence 17, Application US/08379452
Patent No. 6040174
GENERAL INFORMATION:
APPLICANT: IMLER, Jean-Luc
APPLICANT: MEHTALI, Majid
APPLICANT: PAVITANI, Andrea
TITLE OF INVENTION: DEFECTIVE ADENOVIRUSES AND CORRESPONDING
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
STREET: 1737 King Street, Suite 500
CITY: Alexandria

STATE: Virginia
COUNTRY: United States
ZIP: 22314-2756
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/379,452
FILING DATE: 26-JAN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/FR94/00624
FILING DATE: 27-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 93 06482
FILING DATE: 28-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Dadio, Susan M.
REGISTRATION NUMBER: 40,373
REFERENCE/DOCKET NUMBER: 029395-002
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Synthetic oligonucleotide (OTG5482)
US-08-379-452-17

Query Match 31.8%; Score 14; DB 3; Length 24;
Best Local Similarity 77.3%; Pred. No. 9.1e+03;
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 23 AACGGTCGCGGTATTAGAA 44
Db 2 AACTGTCACCGTGATTAAAA 23

RESULT 33
US-09-409-670-17
Sequence 17, Application US/09409670
Patent No. 6133028
GENERAL INFORMATION:
APPLICANT: IMLER, Jean-Luc
APPLICANT: MEHTALI, Majid
APPLICANT: PAVIRANT, Andrea
TITLE OF INVENTION: DEFECTIVE ADENOVIRUSES AND CORRESPONDING
TITLE OF INVENTION: COMPLEMENTATION LINES
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
STREET: 1737 King Street, Suite 500
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22314-2756
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/409,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/379,452

FILING DATE: 26-JAN-1995
APPLICATION NUMBER: WO PCT/FR94/00624
FILING DATE: 27-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 93 06482
FILING DATE: 28-MAY-1993
ATTORNEY/AGENT INFORMATION:
NAME: Dadio, Susan M.
REGISTRATION NUMBER: 40,373
REFERENCE/DOCKET NUMBER: 029395-002
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Synthetic oligonucleotide (OTG5482)
US-09-409-670-17

Query Match 31.8%; Score 14; DB 3; Length 24;
Best Local Similarity 77.3%; Pred. No. 9.1e+03;
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 23 AACGGTCGCGGTATTAGAA 44
Db 2 AACTGTCACCGTGATTAAAA 23

RESULT 34
US-09-461-697-456
Sequence 456, Application US/09461697
Patent No. 6277974
GENERAL INFORMATION:
APPLICANT: COGENT NEUROSCIENCE, Inc.
APPLICANT: Lo, Donald C.
APPLICANT: Barney, Shawn
APPLICANT: Thomas, Mary Beth
APPLICANT: Portbury, Stuart D.
APPLICANT: Putnam, Kasuri L.
APPLICANT: Katz, Lawrence C.
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING
TITLE OF INVENTION: AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING
TITLE OF INVENTION: CELL DEATH
FILE REFERENCE: 10001-005-999
CURRENT APPLICATION NUMBER: US/09/461,697
CURRENT FILING DATE: 1999-12-14
NUMBER OF SEQ ID NOS: 466
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 456
LENGTH: 30
TYPE: DNA
ORGANISM: Homo sapiens
US-09-461-697-456

Query Match 31.8%; Score 14; DB 3; Length 30;
Best Local Similarity 77.3%; Pred. No. 9.6e+03;
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 20 AATAACGGTCGCGGTATTAA 41
Db 9 AACACCGGTTGGGTTGTAA 30

RESULT 35
US-09-709-103-34
Sequence 34, Application US/09709103
Patent No. 6733991
GENERAL INFORMATION:
APPLICANT: Cismowski, Mary

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/043,553
FILING DATE: 15-APR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/048,740
FILING DATE: 05-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: B.J.Sadoff
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 620-35
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)816-4091
TELEFAX: (703)816-4100
INFORMATION FOR SEQ ID NO: 117:
SEQUENCE CHARACTERISTICS:
LENGTH: 41 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-060-299-117

Query Match 31.8%; Score 14; DB 4; Length 41;
Best Local Similarity 66.7%; Pred. No. 1e+04;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 9 CGTTCCTTCTTAATACCGGTGCGGTTAT 38
DB 39 CGTTCCTTCTTAATCAAGGGCGTAATCAT 10

RESULT 40
US-09-402-923A-117/c
Sequence 117, Application US/09402923A
Patent No. 6555654

GENERAL INFORMATION:

APPLICANT: Todd, John A
Hess, John W
Caskey, Charles T
Cox, Roger D
Gerhold, David
Hammond, Holly
Hey, Patricia
Kawaguchi, Yoshihiko
Merriman, Tony R
Metzker, Michael L
TITLE OF INVENTION: No. 6555654e1 LDL-Receptor
NUMBER OF SEQUENCES: 455
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Nixon and Vanderhye
STREET: 1100 No. 6555654th Glebe Road, Bighch Floor
CITY: Arlington
STATE: Virginia
COUNTRY: US
ZIP: VA 22201-4714

COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk

OPERATING SYSTEM: IBM PC compatible
SOFTWARE: Patent Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/402,923A
FILING DATE: 14-Feb-2001

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/GB98/01102
FILING DATE: 15-APR-1998
APPLICATION NUMBER: US 60/043,553
FILING DATE: 15-APR-1997
APPLICATION NUMBER: US 60/048,740
FILING DATE: 05-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: B.J.Sadoff

REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 620-81

TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)816-4091
TELEFAX: (703)816-4100
INFORMATION FOR SEQ ID NO: 117:
SEQUENCE CHARACTERISTICS:
LENGTH: 41 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 117:
US-09-402-923A-117

Query Match 31.8%; Score 14; DB 4; Length 41;
Best Local Similarity 66.7%; Pred. No. 1e+04;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 9 CGTTCCTTCTTAATACCGGTGCGGTTAT 38
DB 39 CGTTCCTTCTTAATCAAGGGCGTAATCAT 10

Search completed: May 24, 2005, 12:45:35
Job time : 101 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 12:10:04 ; Search time 339 Seconds
(without alignments)
795.936 Million cell updates/sec

Title: US-10-673-063-3_COPY_900_943
Perfect score: 44
Sequence: 1 gcgggtccgcctctctta.....ccggtcgggttaagaagaa 44

Scoring table:
IDENTITY NUC
Gapop 10'-0 , Gapext 1.0

Searched: 5695437 seqs, 306610638 residues

Total number of hits satisfying chosen parameters: 5377818

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : Published Applications NA:*

1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq:*
3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq:*
4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq:*
7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
9: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
10: /cgn2_6/ptodata/1/pubpna/US09_PUBCOMB.seq:*
11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq:*
12: /cgn2_6/ptodata/1/pubpna/US09C_NEW_PUB.seq:*
13: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
14: /cgn2_6/ptodata/1/pubpna/US10_PUBCOMB.seq:*
15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
16: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq:*
18: /cgn2_6/ptodata/1/pubpna/US10F_PUBCOMB.seq:*
19: /cgn2_6/ptodata/1/pubpna/US10F_NEW_PUB.seq:*
20: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq:*
21: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
22: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	16	36.4	27	9	US-09-854-122-8
2	16	36.4	27	9	US-09-854-122-9
3	16	36.4	30	19	US-10-823-259-45
4	16	36.4	30	19	US-10-823-254-45
5	16	36.4	33	19	US-10-792-498-20
6	15.8	35.9	25	19	US-10-809-189-29372
7	15.8	35.9	41	17	US-10-035-833A-1851
8	15.8	35.9	41	17	US-10-035-833A-4446
9	15.6	35.5	33	18	US-10-466-347-11
10	15.4	35.0	25	18	US-10-719-895-20
11	15.4	35.0	25	19	US-10-719-900-918103

C 12	15.2	34.5	47	18	US-10-343-561-98	Sequence 98, Appl
C 13	15	34.1	25	19	US-10-719-900-350576	Sequence 350576,
C 14	15	34.1	25	19	US-10-719-900-825969	Sequence 825969,
C 15	15	34.1	31	9	US-09-801-274-523	Sequence 523, App
C 16	15	34.1	50	17	US-10-131-827-2605	Sequence 2605, Ap
C 17	15	34.1	50	17	US-10-131-827-7716	Sequence 7716, Ap
C 18	14.8	33.6	25	19	US-10-719-900-81188	Sequence 81188, A
C 19	14.8	33.6	25	19	US-10-719-900-927327	Sequence 927327, A
C 20	14.8	33.6	31	10	US-10-809-189-29373	Sequence 29373, A
C 21	14.8	33.6	31	10	US-09-927-046-4154	Sequence 4154, Ap
C 22	14.8	33.6	47	17	US-10-349-143-240	Sequence 240, App
C 23	14.8	33.6	47	17	US-10-349-143-1725	Sequence 1725, Ap
C 24	14.8	33.6	50	10	US-09-993-346-585	Sequence 585, App
C 25	14.8	33.6	50	17	US-10-131-827-2809	Sequence 2809, Ap
C 26	14.6	33.2	25	15	US-10-098-2638-97505	Sequence 97505, A
C 27	14.6	33.2	25	19	US-10-719-900-202404	Sequence 202404,
C 28	14.6	33.2	25	19	US-10-719-900-728815	Sequence 728815,
C 29	14.6	33.2	25	19	US-10-719-900-797256	Sequence 797256,
C 30	14.6	33.2	25	19	US-10-719-900-816976	Sequence 816976,
C 31	14.6	33.2	25	19	US-10-719-900-854921	Sequence 854921,
C 32	14.6	33.2	25	19	US-10-719-900-896407	Sequence 896407,
C 33	14.6	33.2	35	19	US-10-489-739-7	Sequence 7,
C 34	14.6	33.2	41	17	US-10-252-155-747	Sequence 747, App
C 35	14.6	33.2	45	9	US-09-991-003B-16	Sequence 16, Appl
C 36	14.6	33.2	47	17	US-10-349-143-3415	Sequence 3415, Ap
C 37	14.4	32.7	25	15	US-10-098-2638-88885	Sequence 88885, A
C 38	14.4	32.7	25	19	US-10-719-900-221631	Sequence 221631,
C 39	14.4	32.7	25	19	US-10-719-900-221632	Sequence 221632,
C 40	14.4	32.7	25	19	US-10-719-900-434524	Sequence 434524,
C 41	14.4	32.7	25	19	US-10-719-900-639025	Sequence 639025,
C 42	14.4	32.7	34	14	US-10-025-222A-7	Sequence 7, Appl
C 43	14.4	32.7	41	17	US-10-252-155-747	Sequence 747, Appl
C 44	14.4	32.7	47	17	US-10-349-143-2970	Sequence 2970, Ap
C 45	14.4	32.7	50	17	US-10-062-188-125	Sequence 128, App
C 46	14.4	32.7	50	17	US-10-062-188-159	Sequence 159, App
C 47	14.2	32.3	20	10	US-09-922-146-31	Sequence 31, Appl
C 48	14.2	32.3	20	17	US-10-289-762-6719	Sequence 6719, Ap
C 49	14.2	32.3	21	18	US-10-786-720-7147	Sequence 7147, Ap
C 50	14.2	32.3	21	18	US-10-786-720-9415	Sequence 9415, Ap
C 51	14.2	32.3	21	19	US-10-848-755A-25	Sequence 25, Appl
C 52	14.2	32.3	32	17	US-10-571-771-16	Sequence 16, Appl
C 53	14.2	32.3	33	18	US-10-799-372-2	Sequence 2, Appl
C 54	14.2	32.3	39	17	US-10-423-828-54	Sequence 54, Appl
C 55	14.2	32.3	50	17	US-10-175-689-10	Sequence 10, Appl
C 56	14.2	32.3	50	17	US-10-131-827-4778	Sequence 4778, Ap
C 57	14	31.8	24	9	US-09-725-720-17	Sequence 17, Appl
C 58	14	31.8	24	10	US-09-739-007-17	Sequence 17, Appl
C 59	14	31.8	25	19	US-10-169-920-1	Sequence 1, Appl
C 60	14	31.8	25	19	US-10-719-900-118945	Sequence 118945,
C 61	14	31.8	25	19	US-10-719-900-118965	Sequence 118965,
C 62	14	31.8	25	19	US-10-719-900-328268	Sequence 328268,
C 63	14	31.8	25	19	US-10-719-900-328269	Sequence 328269,
C 64	14	31.8	25	19	US-10-719-900-328269	Sequence 328269,
C 65	14	31.8	25	19	US-10-719-900-349040	Sequence 349040,
C 66	14	31.8	25	19	US-10-719-900-349041	Sequence 349041,
C 67	14	31.8	25	19	US-10-719-900-350580	Sequence 350580,
C 68	14	31.8	25	19	US-10-719-900-572728	Sequence 572728,
C 69	14	31.8	25	19	US-10-719-900-804828	Sequence 804828,
C 70	14	31.8	25	19	US-10-719-900-818986	Sequence 818986,
C 71	14	31.8	30	9	US-09-922-261-456	Sequence 456, App
C 72	14	31.8	32	18	US-10-804-491-34	Sequence 34, Appl
C 73	14	31.8	35	18	US-10-804-491-8	Sequence 8, Appl
C 74	14	31.8	38	15	US-10-382-287-29	Sequence 29, Appl
C 75	14	31.8	41	16	US-10-331-907-117	Sequence 117, App
C 76	14	31.8	42	18	US-10-804-408-96	Sequence 96, Appl
C 77	14	31.8	45	14	US-10-294-171-5	Sequence 5, Appl
C 78	14	31.8	47	10	US-09-993-346-250	Sequence 250, App
C 79	13.8	31.4	21	17	US-10-349-143-990	Sequence 990, App
C 80	13.8	31.4	21	18	US-10-786-720-7148	Sequence 7148, App
C 81	13.8	31.4	21	18	US-10-786-720-7149	Sequence 7149, App
C 82	13.8	31.4	21	18	US-10-786-720-9416	Sequence 9416, App
C 83	13.8	31.4	21	18	US-10-786-720-9417	Sequence 9417, App
C 84	13.8	31.4	24	10	US-09-940-185-1982	Sequence 1982, Ap
C 85	13.8	31.4	25	14	US-10-215-112-12954	Sequence 12954, A

```
C 85 13.8 31.4 25 15 US-10-098-263B-71257 Sequence 71257, A
C 86 13.8 31.4 25 15 US-10-098-263B-71258 Sequence 71258, A
C 87 13.8 31.4 25 15 US-10-098-263B-87670 Sequence 87670, A
C 88 13.8 31.4 25 15 US-10-098-263B-124443 Sequence 124443, A
C 89 13.8 31.4 25 15 US-10-098-263B-130243 Sequence 130243, A
C 90 13.8 31.4 25 19 US-10-098-389023 Sequence 389023, A
C 91 13.8 31.4 25 19 US-10-719-800-389024 Sequence 389024, A
C 92 13.8 31.4 25 19 US-10-719-800-690492 Sequence 690492, A
C 93 13.8 31.4 25 19 US-10-719-900-918104 Sequence 918104, A
C 94 13.8 31.4 25 19 US-10-809-189-50594 Sequence 50594, A
C 95 13.8 31.4 26 14 US-10-224-836-190 Sequence 190, App
C 96 13.8 31.4 26 16 US-10-347-183-111 Sequence 11, App
C 97 13.8 31.4 38 10 US-09-861-257-99 Sequence 99, App
C 98 13.8 31.4 38 15 US-10-189-360-124 Sequence 124, App
C 99 13.8 31.4 47 9 US-09-908-599-20 Sequence 20, App
C 100 13.8 31.4 47 9 US-09-908-599-22 Sequence 22, App
```

ALIGNMENTS

```
RESULT 1
US-09-854-122-8/c
; Sequence 8, Application US/09854122
; Patent No. US20020016980A1
; GENERAL INFORMATION:
; APPLICANT: ALBERTE, RANDALL S.
; TITLE OF INVENTION: TRANSGENIC PLANTS INCORPORATING TRAIT OF ZOSTERA MARINA
; FILE REFERENCE: PHA-007.01
; CURRENT APPLICATION NUMBER: US/09/854,122
; CURRENT FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/202,529
; PRIOR FILING DATE: 2000-05-10
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-854-122-8
Query Match 36.4%; Score 16; DB 9; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.8e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 20 AATAACCGGTCCGGCTTTATTAGA 43
Db 25 AATACTTGTCGGGTATATCAGA 2

RESULT 2
US-09-854-122-9
; Sequence 9, Application US/09854122
; Patent No. US20020016980A1
; GENERAL INFORMATION:
; APPLICANT: ALBERTE, RANDALL S.
; TITLE OF INVENTION: TRANSGENIC PLANTS INCORPORATING TRAIT OF ZOSTERA MARINA
; FILE REFERENCE: PHA-007.01
; CURRENT APPLICATION NUMBER: US/09/854,122
; CURRENT FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/202,529
; PRIOR FILING DATE: 2000-05-10
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
```

```
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-854-122-9
Query Match 36.4%; Score 16; DB 9; Length 27;
Best Local Similarity 79.2%; Pred. No. 5.8e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
Qy 20 AATAACCGGTCCGGCTTTATTAGA 43
Db 3 AATACTTGTCGGGTATATCAGA 26
```

```
RESULT 3
US-10-823-259-45
; Sequence 45, Application US/10823259
; Publication No. US20050049176A1
; GENERAL INFORMATION:
; APPLICANT: Kiener, Peter
; APPLICANT: Langermann, Solomon
; TITLE OF INVENTION: EphA2 and Hyperproliferative Cell Disorders and Epithelial and
; FILE REFERENCE: 10271-058-999
; CURRENT APPLICATION NUMBER: US/10/823,259
; CURRENT FILING DATE: 2004-04-12
; PRIOR APPLICATION NUMBER: 60/462,009
; PRIOR FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence: phosphorothioate-modified ant
US-10-823-259-45
```

```
Query Match 36.4%; Score 16; DB 19; Length 30;
Best Local Similarity 79.2%; Pred. No. 6e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
Qy 2 CGGTCGCCGTCCTTCTTAATAC 25
Db 3 CGGTCGCCGTCCTTCAACATGAC 26
```

```
RESULT 4
US-10-823-254-45
; Sequence 45, Application US/10823254
; Publication No. US20050059592A1
; GENERAL INFORMATION:
; APPLICANT: Kiener, Peter
; APPLICANT: Langermann, Solomon
; APPLICANT: Reed, Jennifer
; TITLE OF INVENTION: EphA2 and Hyperproliferative Cell Disorders
; FILE REFERENCE: 10271-060-999
; CURRENT APPLICATION NUMBER: US/10/823,254
; CURRENT FILING DATE: 2004-04-12
; PRIOR APPLICATION NUMBER: 60/462,024
; PRIOR FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of artificial sequence: phosphorothioate-modified an
US-10-823-254-45
Query Match 36.4%; Score 16; DB 19; Length 30;
```


Best Local Similarity 79.2%; Pred. No. 6e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 2 CGGGTCCGGTCTCTTAATAC 25
Db 3 CGGTCGGTCTCTTACCATGAC 26

RESULT 5

US-10-792-498-20/c
; Sequence 20, Application US/10792498
; Publication No. US20050074865A1

GENERAL INFORMATION:

; APPLICANT: Afeyan, Noudar B.
; APPLICANT: Lee, Frank D.
; APPLICANT: Wong, Gordon G.
; APPLICANT: Das Gupta, Ruchira
; APPLICANT: Baynes, Brian
; TITLE OF INVENTION: ADZYMES AND USES THEREOF
; FILE REFERENCE: COTH-P03-001
; CURRENT APPLICATION NUMBER: US/10/792,498
; PRIOR FILING DATE: 2004-03-02
; PRIOR APPLICATION NUMBER: US 10/650,592
; PRIOR FILING DATE: 2003-08-27
; PRIOR APPLICATION NUMBER: US 60/406,517
; PRIOR FILING DATE: 2002-08-27
; PRIOR APPLICATION NUMBER: US 60/423,754
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/430,001
; PRIOR FILING DATE: 2002-11-27
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligo prethrombinfwdH3
US-10-792-498-20

Query Match 36.4%; Score 16; DB 19; Length 33;
Best Local Similarity 79.2%; Pred. No. 6.1e+03;
Matches 19; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 19 TAATAACGGTCCGGTATTAAAG 42
Db 32 TACTCACTGTCGGCGTCAATTAG 9

RESULT 6

US-10-809-189-29372/c
; Sequence 29372, Application US/10809189
; Publication No. US20050048531A1

GENERAL INFORMATION:

; APPLICANT: Michael Miltmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29372
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-29372

Query Match 35.9%; Score 15.8; DB 19; Length 25;
Best Local Similarity 89.5%; Pred. No. 7e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 26 CGGTCCGGTCTTATTAGAA 44
Db 19 CAGTCCGGTATTATAGAA 1

RESULT 7

US-10-035-833A-1851
; Sequence 1851, Application US/10035833A
; Publication No. US20040072156A1

GENERAL INFORMATION:

; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Artoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035,833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1851
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-1851

Query Match 35.9%; Score 15.8; DB 17; Length 41;
Best Local Similarity 81.0%; Pred. No. 7.9e+03;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 5 GTCCCGTCTCTTAAATAC 25
Db 16 GTCCCGTCTCTTAAATAC 36

RESULT 8

US-10-035-833A-4446
; Sequence 4446, Application US/10035833A
; Publication No. US20040072156A1

GENERAL INFORMATION:

; APPLICANT: Nakamura, Yuho
; APPLICANT: Sekine, Akihiro
; APPLICANT: Iida, Artoshi
; APPLICANT: Saito, Osamu
; TITLE OF INVENTION: Detection of Genetic Polymorphisms
; FILE REFERENCE: FORS-06904
; CURRENT APPLICATION NUMBER: US/10/035,833A
; CURRENT FILING DATE: 2001-12-27
; NUMBER OF SEQ ID NOS: 7669
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4446
; LENGTH: 41
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-035-833A-4446

Query Match 35.9%; Score 15.8; DB 17; Length 41;
Best Local Similarity 81.0%; Pred. No. 7.9e+03;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 5 GTCCCGTCTCTTAAATAC 25
Db 16 GTCCCGTCTCTTAAATAC 36

RESULT 9

US-10-466-347-11/c
; Sequence 11, Application US/10466347

```

; Publication No. US20040103849A1
; GENERAL INFORMATION:
; APPLICANT: Fazio, Vito M.
; TITLE OF INVENTION: DNA VACCINES EXPRESSING HYPERVARIABLE VH-CDR3 IDIOTYPIC DETERMINA
; FILE REFERENCE: 02901/000028-US00
; CURRENT APPLICATION NUMBER: US/10/466,347
; PRIOR FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: PCT/IT01/00014
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-466-347-11

Query Match          35.5%; Score 15.6; DB 18; Length 33;
Best Local Similarity 70.0%; Pred. No. 9,1e+03;
Matches 21; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy      3 GGGTCCCGTCTCTCTTAATAACCGGTGC 32
Db      33 GGTACCGTCTCTCTTAATAACCGCGCCGC 4

RESULT 10
US-10-719-895-20/c
; Sequence 20, Application US/10719895
; Publication No. US20040213805A1
; GENERAL INFORMATION:
; APPLICANT: Verheijde, Monique H.
; TITLE OF INVENTION: Deletions in Arterivirus replicons
; FILE REFERENCE: P55434US
; CURRENT APPLICATION NUMBER: US/10/719,895
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: EP 01201921.2
; PRIOR FILING DATE: 2001-05-21
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 20
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer LV266
US-10-719-895-20

Query Match          35.0%; Score 15.4; DB 18; Length 25;
Best Local Similarity 76.0%; Pred. No. 1e+04;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy      6 TCCGCTTCTTTAATAACCGGTC 30
Db      25 TCGCGTACTTCTTAATAACAGTC 1

RESULT 11
US-10-719-900-918103/c
; Sequence 918103, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
```

```

; SEQ ID NO 918103
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-918103

Query Match          35.0%; Score 15.4; DB 19; Length 25;
Best Local Similarity 76.0%; Pred. No. 1e+04;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy      17 CTTAATAACCGGTGCGGTATTAA 41
Db      25 CTGAAGAATCTGTAGCTTATTAA 1

RESULT 12
US-10-343-561-98/c
; Sequence 98, Application US/10343561
; Publication No. US20040126389A1
; GENERAL INFORMATION:
; APPLICANT: Berthet, Francois-Xavier Jacques
; APPLICANT: Dalemans, Wilfried
; APPLICANT: Denoel, Philippe
; APPLICANT: Dequeune, Guy
; APPLICANT: Peron, Christiane
; APPLICANT: Garcon, Nathalie
; APPLICANT: Lobet, Yves
; APPLICANT: Poolman, Jan
; APPLICANT: Thiry, Georges
; APPLICANT: Thonnard, Joelle
; APPLICANT: Voet, Pierre
; TITLE OF INVENTION: Vaccines Comprising Outer Membrane
; TITLE OF INVENTION: Vesicles from Gram Negative Bacteria
; FILE REFERENCE: B45260
; CURRENT APPLICATION NUMBER: US/10/343,561
; CURRENT FILING DATE: 2003-01-31
; PRIOR APPLICATION NUMBER: PCT/EP01/08857
; PRIOR FILING DATE: 2001-07-31
; PRIOR APPLICATION NUMBER: EP 00956369.3
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: GB 0103170.7
; PRIOR FILING DATE: 2001-02-08
; NUMBER OF SEQ ID NOS: 156
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 98
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: EMS4 primer
US-10-343-561-98

Query Match          34.5%; Score 15.2; DB 18; Length 47;
Best Local Similarity 71.4%; Pred. No. 1.5e+04;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy      17 CTTAATAACCGGTGCGGTATTAA 44
Db      41 CATATTTCGAGCGGTTAATTAAGA 14

RESULT 13
US-10-719-900-350576/c
; Sequence 350576, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
```

NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 350576
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-350576

Query Match 34.1%; Score 15; DB 19; Length 25;
Best Local Similarity 78.3%; Pred. No. 1.5e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

12 TCCTTCTTAATACCGGTGCGG 34
Db 23 TCTGCTTAATACGTGCGG 1

RESULT 14
US-10-719-900-825969
Sequence 825969, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT APPLICATION NUMBER: US/10/719,900
CURRENT FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
PRIOR FILING DATE: 2002.11.20
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 825969
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-825969

Query Match 34.1%; Score 15; DB 19; Length 25;
Best Local Similarity 78.3%; Pred. No. 1.5e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

1 GCGGTCGCCGTTCTTCTTATA 23
Db 3 GTGGTTCAGTTGATCTTATA 25

RESULT 15
US-09-801-274-523/C
Sequence 523, Application US/09801274
Patent No. US20020032319A1
GENERAL INFORMATION:
APPLICANT: Caregill, Michele
APPLICANT: Ireland, James S.
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS
FILE REFERENCE: 2825.2009-001
CURRENT APPLICATION NUMBER: US/09/801,274
CURRENT FILING DATE: 2001-03-07
PRIOR APPLICATION NUMBER: US 60/187,510
PRIOR FILING DATE: 2000-03-07
PRIOR APPLICATION NUMBER: US 60/206,129
PRIOR FILING DATE: 2000-05-22
NUMBER OF SEQ ID NOS: 1802
SOFTWARE: PasteSeq for Windows Version 4.0
SEQ ID NO 523
LENGTH: 31
TYPE: DNA
ORGANISM: Homo sapiens
US-09-801-274-523

Query Match 34.1%; Score 15; DB 9; Length 31;
Best Local Similarity 78.3%; Pred. No. 1.6e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

12 TCCTTCTTAATACCGGTGCGG 34
Db 29 TCTTCTTAATGACTGTGCGG 7

RESULT 16
US-10-131-827-2605
Sequence 2605, Application US/10131827
Publication No. US20040009479A1
GENERAL INFORMATION:
APPLICANT: Wohlgenuth, Jay
APPLICANT: Fry, Kirk
APPLICANT: Woodward, Robert
APPLICANT: Ly, Ngoc
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
FILE REFERENCE: 506612000120
CURRENT APPLICATION NUMBER: US/10/131,827
CURRENT FILING DATE: 2002-09-06
PRIOR APPLICATION NUMBER: US 10/006,290
PRIOR FILING DATE: 2001-10-22
PRIOR APPLICATION NUMBER: US 60/296,764
PRIOR FILING DATE: 2001-06-08
NUMBER OF SEQ ID NOS: 9090
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2605
LENGTH: 50
TYPE: DNA
ORGANISM: Homo sapiens
US-10-131-827-2605

Query Match 34.1%; Score 15; DB 17; Length 50;
Best Local Similarity 67.7%; Pred. No. 1.8e+04;
Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

14 CTTCTTAATACCGGTGCGGTTATTAGAA 44
Db 2 CTGCTCATCTCTTTGCGGCTTATTGAA 32

RESULT 17
US-10-131-827-7716/C
Sequence 7716, Application US/10131827
Publication No. US20040009479A1
GENERAL INFORMATION:
APPLICANT: Wohlgenuth, Jay
APPLICANT: Fry, Kirk
APPLICANT: Woodward, Robert
APPLICANT: Ly, Ngoc
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
FILE REFERENCE: 506612000120
CURRENT APPLICATION NUMBER: US/10/131,827
CURRENT FILING DATE: 2002-09-06
PRIOR APPLICATION NUMBER: US 10/006,290
PRIOR FILING DATE: 2001-10-22
PRIOR APPLICATION NUMBER: US 60/296,764
PRIOR FILING DATE: 2001-06-08
NUMBER OF SEQ ID NOS: 9090
SOFTWARE: PatentIn version 3.1
SEQ ID NO 7716
LENGTH: 50
TYPE: DNA
ORGANISM: Homo sapiens
US-10-131-827-7716

Query Match 34.1%; Score 15; DB 17; Length 50;
Best Local Similarity 67.7%; Pred. No. 1.8e+04;
Matches 21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

12 TCCTTCTTAATACCGGTGCGGTTATTAG 42
11

Db 49 TTCTTCTCATATGAGTCGCTTTGAAAAG 19

RESULT 18

US-10-719-900-81188

; Sequence 81188, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002.11.20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 81188

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-81188

Query Match 33.6%; Score 14.8; DB 19; Length 25;

Best Local Similarity 88.9%; Pred. No. 1.9e+04;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 6 TCCGCTCCCTCTTAATA 23

Db 8 TCCTGTTACTTCTTAATA 25

RESULT 19

US-10-719-900-927327/c

; Sequence 927327, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002.11.20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 927327

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-927327

Query Match 33.6%; Score 14.8; DB 19; Length 25;

Best Local Similarity 88.9%; Pred. No. 1.9e+04;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 24 ACCGTCGCGGTATTAA 41

Db 22 ACCTGTCGCGATTATTA 5

RESULT 20

US-10-809-189-29373/c

; Sequence 29373, Application US/10809189

; Publication No. US20050048531A1

; GENERAL INFORMATION:

; APPLICANT: Michael Miltmann

; APPLICANT: David Mack

; APPLICANT: David Lockhart

; APPLICANT: Affimetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1

; CURRENT APPLICATION NUMBER: US/10/809,189

; CURRENT FILING DATE: 2004-03-25

; PRIOR APPLICATION NUMBER: US/09/396,196

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 29373

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-809-189-29373

Query Match 33.6%; Score 14.8; DB 19; Length 25;

Best Local Similarity 88.9%; Pred. No. 1.9e+04;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 26 CGTCCGCGGTATTAGA 43

Db 18 CAGTCGCGGTATTAGA 1

RESULT 21

US-09-927-046-4154/c

; Sequence 4154, Application US/09927046

; Publication No. US20030064946A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc

; APPLICANT: McSwigen, Jim

; APPLICANT: Thompson, Jim

; APPLICANT: McKenzie, Tim

; APPLICANT: Ayers, Dave

; APPLICANT: Szymkowski, Edmund

; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride

; FILE REFERENCE: 249/021

; CURRENT APPLICATION NUMBER: US/09/927,046

; CURRENT FILING DATE: 2001-08-09

; NUMBER OF SEQ ID NOS: 5450

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 4154

; LENGTH: 31

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Enzymatic Nucleic Acid

US-09-927-046-4154

Query Match 33.6%; Score 14.8; DB 10; Length 31;

Best Local Similarity 73.1%; Pred. No. 2e+04;

Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 5 GTCCCGTCCCTCTTAATACCGGTC 30

Db 30 GTCCCGTCCGTGTAGCTAGCCGCTC 5

RESULT 22

US-10-349-143-240/c

; Sequence 240, Application US/10349143

; Publication No. US20040005584A1

; GENERAL INFORMATION:

; APPLICANT: Cohen, Daniel

; APPLICANT: Blumenfeld, Marta

; APPLICANT: Chumakov, Ilya

; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

; FILE REFERENCE: GENSET.020CPI

; CURRENT APPLICATION NUMBER: US/10/349,143

; CURRENT FILING DATE: 2003-01-21

; PRIOR APPLICATION NUMBER: US/09/422,978

; PRIOR FILING DATE: 1999-10-20

; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850

```

; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 240
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 99-1368-299 : polymorphic base C or T
US-10-349-143-240

Query Match          33.6% Score 14.8; DB 17; Length 47;
Best Local Similarity 61.1%; Pred. No. 2.2e+04;
Matches 22; Conservative 1; Mismatches 13; Indels 0; Gaps 0;

Qy 9 GGTTCCTCTTATATACCGGTGCGGTTATTAGAA 44
Db 46 CATTATATTTATATCATGCTCCTGTTTGA AAA 11

RESULT 23
US-10-349-143-1725/c
; Sequence 1725, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Ballelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; PRIOR FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 1725
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 99-5951-438 : polymorphic base C or T
US-10-349-143-1725

Query Match          33.6% Score 14.8; DB 17; Length 47;
Best Local Similarity 59.5%; Pred. No. 2.2e+04;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 3 GGGTCCCGTTCCTCTTATATACCGGTGCGGTTATTAGAA 44
Db 46 GGGTCCCATCTCTCTTATATATAGACCATTAATATATA 5

RESULT 24
US-09-993-346-585/c
; Sequence 585, Application US/0993346
; Publication No. US20030124530A1
; GENERAL INFORMATION:
; APPLICANT: Edwards, Cynthia A.
; APPLICANT: Cantor, Charles R.
; APPLICANT: Andrews, Beth M.
```

```

Turin, Lisa M.
Fry, Kirk E.
TITLE OF INVENTION: Sequence-Directed DNA Binding
Molecules, Compositions and Methods
NUMBER OF SEQUENCES: 664
CORRESPONDENCE ADDRESS:
ADDRESSER: Genelabs Technologies, Inc.
STREET: 505 Penobscot Drive
CITY: Redwood City
STATE: CA
COUNTRY: USA
ZIP: 94063
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/993,346
FILING DATE: 13-NO. US20030124530A1-2001
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/354,947
FILING DATE: <Unknown>
APPLICATION NUMBER: US 08/171,389
FILING DATE: 20-DEC-1993
APPLICATION NUMBER: US 08/123,936
FILING DATE: 17-SEP-1993
APPLICATION NUMBER: US 07/996,783
FILING DATE: 23-DEC-1992
APPLICATION NUMBER: US 07/723,618
FILING DATE: 27-JUN-1991
APPLICATION NUMBER: US 08/081,070
FILING DATE: 22-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Brady, John F.
REGISTRATION NUMBER: 39,118
REFERENCE/DOCKET NUMBER: 4600-0175.20/G19P3D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 324-0880
TELEFAX: (650) 324-0960
INFORMATION FOR SEQ ID NO: 585:
SEQUENCE CHARACTERISTICS:
LENGTH: 50 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Human papilloma virus type-16 B6/E7
(start site 97)
SEQUENCE DESCRIPTION: SEQ ID NO: 585:
US-09-993-346-585

Query Match          33.6% Score 14.8; DB 10; Length 50;
Best Local Similarity 73.1%; Pred. No. 2.2e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

Qy 11 TTCCTCTTATATACCGGTGCGGTT 36
Db 27 TGCCTTATATACCGGTTCGGTT 2

RESULT 25
US-10-131-827-2809
; Sequence 2809, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgenuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
```

```

; TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131,827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2809
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-2809

Query Match          33.2%; Score 14.6; DB 17; Length 50;
Best Local Similarity 64.7%; Pred. No. 2.2e+04;
Matches 22; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy      11 TTCCTTTAATTAACCGGTGCGGTTATTAGAA 44
      |||||
Db      10 TTTCGACAGATTAAAGCTGGGCGTTAATAGAA 43

RESULT 26
US-10-098-263B-97505
; Sequence 97505, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
; APPLICANT: Miltman, Michael
; TITLE OF INVENTION: Human Microarray
; FILE REFERENCE: 3118.1
; CURRENT APPLICATION NUMBER: US/10/098,263B
; CURRENT FILING DATE: 2003-01-08
; PRIOR APPLICATION NUMBER: 60/276,759
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 131066
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 97505
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-098-263B-97505

Query Match          33.2%; Score 14.6; DB 15; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy      2 CGGGTCCGTTCTCTTAAT 22
      |||||
Db      3 CGGGTCCGTTCTGTTACTACT 23

RESULT 27
US-10-719-900-202404
; Sequence 202404, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 202404
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-202404
```

```

Query Match          33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy      4 GGTCCGTTCTCTTAATA 24
      |||||
Db      2 GGTCACTCTCTTCTTAATA 22

RESULT 28
US-10-719-900-728815
; Sequence 728815, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 728815
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-728815

Query Match          33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy      10 GTTCTTCTTAATTAACCGGTC 30
      |||||
Db      1 GTTCTTCTCACTTACCAATC 21

RESULT 29
US-10-719-900-797256
; Sequence 797256, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 797256
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-797256

Query Match          33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy      4 GGTCCGTTCTCTTAATA 24
      |||||
Db      5 GGTCCCTTACTGCTTAATA 25

RESULT 30
US-10-719-900-816976
; Sequence 816976, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
```

APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT FILING DATE: 2003-11-20
PRIOR FILING DATE: 2003-11-20
PRIOR APPLICATION NUMBER: 60/427,808
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 816976
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-816976

Query Match 33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 6 TCCCGTCTCTTATTAATACC 26
DB 1 TCCCTTCTCTTATTAATCC 21

RESULT 31
US-10-719-900-854921
Sequence 854921, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT FILING DATE: 2003-11-20
PRIOR FILING DATE: 2002-11-20
PRIOR APPLICATION NUMBER: 60/427,808
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 854921
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-854921

Query Match 33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 GCGGCTCCGCTTCTTTTAA 21
DB 5 GCGGCTCCGCTTCTTCACTTAA 25

RESULT 32
US-10-719-900-896407
Sequence 896407, Application US/10719900
Publication No. US20050026164A1
GENERAL INFORMATION:
APPLICANT: Xue Mei Zhou
TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
FILE REFERENCE: 3528.1
CURRENT FILING DATE: 2003-11-20
PRIOR FILING DATE: 2002-11-20
PRIOR APPLICATION NUMBER: 60/427,808
NUMBER OF SEQ ID NOS: 982914
SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
SEQ ID NO 896407
LENGTH: 25
TYPE: DNA
ORGANISM: Mus musculus
US-10-719-900-896407

Query Match 33.2%; Score 14.6; DB 19; Length 25;
Best Local Similarity 81.0%; Pred. No. 2.3e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 10 GTTCCTCTTAATACCGGTC 30
DB 3 GTTCCTACGTATTCGGGTC 23

RESULT 33
US-10-489-739-7/c
Sequence 7, Application US/10489739
Publication No. US20050070690A1
GENERAL INFORMATION:
APPLICANT: The University of Bristol
APPLICANT: Dawbarn, David
APPLICANT: Allen, Shelley Jane
APPLICANT: Robertson, Alan George Simpson
TITLE OF INVENTION: Polypeptide Purification Method
FILE REFERENCE: 62637.000006
CURRENT FILING DATE: 2004-03-16
PRIOR FILING DATE: 2004-03-16
PRIOR APPLICATION NUMBER: GB0122400.5
PRIOR FILING DATE: 2001-09-17
PRIOR APPLICATION NUMBER: PCT/GB02/04214
PRIOR FILING DATE: 2002-09-17
NUMBER OF SEQ ID NOS: 44
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 35
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: T-KB1g2 6His Reverse Primer
US-10-489-739-7

Query Match 33.2%; Score 14.6; DB 19; Length 35;
Best Local Similarity 73.9%; Pred. No. 2.5e+04;
Matches 17; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

QY 21 ATTAACCGGTCCGGTTATTAGA 43
DB 32 AAAACCGGTCCGGYCATTTATA 10

RESULT 34
US-10-252-155-747/c
Sequence 747, Application US/10252155
Publication No. US20040068096A1
GENERAL INFORMATION:
APPLICANT: Bristol-Myers Squibb Company
TITLE OF INVENTION: HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS IN ORGANIC ANION TRANSPORT
FILE REFERENCE: D0152 NP
CURRENT FILING DATE: 2002-09-20
PRIOR FILING DATE: 2001-09-21
PRIOR APPLICATION NUMBER: US 60/324,172
PRIOR FILING DATE: 2001-09-21
PRIOR APPLICATION NUMBER: US 60/333,700
NUMBER OF SEQ ID NOS: 783
SOFTWARE: PatentIn version 3.1
SEQ ID NO 747
LENGTH: 41
TYPE: DNA
ORGANISM: Homo sapiens
US-10-252-155-747

Query Match 33.2%; Score 14.6; DB 17; Length 41;
Best Local Similarity 69.0%; Pred. No. 2.6e+04;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 10 GTTCCTCTTAATACCGGTTCGGTTAT 38

Db 41 GCTCTCTCTTTTAACCTTACCGGTGAT 13

RESULT 35
US-09-991-003B-16/c
; Sequence 16, Application US/09991003B
; Patent No. US20020177125A1
; GENERAL INFORMATION:
; APPLICANT: KAME, Carl Alexander
; APPLICANT: FORITZ, Mark Aaron
; APPLICANT: TENG, David Heng-Fai
; TITLE OF INVENTION: Human Rhinovirus Assays, and Compositions Therefrom
; FILE REFERENCE: 29345/36971A
; CURRENT APPLICATION NUMBER: US/09/991,003B
; CURRENT FILING DATE: 2002-11-16
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 45
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: rh1D.R2 primer
US-09-991-003B-16

Query Match 33.2%; Score 14.6; DB 9; Length 45;
Best Local Similarity 62.2%; Pred. No. 2.6e+04;
Matches 23; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 4 GGTCCGCTCTTCTTAATACCGGTGCTTATTA 40
Db 37 GGTGACATTAACTCTATTAAAGCGCGCTGATTGA 1

RESULT 36
US-10-349-143-3415
; Sequence 3415, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 3415
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 99-3812-243 : polymorphic base T or G
US-10-349-143-3415

Query Match 33.2%; Score 14.6; DB 17; Length 47;
Best Local Similarity 64.5%; Pred. No. 2.7e+04;
Matches 20; Conservative 1; Mismatches 10; Indels 0; Gaps 0;

Qy 10 GTTCTCTTCTTAATACCGGTGCTTATTA 40
Db 16 GTTCATCKTAAACCAATTCTCAGCTCCTA 46

RESULT 37
US-10-098-263B-88885/c
; Sequence 88885, Application US/10098263B
; Publication No. US20030104410A1
; GENERAL INFORMATION:
; APPLICANT: Miltman, Michael
; APPLICANT: Human Microarray
; TITLE OF INVENTION: 3118.1
; FILE REFERENCE: 3118.1
; CURRENT APPLICATION NUMBER: US/10/098,263B
; CURRENT FILING DATE: 2003-01-08
; PRIOR APPLICATION NUMBER: 60/276,759
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 131066
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 88885
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-098-263B-88885

Query Match 33.7%; Score 14.4; DB 15; Length 25;
Best Local Similarity 75.0%; Pred. No. 2.8e+04;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 3 GGTCCGCTCTTCTTAAATACCG 26
Db 25 GAGTACCGGTCTCTCTGATTAAC 2

RESULT 38
US-10-719-900-221631
; Sequence 221631, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 221631
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-221631

Query Match 32.7%; Score 14.4; DB 19; Length 25;
Best Local Similarity 75.0%; Pred. No. 2.8e+04;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 10 GTTCTCTTCTTAATACCGGTGCG 33
Db 2 GTTCTTGCTACTAACCACTCAGC 25

RESULT 39
US-10-719-900-221632
; Sequence 221632, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914

Query Match 32.7%; Score 14.4; DB 19; Length 25;
Best Local Similarity 75.0%; Pred. No. 2.8e+04;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;


```
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 221632
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-221632
```

```
Query Match          32.7%; Score 14.4; DB 19; Length 25;
Best Local Similarity 75.0%; Pred. No. 2.8e+04;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
```

```
QY      10 GTTCCTCTTATACCGGTGCG 33
          ||||| ||||| |||||
DB       2 GTCTTGTCTAGTACCGATCAG 25
```

RESULT 40

```
US-10-719-900-434524/c
; Sequence 434524, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 434524
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-434524
```

```
Query Match          32.7%; Score 14.4; DB 19; Length 25;
Best Local Similarity 75.0%; Pred. No. 2.8e+04;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
```

```
QY      16 TCTTATATACCGGTGCGGTATTT 39
          ||||| ||||| |||||
DB       25 TCTTACGACGAGTCTGGGTATTT 2
```

Search completed: May 24, 2005, 13:22:14
Job time : 340 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 24, 2005, 11:54:00 ; Search time 1848 Seconds
(without alignments)
906.292 Million cell updates/sec

Title: US-10-673-063-3_COPY_900_943

Perfect score: 44
Sequence: 1 gcggggtccgcgttcctctta.....ccggtcgcgttataagaa 44

Scoring table: IDENTITY NUC
Gapop 10-0, Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 159776

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 100 summaries

Database :

EST: *
1: gb_est1: *
2: gb_est2: *
3: gb_hlc: *
4: gb_est3: *
5: gb_est4: *
6: gb_est5: *
7: gb_est6: *
8: gb_g881: *
9: gb_g882: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	* Query Match Length DB ID	Description
1	16	36.4	35 8 B2763244 SALK_1156
2	15.8	35.9	50 9 CR191751 Forward s
3	15.4	35.0	50 9 AL754601
4	15.2	34.5	46 8 AZ438384
5	15.2	34.5	50 1 AU104874
6	15.2	34.5	50 1 AU106701 AU104874
7	15	34.1	49 8 AZ808932
8	14.8	33.6	46 4 BU049506
9	14.6	33.2	41 8 AZ795288
10	14.6	33.2	50 9 CR147596
11	14.4	32.7	32 8 BH811169 Forward s
12	14.4	32.7	45 8 BH636447
13	14.4	32.7	46 8 BH904918
14	14.4	32.7	49 6 CB190523
15	14.4	32.7	50 9 BH791926
16	14.4	32.7	50 9 CR147596
17	14.2	32.3	50 1 AU102908
18	14	31.8	41 8 AU102908
19	14	31.8	41 8 AU102908
20	14	31.8	41 8 AU102908
21	14	31.8	41 8 AU102908
22	13.8	31.4	45 8 BH636447
23	13.8	31.4	45 8 BH636447
24	13.8	31.4	45 8 BH636447

25	13.8	31.4	50 1 AU104153
26	13.8	31.4	50 1 AU106910
27	13.6	30.9	37 9 AU1771100
28	13.6	30.9	38 1 AU803928
29	13.6	30.9	44 9 AG204200
30	13.6	30.9	45 4 BU035009
31	13.6	30.9	48 9 CR405537
32	13.6	30.9	50 1 AU102726
33	13.6	30.9	50 1 AU106009
34	13.4	30.5	33 9 CG724001
35	13.4	30.5	35 9 CL436566
36	13.4	30.5	38 8 AZ642621
37	13.4	30.5	39 1 AU011134
38	13.4	30.5	39 1 AU011134
39	13.4	30.5	39 1 AU012105
40	13.4	30.5	39 1 AU012381
41	13.4	30.5	39 1 AU012381
42	13.4	30.5	40 8 BH796426
43	13.4	30.5	45 9 TA3G04P
44	13.4	30.5	48 7 D18810
45	13.4	30.5	50 1 AU107655
46	13.4	30.5	50 9 CR236244
47	13.2	30.0	29 1 AU256798
48	13.2	30.0	38 8 BH910864
49	13.2	30.0	38 9 TA360D04P
50	13.2	30.0	40 8 AZ310280
51	13.2	30.0	42 8 AZ665709
52	13.2	30.0	43 1 AU165730
53	13.2	30.0	44 1 AU196741
54	13.2	30.0	44 9 CL528318
55	13.2	30.0	46 1 AU696689
56	13.2	30.0	46 4 BU049506
57	13.2	30.0	46 7 W58703
58	13.2	30.0	47 8 AZ783792
59	13.2	30.0	47 8 BH848002
60	13.2	30.0	48 1 AU266867
61	13.2	30.0	48 9 AG204400
62	13.2	30.0	49 1 AU265180
63	13.2	30.0	49 8 AU034111
64	13.2	30.0	50 1 AU102858
65	13.2	30.0	50 1 AU104031
66	13.2	30.0	50 1 AU104033
67	13.2	30.0	50 1 AU104035
68	13.2	30.0	50 1 AU104035
69	13.2	30.0	50 1 AU104036
70	13.2	30.0	50 1 AU104037
71	13.2	30.0	50 1 AU104038
72	13.2	30.0	50 1 AU104039
73	13.2	30.0	50 1 AU104254
74	13	29.5	28 6 CA795703
75	13	29.5	31 1 AU789302
76	13	29.5	32 7 D21043
77	13	29.5	35 4 BU047401
78	13	29.5	37 1 AU666664
79	13	29.5	37 8 AZ592382
80	13	29.5	42 9 AU757728
81	13	29.5	44 7 T17569
82	13	29.5	45 1 AA676774
83	13	29.5	48 6 CA968570
84	13	29.5	49 1 AL643698
85	13	29.5	49 9 CG719534
86	13	29.5	50 1 AU010193
87	13	29.5	50 1 AU010193
88	13	29.5	50 1 AU105439
89	13	29.5	50 1 AU105441
90	13	29.5	50 1 AU105446
91	12.8	29.1	50 1 AU107549
92	12.8	29.1	23 8 BH811030
93	12.8	29.1	23 9 AU587643
94	12.8	29.1	28 4 BM395440
95	12.8	29.1	32 1 AU014466
96	12.8	29.1	36 8 AZ604700
97	12.8	29.1	38 8 B2660720

AU104153	AU104153
AU106910	AU106910
AL771100	Arabidops
AU803928	AU803928
AG204200	Pan trogl
BU035009	BU035009
CR405537	Arabidops
AU102726	AU102726
AU106009	AU106009
CG724001	111907980
CL436566	PST3252-N
AZ642621	1M0505813
AU106006	AU106006
AU011134	AU011134
AU012105	AU012105
AU012381	AU012381
AU012382	AU012382
BH796426	100809481
AL451566	T. brucei
D18810	MUSGS00961
AU107655	AU107655
CR236244	Forward s
AU256798	AU256798
BH910864	SAUK_0629
AL494047	T. brucei
AZ310280	1M0025K10
AZ665709	1M0047K13
W183G12	x
AA196741	q093002.s
CL528318	ASV14E08.
AL669689	wc12d11.x
BU049506	BU049506
W58703	zq23a04.r1
AZ783792	2M0025N23
BH848002	SAUK_0673
AU266867	AU266867
AG204400	Pan trogl
AU265180	AU265180
AO034111	1(2)k0752
AU102858	AU102858
AU104031	AU104031
AU104033	AU104033
AU104035	AU104035
AU104036	AU104036
AU104037	AU104037
AU104038	AU104038
AU104039	AU104039
AU104254	AU104254
CA795703	Cac BL 27
AU789302	AU789302
D21043	HMG502027
BU047401	BU047401
AU666664	AJ666664
AZ592382	1M0403G13
AL757728	Arabidops
T17569	mpe vs tpe
AA676774	zj71f12.s
CA968570	CA968570
AL643698	AL643698
CG719534	1119058A1
AU010193	AU010193
AU105439	AU105439
AU105441	AU105441
AU105446	AU105446
AU107549	AU107549
BH811030	SAUK_0571
AU587643	Arabidops
BM395440	50072-2-9
AU014466	AU014466
AZ604700	1M0425T10
B2660720	SAUK_0241
B2660721	SAUK_0241

Query Match	34.5%	Score 15.2;	DB 1;	Length 50;
Best Local Similarity	63.9%	Pred. No. 1.2+05;		
Matches 23; Conservative	0;	Mismatches 13;	Indels 0;	Gaps 0;

```

/clone="HEP03014"
/clone_lib="Sugano Homo sapiens cDNA library"
ORIGIN

```

Oy	5	GTCCCGTTCTTCTTAATAACCGGTGCGGTATTA	40
Db	13	GTCCCTGTCTTTGTACACACCGCCGTGCTACTA	48
RESULT 6			
LOCUS	AUI06701	50 bp	mRNA
DEFINITION	AUI06701 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone		
ACCESSION	KAT09190, mRNA sequence.		
VERSION	AUI06701		
KEYWORDS	AUI06701.1 GI:13556222		
SOURCE	EST.		
ORGANISM	Homo sapiens (human)		
REFERENCE	Homo sapiens		
AUTHORS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
TITLE	1 (bases 1 to 50)		
JOURNAL	Suzuki,Y., Taira,H., Tanoda,T., Mizushima-Sugano,J., Seee,J., Hata,H., Ota,T., Isegai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.		
MEDLINE	Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites		
PUBMED	EMBO Rep. 2 (5), 388-393 (2001)		
COMMENT	21270072		
	11375929		
	Contact: Yutaka Suzuki		
	Department of Virology		
	Institute of Medical Science, University of Tokyo		
	4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan		
	Email: yezuki@ims.u-tokyo.ac.jp		
	Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997).		
FEATURES			
Source	location/Qualifiers		
	1..50		
	/organism="Homo sapiens"		
	/mol_type="mRNA"		
	/db_xref="taxon:9606"		
	/clone="KAT09190"		
	/clone_lib="Sugano Homo sapiens cDNA library"		
ORIGIN			
Query Match	34.5%;	Score 15.2;	DB 1;
Best Local Similarity	71.4%;	Pred. NO. 1.2e+05;	
Matches	20;	Conservative 0;	Mismatches 8;
		Indels 0;	Gaps 0;
Oy	10	GTTCCTTCTTAATAACCGGTGCGGTTA	37
Db	13	GTCCCTTTTAACAGCTGACGCTGTA	40
RESULT 7			
LOCUS	AZ808932	49 bp	DNA
DEFINITION	2M0072809R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0072M09 R, genomic survey sequence.		
ACCESSION	AZ808932		
VERSION	AZ808932.1		
KEYWORDS	GI:12974784		
SOURCE	GSS.		
ORGANISM	Mus musculus (house mouse)		
	Mus musculus		
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.		
REFERENCE	1 (bases 1 to 49)		
AUTHORS	Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D. Weiss,R.		
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts		

JOURNAL	Unpublished (2000)
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA Tel.: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0072 row: N column: 09 Seq primer: CACACACGAACAGCTATGACC Class: plasmid ends High quality sequence stop: 49. Location/Qualifiers
FEATURES	
SOURCE	1. 49 /organism="Mus musculus" /mol_type="genomic DNA" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="UUC2M0072N09" /sex="Male" /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-" /clone_id="Mouse 10kb plasmid UUGC1M library" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 [gil4732114[gb][AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
ORIGIN	
Query Match	34.1%; Score 15; DB 8; Length 49;
Best Local Similarity	67.7%; Pred. No. 1.4e+05;
Matches	21; Conservative 0; Mismatches 10; Indels 0; Gaps 0;
OR	7 CCCGTTCTTCTTAATACCGGTCGCGGTTA 37 18 CCCGTACTCTTTAAAGTCTATAGAGCTA 48
RESUT.F 8	B0049506 46 bp mRNA linear EST 29-SEP-2003
LOCUS	B0049506 NIBB Mochii normalized Xenopus neurula library Xenopus
DEFINITION	laevis cDNA clone XL026f15 3', mRNA sequence.
ACCESSION	B0049506
VERSION	B0049506.1 GI:17378905
KEYWORDS	EST.
SOURCE	Xenopus laevis (African clawed frog)
ORGANISM	Xenopus laevis
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoidea; Pipidae; Xenopodinae; Xenopus; Xenopus. 1 (bases 1 to 46) Kikayama,A., Terasaka,C., Mochii,M., Ueno,N., Shin-i,T. and Kohara,Y. Expressed genes in X. laevis embryo Unpublished (2001) Contact: Tadasu Shin-i
TITLE	
JOURNAL	
COMMENT	

Center For Genetic Resource Information
National Institute of Genetics
1111 Yata, Mishima, Shizuoka 411-8540, Japan
Tel: 81-559-81-6856
Fax: 81-559-81-6855
Email: tehin@genes.nig.ac.jp

The information of this clone is available through the following URL.
<http://xenopus.nibb.ac.jp>.

FEATURES

source

Location/Qualifiers

1..46
/organism="Xenopus laevis"
/mol_type="mRNA"
/db_xref="taxon:8355"
/clone="XL026f15"
/tissue_type="whole embryo"
/dev_stage="stage 15"
/clone_lib="NIBB Mochi normalized Xenopus neurula library"

ORIGIN

Query Match 33.6%; Score 14.8; DB 4; Length 46;
Best Local Similarity 67.9%; Pred. No. 1.7e+05;
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 17 CTTAATAACCGTCGCGGTATTAGAA 44
13 CATAATAACAGTACTTGTATTATAGAA 40

Db

RESULT 9
AZ795288/c 41 bp DNA linear GSS 16-FEB-2001

LOCUS 2M0049M22F Mouse 10kb plasmid UUGCIM library Mus musculus genomic

DEFINITION clone UUGC2M0049M22 F, genomic survey sequence.

ACCESSION AZ795288.1 GI:12942154

VERSION GSS.

KEYWORDS Mus musculus (house mouse)

SOURCE Mus musculus

ORGANISM Mus musculus

REFERENCE Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS 1 (bases 1 to 41)

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,B., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

Unpublished (2000)

CONTACT: Robert B. Weiss

UNIVERSITY OF UTAH Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0049 row: A column: 22

Seq primer: GGTGTAAACGACGCGCAGT

Class: plasmid ends

High quality sequence atp: 41.

FEATURES

source

Location/Qualifiers

1..41
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0049M22"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGCIM library"

/note="Vector: pMD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(<http://www.jax.org/resources/documents/dnares/>). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of pMD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and

purified. The sheared, adapted mouse DNA was annealed to

adapted vector DNA, and transformed into

chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

ORIGIN

Query Match 33.2%; Score 14.6; DB 8; Length 41;
Best Local Similarity 69.0%; Pred. No. 2.1e+05;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 8 CCGTTCCTTCTAATAACCGTCGCGGTT 36
38 CTTATGATCTTATTAACCTATCTATGTT 10

Db

RESULT 10
CR147596 50 bp DNA linear GSS 06-JUL-2004

LOCUS CR147596

DEFINITION Forward strand read from insert in 5'HPT insertion targeting and

chromosome engineering clone MHPN78d19, genomic survey sequence.

ACCESSION CR147596.1 GI:49906067

VERSION GSS; genome survey sequence; MICR.

KEYWORDS Mus musculus (house mouse)

SOURCE Mus musculus

ORGANISM Mus musculus

REFERENCE Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS 1 (bases 1 to 50)

Adams,D.J., Biggs,P.J., Cox,A.V., Davies,R.M., van der Weijden,L., Jonkers,J., Smith,J., Plumb,R.W., Taylor,R.G., Nishijima,I., Yu,Y., Rogers,J. and Bradley,A.

Direct Submission
Submitted (20-FEB-2004) Sanger Centre, Hinxton, Cambridgeshire,
CB10 1SA, UK. <http://www.sanger.ac.uk/MICR>

Location/Qualifiers

1..50
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/clone="MHPN78d19"
/clone_lib="MHPN"

ORIGIN

Query Match 33.2%; Score 14.6; DB 9; Length 50;
Best Local Similarity 69.0%; Pred. No. 2.1e+05;
Matches 20; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 11 TTCCTCTAATAACCGTCGCGGTATT 39
12 TTGTCCTTAATAACCTATGATGTT 40

Db

RESULT 11
BH811169 32 bp DNA linear GSS 02-MAY-2002

LOCUS BH811169

DEFINITION SALK_057563 Arabidopsis thaliana TMDA insertion lines Arabidopsis

thaliana genomic clone SALK_057563, genomic survey sequence.

ACCESSION BH811169

VERSION BH61169.1 GI:20389052
KEYWORDS GSS.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Bukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1 (bases 1 to 32)
Alonso,J.M., Leisese,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadriab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
Shim,P., Zimmerman,J. and Ecker,J.R.
TITLE A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA.
Class: TDNA tagged.
Location/Qualifiers
1..32
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/ecotype="Col-0"
/db_xref="taxon:3702"
/clone_lib="SALK_057363"
/clone_id="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna_protocols.html"
ORIGIN
Query Match 32.7%; Score 14.4; DB 8; Length 32;
Best Local Similarity 65.6%; Pred. No. 2.4e+05;
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 11 TTCTTCTTAATACCGGTGGCGTTATTAG 42
||||| ||||| ||||| |||||
1 TTCCTTAATATTTCGGTAAGGTTGTTATG 32
DB
RESULT 12
BH636447 45 bp DNA linear GSS 14-FEB-2002
LOCUS 1008011D08.1BL x1 1008 - RescueMu Grid I Zea mays genomic, genomic
DEFINITION survey sequence.
ACCESSION BH636447
KEYWORDS BH636447.1 GI:18658684
SOURCE GSS.
ORGANISM Zea mays
Bukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
1 (bases 1 to 45)
Alonso,J.M., Leisese,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadriab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
Shim,P., Zimmerman,J. and Ecker,J.R.
TITLE A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA. This sequence lies within 300 bases of the 3' end of
At1g25570.
Class: TDNA tagged.
Location/Qualifiers
1..46
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"

Very probable ligation site of ends cut by single endonuclease.
Reverse complemented post-ligation sequence from source sequence.
Plate: 1008011 row: 35
Class: transposon-caged.
Location/Qualifiers
1..45
/organism="Zea mays"
/mol_type="genomic DNA"
/cultivar="mixed background W23/Al8/B73"
/db_xref="taxon:4577"
/tissue_type="leaf"
/dev_stage="adult"
/lab_host="DH10B"
/clone_id="1008 - RescueMu Grid I"
/note="Organ: leaf; Vector: RescueMu (engineered from
pBluescript backbone); Site 1: BamHI; Site 2: BglII;
RescueMu is a 4.9 kb, modified maize Mu transposon
designed to allow plasmid rescue from total genomic DNA.
Mu elements insert preferentially into transcription
units. For more information on RescueMu, go to the web
site www.zmdb.iastate.edu and follow the links for
'RescueMu.' Grid I was grown at Berkeley in 2001. DNA was
extracted from leaf punches, double digested using BamHI
and BglII, and ligated to form circular plasmids. DH10B
cells were transformed and then screened on LB plates with
ampicillin."
ORIGIN
Query Match 32.7%; Score 14.4; DB 8; Length 45;
Best Local Similarity 75.0%; Pred. No. 2.5e+05;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 21 ATTAACCGGTCCGCGTTATTAGAA 44
||||| ||||| ||||| |||||
DB 12 ATTAACGTGTACGGGTTTTCGAA 35
RESULT 13
BH904918 46 bp DNA linear GSS 04-SEP-2002
LOCUS SALK_105328.44.50.x Arabidopsis thaliana TDNA insertion lines
DEFINITION Arabidopsis thaliana genomic clone SALK_105328.44.50.x, genomic
survey sequence.
ACCESSION BH904918
KEYWORDS BH904918.1 GI:22717592
SOURCE GSS.
ORGANISM Arabidopsis thaliana (thale cress)
Bukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1 (bases 1 to 46)
Alonso,J.M., Leisese,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadriab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
Shim,P., Zimmerman,J. and Ecker,J.R.
TITLE A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA. This sequence lies within 300 bases of the 3' end of
At1g25570.
Class: TDNA tagged.
Location/Qualifiers
1..46
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"

SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 50)
AUTHORS Adams,D.J., Biggs,P.J., Cox,A.V., Davies,R.M., van der Weyden,L.,
Jonkers,J., Smith,D., Plumb,R.W., Taylor,R.G., Nishijima,I., Yu,Y.,
Rogers,J. and Bradley,A.
TITLE Direct Submission
JOURNAL Submitted (20-FEB-2004) Sanger Centre, Hinxton, Cambridgeshire,
CB10 1SA, UK. <http://www.sanger.ac.uk/MICER>
FEATURES
SOURCE Location/Qualifiers
1..50
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
/clone="MH078d19"
/clone_lib="MH078d19"
ORIGIN
Query Match 32.7%; Score 14.4; DB 9; Length 50;
Best Local Similarity 75.0%; Pred. No. 2.6e+05;
Matches 18; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
Oy 20 AATAACCGTCGCGGTTATTAGA 43
Db 40 AATAACCTCTTAAAGATTATTAGA 17
RESULT 17
AUI02908/c 50 bp mRNA linear EST 28-JAN-2004
LOCUS AUI02908 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
DEFINITION HEP13140, mRNA sequence.
ACCESSION AUI02908
VERSION AUI02908.1 GI:13552429
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 50)
AUTHORS Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Seese,J.,
Hata,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K.,
Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.
TITLE Diverse transcriptional initiation revealed by fine, large-scale
mapping of mRNA start sites
JOURNAL EMBO Rep. 2 (5), 388-393 (2001)
MEDLINE 21270072
PUBMED 11375929
COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: yusuzuki@ims.u-tokyo.ac.jp
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and
Sugano,S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
143-156 (1997)
FEATURES
SOURCE Location/Qualifiers
1..50
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="HEP13140"
/clone_lib="Sugano Homo sapiens cDNA library"
ORIGIN
Query Match 32.3%; Score 14.2; DB 1; Length 50;
Best Local Similarity 70.4%; Pred. No. 3.1e+05;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
Oy 16 TCTTAATAACCGTCGCGGTTATTAG 42

Db 30 TCTGACAAACCGTCGCGATTACCAAG 4
RESULT 18
TA192A12Q 41 bp DNA linear GSS 13-DEC-2000
LOCUS T. brucei sheared genomic DNA clone 192a12, reverse sequence,
DEFINITION genomic survey sequence.
ACCESSION AL478202
VERSION AL478202.1 GI:11842012
KEYWORDS GSS.
SOURCE Trypanosoma brucei
ORGANISM Trypanosoma brucei
REFERENCE 1 (bases 1 to 41)
AUTHORS Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R.,
Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L.,
Melville,S.E., Rajandream,M.A. and Barrell,B.G.
TITLE Direct Submission
JOURNAL Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing
project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and
nh@sanger.ac.uk
COMMENT Constructed at the Institute for Genomic Research (TIGR),
Rockville, MD. Genomic DNA isolated from a cloned population of
Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared
to give a tight size distribution (4 kb). The v + i method used for the library construction is
described in detail in Smith, H. and Venter, J.C. (Making small
insert libraries for whole genome shotgun sequencing projects. In
Genome Sequencing: A Practical Approach, eds. M. Vaubin and B.
Barrell, Oxford University Press, 1999).
Email: nelsayed@tigr.org
Details of T. brucei sequencing at the Sanger Centre are available
at http://www.sanger.ac.uk/Projects/T_brucei/.
FEATURES
SOURCE Location/Qualifiers
1..41
/organism="Trypanosoma brucei"
/mol_type="genomic DNA"
/strain="TREU927"
/db_xref="taxon:5691"
/clone="192a12"
ORIGIN
Query Match 31.8%; Score 14; DB 9; Length 41;
Best Local Similarity 64.5%; Pred. No. 3.7e+05;
Matches 20; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
Oy 8 CCGTTCCTTTAATAACCGTCGCGGTTAT 38
Db 10 CAGGTCTTCTTTTAAGCTGNGCAGGTTT 40
RESULT 19
A2801189 48 bp DNA linear GSS 16-FEB-2001
LOCUS 2M0059X02R Mouse 10kb plasmid U0GCM library Mus musculus genomic
DEFINITION clone U0GCM0059X02 R, genomic survey sequence.
ACCESSION A2801189
VERSION A2801189.1 GI:12953512
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 48)
AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,B., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
TITLE Mouse whole genome scaffolding with paired end reads from 10kb

RESULT 22
BH636447/c 45 bp DNA linear GSS 14-FEB-2002
LOCUS 1008011D08.1EL.X1 1008 - Rescuemu Grid I Zea mays genomic, genomic
DEFINITION survey sequence.
ACCESSION BH636447
VERSION BH636447.1 GI:18658684
KEYWORDS GSS.
SOURCE Zea mays
ORGANISM Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
Clade; Panicoideae; Andropogoneae; Zea.
1 (bases 1 to 45)
Walbot, V.
Maize genomic sequences found using engineered Rescuemu transposon
JOURNAL Unpublished (2001)
COMMENT Department of Biological Sciences
Stanford University
855 California Ave, Palo Alto, CA 94304, USA
Tel: 650 723 2227
Fax: 650 723 8221
Email: walbot@stanford.edu
Very probable ligation site of ends cut by single endonuclease.
Reverse complemented post-ligation sequence from source sequence.
Plate: 1008011 row: 35
Class: transposon-tagged.
Location/Qualifiers
1..45
/organism="Zea mays"
/mol_type="genomic DNA"
/cullivar="mixed background W23/A188/B73"
/db_xref="taxon:4577"
/tissue_type="leaf"
/dev_stage="adult"
/lab_host="DH10B"
/clone_id="1008 - Rescuemu Grid I"
/note="Organ: leaf; Vector: Rescuemu (engineered from
pBluescript backbone); Site 1: BamHI, Site 2: BglII;
Rescuemu is a 4.9 kb, modified maize Mu transposon
designed to allow plasmid rescue from total genomic DNA.
Mu elements insert preferentially into transcription
units. For more information on Rescuemu, go to the web
site www.zmdb.laetate.edu and follow the links for
'Rescuemu.' Grid I was grown at Berkeley in 2001. DNA was
extracted from leaf punches, double digested using BamHI
and BglII, and ligated to form circular plasmids. DH10B
cells were transformed and then screened on LB plates with
ampicillin."

Query Match 31.4%; Score 13.8; DB 8; Length 45;
Best Local Similarity 63.6%; Pred. No. 4.5e+05;
Matches 21; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

CY 6 TCCCGTTCCTCTTATAACCGCGCGTTAT 38
| | | | | | | | | | | | | | | | | | | | | |
DB 44 TCCACTAGCTTCGAAACCGCGCTACAGATTAT 12

RESULT 23
BZ292212 46 bp DNA linear GSS 24-OCT-2002
LOCUS SALK_123631.34.00.x Arabidopsis thaliana TDNA insertion lines
DEFINITION Arabidopsis thaliana genomic clone SALK_123631.34.00.x, genomic
survey sequence.
ACCESSION BZ292212
VERSION BZ292212.1 GI:24338860
KEYWORDS GSS.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana

REFERENCE
AUTHORS Alonso, J.M., Leisner, T.J., Barajas, P., Chen, H., Cheuk, R.,
Gadrian, C., Jeske, A., Karne, M., Kim, C.J., Parker, H., Prednis, L.,
Shim, P., Zimmerman, J. and Becker, J.R.
A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Becker
Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ebecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA.
Class: TDNA tagged.
Location/Qualifiers
1..46
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/ecotype="Col-0"
/db_xref="taxon:3702"
/clone="SALK_123631.34.00.x"
/clone_id="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/cdna_protocols.html

ORIGIN

Query Match 31.4%; Score 13.8; DB 8; Length 46;
Best Local Similarity 72.0%; Pred. No. 4.5e+05;
Matches 18; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

CY 4 GGTCCGTTCTCTTATAACCGG 28
| | | | | | | | | | | | | | | | | | | | | |
DB 5 GTCCCAATCTCTCTTAGTAGG 29

RESULT 24
AZ831243 48 bp DNA linear GSS 20-FEB-2001
LOCUS 2M010F20R Mouse 10kb plasmid UUGCLM library Mus musculus genomic
DEFINITION clone UUGC2M010F20 R, genomic survey sequence.
ACCESSION AZ831243
VERSION AZ831243.1 GI:13001151
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
AUTHORS Dunn, P., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
 Plate: 0110 row: F column: 20
 Seq primer: CACACGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 48.

FEATURES

SOURCE

Location/Qualifiers

1..48

/organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="U06C2M0110F20"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone_lib="Mouse 10kb plasmid U06C1M library"

/note="Vector: PMD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male); was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adaptor DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of pMD42 (g1473214[gbl]AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and

purified. The sheared, adaptor mouse DNA was annealed to

adaptor vector DNA, and transformed into

chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

ORIGIN

Query Match

Best Local Similarity 31.4%; Score 13.8; DB 8; Length 48;

Matches 21; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

8 CCGTTCCTTCTTATTAACCGGCGGCTTATTA 40

47 CCCTTCATTCAGAAACCTGTCAGCATTTATTA 15

RESULT 25

AU104153/c

LOCUS

DEFINITION AU104153 Sugano Homo sapiens cDNA library Homo sapiens CDNA clone

HEP15323, mRNA sequence.

ACCESSION AU104153

VERSION AU104153.1 GI:13553674

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

1 (bases 1 to 50)

Suzuki, Y., Taira, H., Tsumoda, T., Mizushima-Sugano, J., Sese, J.,

Hata, H., Ota, T., Isogai, T., Tanaka, T., Morishita, S., Okubo, K.,

Sakaki, Y., Nakamura, Y., Suyama, A. and Sugano, S.

Diverse transcriptional initiation revealed by fine, large-scale

mapping of mRNA start sites

EMBO Rep. 2 (5), 388-393 (2001)

JOURNAL MEDLINE

PUBMED 21270072

COMMENT Contact: Yutaka Suzuki

Department of Virology

Institute of Medical Science, University of Tokyo

4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan

Email: yusuzuki@ims.u-tokyo.ac.jp

Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and

Sugano, S. Construction and characterization of a full

length-enriched and a 5'-end-enriched CDNA library. Gene 200 (1-2),
 149-156 (1997).

FEATURES

SOURCE

Location/Qualifiers

1..50

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="HEP15323"

/clone_lib="Sugano Homo sapiens CDNA library"

ORIGIN

Query Match

Best Local Similarity 31.4%; Score 13.8; DB 1; Length 50;

Matches 18; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

1 GCGGTCCTTCTTATTAACG 25

37 GCGGTCCTTCTTATTAAC 13

RESULT 26

AU106910

LOCUS

DEFINITION AU106910 Sugano Homo sapiens cDNA library Homo sapiens CDNA clone

HRC01450, mRNA sequence.

ACCESSION AU106910

VERSION AU106910.1 GI:13556431

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

1 (bases 1 to 50)

Suzuki, Y., Taira, H., Tsumoda, T., Mizushima-Sugano, J., Sese, J.,

Hata, H., Ota, T., Isogai, T., Tanaka, T., Morishita, S., Okubo, K.,

Sakaki, Y., Nakamura, Y., Suyama, A. and Sugano, S.

Diverse transcriptional initiation revealed by fine, large-scale

mapping of mRNA start sites

EMBO Rep. 2 (5), 388-393 (2001)

JOURNAL MEDLINE

PUBMED 21270072

COMMENT Contact: Yutaka Suzuki

Department of Virology

Institute of Medical Science, University of Tokyo

4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan

Email: yusuzuki@ims.u-tokyo.ac.jp

Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and

Sugano, S. Construction and characterization of a full

length-enriched and a 5'-end-enriched CDNA library. Gene 200 (1-2),

149-156 (1997).

Location/Qualifiers

1..50

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="HRC01450"

/clone_lib="Sugano Homo sapiens CDNA library"

ORIGIN

Query Match 31.4%; Score 13.8; DB 1; Length 50;

Best Local Similarity 72.0%; Pred. No. 4.6e+05;

Matches 18; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

3 GCGGTCCTTCTTATTAACG 27

24 GCGGTCCTTCTTATTAACG 48

RESULT 27

AU1771100/c

LOCUS

DEFINITION AU1771100 37 bp DNA linear GSS 01-APR-2004

Arabidopsis thaliana T-DNA flanking sequence GK-177C09-013534,

genomic survey sequence.

ACCESSION AL771100
 VERSION AL771100.1 GI:21533302
 KEYWORDS
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 REFERENCE 1
 AUTHORS Li, Y., Rosso, M.G., Strizhov, N., Viehoveer, P. and Weishaar, B.
 TITLE GABI-Kat Simplesearch: a flanking sequence tag (FST) database for
 the identification of T-DNA insertion mutants in Arabidopsis
 thaliana
 JOURNAL Bioinformatics 19 (11), 1441-1442 (2003)
 MEDLINE 22755829
 PUBMED 12874060
 REFERENCE 2
 AUTHORS Rosso, M.G., Li, Y., Strizhov, N., Reiss, B., Dekker, K. and
 Weishaar, B.
 TITLE An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for
 flanking sequence tag-based reverse genetics
 JOURNAL Plant Mol. Biol. 53 (1-2), 247-259 (2003)
 MEDLINE 23117147
 PUBMED 14756321
 REFERENCE 3
 AUTHORS Strizhov, N., Li, Y., Rosso, M.G., Viehoveer, P., Dekker, K.A. and
 Weishaar, B.
 TITLE High-throughput generation of sequence indexes from T-DNA
 mutagenized Arabidopsis thaliana lines
 JOURNAL Biotechniques 35 (6), 1164-1168 (2003)
 PUBMED 14682050
 REFERENCE 4 (bases 1 to 37)
 AUTHORS Li, Y., Strizhov, N., Rosso, M.G. and Weishaar, B.
 TITLE Direct Subtilisin
 JOURNAL Submitted (31-MAR-2004) Weishaar, B., Max-Planck-Institut fuer
 Zuechtungsforchung, Carl-von-Linne-Weg 10, Koeln, 50829, Germany
 COMMENT This sequence has been recovered from the left border of the T-DNA.
 It indicates an insertion within the locus defined by BAC clone
 TX10. Details on the protocols used for generation of the sequence
 are described in References 1-3. The sequences are generated at the
 MPI for Plant Breeding Research in the context of the GABI-Kat
 project. GABI-Kat is part of the German Plant Genomics program
 designated 'GABI'. Information on line availability can be found
 at: <http://www.mpiz-koeln.mpg.de/GABI-Kat/>.
 Location/Qualifiers
 1..37
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="GK-177C09-013534"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 /ecotype="Col-0"
 /note="PCR was performed on DNA from Arabidopsis thaliana
 plants (T1) which were transformed with the T-DNA from
 vector PAC161 (GenBank accession number: AJ337514). The
 lines contain one or more T-DNA insertions. The DNA
 fragment(s) resulting from the PCR were directly sequenced
 to determine the genomic sequence flanking the insertion.
 T-DNA derived sequences were removed."
 ORIGIN
 Query Match 30.9%; Score 13.6; DB 9; Length 37;
 Best Local Similarity 67.9%; Pred. No. 5.3e+05;
 Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

LOCUS AJ803928 38 bp mRNA linear EST 11-AUG-2004
 DEFINITION AJ803928 Antirrhinum majus whole plant Antirrhinum majus cDNA clone
 018_5_08_107, mRNA sequence.
 ACCESSION AJ803928
 VERSION AJ803928.1 GI:51119256
 KEYWORDS EST.
 SOURCE Antirrhinum majus (snapdragon)
 ORGANISM Antirrhinum majus
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 asterids; lamids; Lamiales; Plantaginaceae; Antirrhineae;
 Antirrhinum.
 REFERENCE 1 (bases 1 to 38)
 AUTHORS Zachgo, S., Scudener, K., Seidler, H., Sommer, H. and Schwarz-Sommer, Z.
 TITLE Antirrhinum EST collection
 JOURNAL Unpublished (2003)
 COMMENT Contact: Schwarz-Sommer Z
 Molekulare Pflanzen-genetik
 MPI fuer Zuechtungsforchung
 Carl-von-Linne Weg 10, D-50829, Germany.
 Location/Qualifiers
 1..38
 /organism="Antirrhinum majus"
 /mol_type="mRNA"
 /db_xref="taxon:4151"
 /clone="018_5_08_107"
 /tissue_type="whole plant"
 /clone_lib="Antirrhinum majus whole plant"
 ORIGIN
 Query Match 30.9%; Score 13.6; DB 1; Length 38;
 Best Local Similarity 80.0%; Pred. No. 5.4e+05;
 Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Oy 6 TCCCGTCTCTTAAATAC 25
 Db 4 TCCATTCGTCATTAATAC 23
 RESULT 29
 AG204200 44 bp DNA linear GSS 06-MAR-2004
 LOCUS Pan troglodytes DNA, clone: RP43-089110.T7, genomic survey
 DEFINITION
 ACCESSION AG204200
 VERSION AG204200.1 GI:45236375
 KEYWORDS GSS.
 SOURCE Pan troglodytes (chimpanzee)
 ORGANISM Pan troglodytes
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pan.
 REFERENCE 1
 AUTHORS Park, H., Kim, Y., Kim, S., Han, Y., Woo, T., Park, K., Eun, C.J.,
 Hoon, S.T., Chu, M., Kim, H., Joo, S., Kim, C., Song, W. and Yoo, H.
 TITLE BAC end sequences of Library RP-43
 JOURNAL Unpublished
 2 (bases 1 to 44)
 AUTHORS Park, H., Kim, Y., Kim, S., Han, Y., Woo, T., Park, K., Eun, C.J.,
 Hoon, S.T., Chu, M., Kim, H., Joo, S., Kim, C., Song, W. and Yoo, H.
 TITLE Direct Submission
 JOURNAL Submitted (07-JAN-2002) Hong-Seog Park, Korea Research Institute of
 Bioscience and Biotechnology (KRIIB), Genome Research Center (GRC);
 52, Oun-dong, Yusong-gu, Daejeon 305-333, Korea
 (E-mail:redstone@mail.kribb.re.kr, URL:<http://phs.grc.kribb.re.kr/>,
 Tel:82-42-866-7181, Fax:82-42-860-4409)
 COMMENT Clones are derived from the chimpanzee BAC library RP-43 This BAC
 end was generated during the Kd process and may have higher chance
 of clone tracking errors.
 PRIMERS
 Sequencing: T7
 LIBRARY
 Vector : pBAC3.6
 R.Site 1 : EcoRI

[illegible]

FEATURES					
source					
Location/Qualifiers					
1..50					
/organism="Homo sapiens"					
/mol_type="rRNA"					
/db_xref="taxon:9606"					
/clone="HEP2332"					
/clone_lib="Sugano Homo sapiens cDNA library"					
ORIGIN					
Query Match 30.9%; Score 13.6; DB 1; Length 50;					
Best Local Similarity 67.9%; Pred. No. 5.e+05;					
Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;					
Oy	9	CGTTCCTTTTAATACCGGCGCGGCTT	36		
Db	15	CGCTTTCAGAGTACCCTGTGGGCTT	42		
RESULT 34					
CG724001/c					
LOCUS	CG724001	33 bp	DNA	linear	GSS 20-OCT-2003
DEFINITION	1119079B05.2EL_X1 1119 - RescueMu Grid AA Zea mays genomic, genomic survey sequence.				
ACCESSION	CG724001				
VERSION	CG724001.1	GI:37760402			
KEYWORDS	GSS.				
SOURCE	Zea mays				
ORGANISM	Zea mays				
	Eukaryote; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD clade; Panicoideae; Andropogoneae; Zea.				
	1 (bases 1 to 33)				
REFERENCE	Walbot,V.				
AUTHORS	Maize genomic sequences found using engineered RescueMu transposon				
TITLE	Unpublished (2001)				
JOURNAL	Contact: Walbot V				
COMMENT	Department of Biological Sciences Stanford University 855 California Ave, Palo Alto, CA 94304, USA Tel: 650 723 2227 Fax: 650 725 8221 Email: walbot@stanford.edu Possible ligation site of ends cut by 2 different endonucleases. Reverse complemented post-ligation sequence from source sequence. Plate: 1119079 row: B column: 05 Class: transposon-tagged. Location/Qualifiers				
FEATURES	1..33				
source	/organism="Zea mays"				
	/mol_type="genomic DNA"				
	/cultivar="mixed background W23/A188/B73/K55"				
	/db_xref="taxon:4577"				
	/tissue_type="leaf"				
	/dev_stage="adult"				
	/lab_host="MDH10B"				
	/clone_lib="1119 - RescueMu Grid AA"				
	/note="Organ: leaf; Vector: RescueMu (engineered from pBluescript backbone); Site 1: BamHI; Site 2: BglII; RescueMu is a 4.9 kb, modified maize Mu transposon designed to allow plasmid rescue from total genomic DNA. Mu elements insert preferentially into transcription units. For more information on RescueMu, go to the web site 'www.zmldb.iastate.edu' and follow the links for 'RescueMu.' Grid AA was grown at UC San Diego in 2002. DNA was extracted from leaf strips, double digested using BamI and BglII, and ligated to form circular plasmids. DH10B cells were transformed and then screened on LB plates with ampicillin."				

SOURCE Schizosaccharomyces pombe (fission yeast)
ORGANISM Schizosaccharomyces pombe
Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
Schizosaccharomycetales; Schizosaccharomycetaceae;
Schizosaccharomyces.
REFERENCE 1 (bases 1 to 39)
AUTHORS Moriyo,M. and Mita,K.
TITLE Identification of expressed sequence tags of Schizosaccharomyces
pombe
JOURNAL Unpublished (1998)
COMMENT Contact: Mitsuoki Moriyo
Genome Research Group
National Institute of Radiological Sciences
9-1, Anagawa-4-chome, Inage-ku, Chiba, Chiba 263-8555, Japan
Email: moriyo@nirs.go.jp.
Location/Qualifiers
FEATURES
source
1..39
/organism="Schizosaccharomyces pombe"
/mol_type="mRNA"
/strain="972"
/db_xref="taxon:4896"
/clone="spc06701"
/sex="h minus"
/clone_lib="Schizosaccharomyces pombe late log phase cDNA"
/note="Vector: M13mp19; The cDNA library of
Schizosaccharomyces pombe was prepared by cloning cDNA
into the SmaI site of M13mp19 DNA and the direction of DNA
sequences was not always from 5' to 3'. The cDNA data of
Schizosaccharomyces pombe are available for searching on
the World Wide Web. (URL, <http://www.nirs.go.jp>)"
ORIGIN
Query Match 30.5%; Score 13.4; DB 1; Length 39;
Best Local Similarity 64.5%; Pred.No.6.5e+05;
Matches 20; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 14 CTCTTAATAACCGGTCGGGTTATTAGAA 44
Db 32 CATATATATTAATGATTCGATTAATAAAAAA 2

Search completed: May 24, 2005, 13:16:40
Job time : 1861 secs

This Page Blank (uspto)